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Abstract
Multimodality imaging agents have the potential to be detected in both MRI 
and optical imaging experiments allowing for visualisation of biological 
systems from the cellular level up to the whole body. Lanthanide complexes 
have shown great promise as components of compounds that can act as either 
MRI contrast agents or luminescent imaging agents dependent on the metal 
centre incorporated (e.g. gadolinium(III) or europium(III)/terbium(III) 
respectively).
This thesis describes the design, synthesis and characterisation of multimodality 
lanthanide imaging agents. The synthesis of a series of lanthanide chelators 
based on DO3A bearing a benzimidazole or a benzyl derivative that can act as 
both a chromophore unit and a linking group for conjugation that has the 
functionality to couple to an optical dye (either rhodamine or BODIPY 
derivatives) is discussed.
A series of lanthanide complexes with either a nitro- or amino-benzyl 
benzimidazole DO3A chelator or with an aminobenzyl DO3A chelator have 
been prepared. A number of strategies have been attempted to couple the 
complexes to an optical dye to form a multimodality imaging agent.
Physical properties and cellular uptake of the lanthanide complexes have been 
investigated. It was shown that the benzimidazole ligands can sensitise the 
luminescence of both the europium(III) and terbium(III) metal ions. Relaxation 
rates of the gadolinium(III) benzimidazole DOS A complexes are comparable to 
that of commercial contrast agents. The relaxivity of the gadolinium(III) 
complex formed with the ligand l,4,7-tris(carboxymethyl)-10-(l-(4- 
nitrobenzyl)-2-methyl benzimidazole)-1,4,7,10-tetraazacyclododecane (34) is 
6.22 mM" 1 s" 1 , with the relaxivity of the gadolinium(III) complex formed with 
1,4,7-tris(carboxymethyl)-10-( 1 -(4-aminobenzyl)-2-methyl benzimidazole)- 
1,4,7,10-tetraazacyclododecane (37) was found to be lower at 4.51 mM" 1 s" 1 . 
The luminescence lifetimes of the europium(III) and terbium(III) complexes in 
and D2O were used to calculate the number of coordinated water
11
molecules in aqueous solution [q = 1.19 for the europium(III) complex of (34), 
0.7-0.8 for the europium(III) complex of (37) and 1.25 for the terbium(III) 
complexes of (34)]
in
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1. Introduction
1.1 General Introduction
In recent years magnetic resonance imaging (MRI) and optical imaging have 
been used extensively in the study of biological function at an anatomical and 
cellular level. MRI has been used to study the human body at an anatomical 
level to identify abnormalities like cancerous tissues as well as understanding 
the process of diseases such as cardiac failure. Optical imaging has been used 
to probe cellular functions including apoptosis (programmed cell death). The 
technique is restricted to a cellular level due to limited tissue penetration, where 
as MRI techniques are better suited to an anatomical level because of lower 
image resolution. Typically images for MRI and optical imaging are shown in 
figure 1.
Figure 1 MRI picture of the heart (left) and an optical image of a heart cell (right)
Multimodality imaging agents have the potential to act as both MRI and optical 
imaging agents allowing for visualisation of biological systems on different 
scales and varying resolution.' 2 They can be further modified to target specific 
cell types or physiological processes. This will allow the same biological 
specimen to be visualised from cellular up to a whole organism level, and the 
additional ability to target cell or tissue types may ultimately provide a greater 
understanding of the human body, which in turn could lead to improved 
treatment of diseases.
Lanthanides have shown great promise as components of contrast agents that 
have the ability to act as both MRI agents [e.g. gadolinium(III)] and optical
agents when sensitised by a chromophore [e.g. europium(III) or terbium(III)). 
Gadolinium(III)] compounds are used as MRI contrast agents due to their long 
electron spin relaxation times and high magnetic field, while luminescent 
lanthanide ions such as europium(III) and terbium(III) are used for optical 
imaging as they have suitable wavelength emissions (visible) and long lived 
excited states. 3 4
Lanthanide ions are toxic to the body and need to be chelated to a ligand in 
order to be used in vivo. Common chelator designs that have been exploited are 
based on incorporating a cyclen macrocycle unit 1,4,7,10- 
tetraazacyclododecane-l,4,7,10-tetraacetic acid, (DOTA) and a linear chelator 
diethylenetriaminepentaacetatic acid (DTPA). They are both know to form 
lanthanide ion complexes of high stability and are shown in figure 2. 5
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Figure 2 The polyaminocarboxylic acid ligands DOTA and DTPA
The application of MRI contrast agents relies on the ability of the 
gadolinium(III) centre to influence the relaxivity of water molecules that results 
in an enhancement of the image quality. For lanthanide complexes to be used as 
luminescent agents a chromophore group needs to be incorporated onto the 
lanthanide(III) chelator. The chromophore is required to either sensitise the 
luminescence of the lanthanide metal centre [europium(III), terbium(III)], or 
could be a separate optical dye in a multimodal agent incorporating 
gadolinium(III). 2 6
The purpose of this work is to synthesise a range of multimodal lanthanide 
contrast agents that can be used in both MRI and optical imaging experiments 
and also specifically localise within a cell. The strategy to achieve this is to 
incorporate a linker unit between the chelated lanthanide and a functional unit
that is either an optical dye or causes cellular localisation/uptake. This linking 
unit could sensitise lanthanide luminescence [for example: europium(III)/ 
terbium(III)/ ytterbium(III)] or act simply as a linker between the MRI contrast 
agent component [gadolinium(III)] and an optical dye (see figure 3).
(Antenna)linkcr Optical ortargeting
group
Figure 3 Design template for dual modality imaging agents
1.2 The lanthanides
The lanthanides are a family of highly electropositive metals in period 6, 
composed of a series of fifteen elements in the /-block that correspond to the 
filling of the seven 4/orbitals (table I). 7
57La 6 |Pm 62 Sm 64Gd 65Tb 66Dy 0Yb
Table 1 Lanthanide metal ions
The chemistry of the lanthanides is dominated by their +3 oxidation state. 
Lanthanides have low charge densities, which leads to their compounds being 
predominantly ionic in character. The ionic radii of the lanthanides decrease 
steadily across the row and this is termed 'the lanthanide contraction' as shown 
in figure 4.
no -i
Ce Pr NH Pm Sm Eu Gd Tb Dy Ho Er Tm Yb Lu 
Figure 4 Ionic radii of the lanthanide ions across the period
The lanthanide contraction is caused by the increase in effective nuclear charge 
(Zeff) across the series due to the poor shielding ability of the 4f electrons. The 
lanthanide ions are classed as being hard in character, they tend to bond to O, N 
and F-donors and often have high coordination numbers ranging from 9-12. 8 
This preference for hard donors is thought to be because the 4f orbitals are too 
contracted to play any significant role in the bonding in lanthanide complexes. 
Thus, ligand-field stabilization energies are small and probably play little role in 
determining the geometry of complexes. Due to the unique properties of the 
lanthanides, they have found many uses in magnetic and luminescent materials. 7 
Some key properties are summarised in table 2.
Ln3+
Ce
Pr
Nd
Pm
Sm
Eu
Gd
Tb
Dy
Ho
Er
Tm
Yb
Lu
4f
1
2
3
4
5
6
7
8
9
10
11
12
13
14
ground level
J F5/2
X
I?/2
\
Hs/2
7F0
8<j^7/2
7 F6
HI 5/2
\
1 15/23 H6
"Fv/2
'So
colour
colourless
green
lilac
pink
yellow
pale pink
colourless
pale pink
yellow
yellow
rose-pink
pale green
colourless
colourless
g[J(J+l)]' /2
2.54
3.58
3.62
2.68
0.85
0
7.94
9.72
10.65
10.60
9.58
7.56
4.54
0
JU.
2.3-2.5
3.4-3.6
3.5-3.6
-
1.4-1.7
3.3-3.5
7.9-8.0
9.5-9.8
10.4-10.6
10.4-10.7
9.4-9.6
7.1-7.5
4.3-4.9
0
Table 2 Summary of the properties of Ln(III) ions, where g 
magnetic moment and |iobs is the observed magnetic moment
[J(J+lXr is the calculated
Gadolinium(III) is widely used in MRI contrast agents due to its magnetic 
properties, and because it has 7 unpaired electrons. Even though 
dysprosium(III) or holmium(III) look like better candidates to be used as MRI 
contrast agents because they have larger magnetic moments, the asymmetry of 
these electronic states leads to a very rapid electron spin relaxation. The 
gadolinium(III) symmetric S state is a more exploitable environment for 
electron spins and results in a slower electronic relaxation rate and a more 
effective MRI agents. 7 Another application of the lanthanides is their potential 
use as components of luminescent imaging agents. Luminescent lanthanides 
have a partially filled 4/ shell and can not be directly excited, therefore 
lanthanide emission is produced by the energy transfer from the excited state of 
a chromophore onto the metal centre. This results in the different energies 
levels of the lanthanide electronic terms, as shown in figure 5. These properties 
result in long wavelength emissions and relatively long lived excited states for 
the lanthanides in solution. As the emissions occur from symmetry forbidden 
excited states the lanthanides are only weakly emissive. 9
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1.3 Current commercial contrast agents
Lanthanide metal complexes have found use in many areas of research, 
including in the area of diagnostic medicine with the development of 
gadolinium(III) complexes for use as MRI contrast agents, and europium(III) 
and terbium(III) complexes being investigated as luminescent biological 
probes. 14 15
The advantage of MRI over other medical imaging techniques, such as X-ray, is 
to differentiate between soft tissues and this has increased its use in the clinical 
field. One of the main parameters in the production of a MR image is the 
proton relaxation time (Ti and r?). When there is poor contrast between healthy 
and pathological regions due to small variations in relaxation times, a contrast 
agent is used to alter the relaxation times of water protons within the tissue. In 
1999 approximately 30% of all MRI scans used a contrast agent, but this has 
increased to around 40 - 50% at present. 16 TI commercial contrast agents 
incoporate gadolinium(III) and manganese(II) ions and a positive image 
enhancement is observed i.e. brighter, while T2 contrast agents are usually based 
on iron(III) oxide particles and a negative image effect is observed i.e. darker.5 
Gadolinium(III) contrast agents affect the image by altering the relaxation times 
of the water protons within the tissue and lead to the enhancement of the 
brightness in the image. As free gadolinium(III) ions are toxic, they are 
therefore chelated to a ligand, with commercially used chelators including 
DOTA and DTPA.5 There are currently around eight gadolinium(III) contrast 
agents that are licensed for clinical use, see figure 6.
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Complex
[GdDTPA(H20)] 2-
[GdDOTA (H2O)]-
[GdHPDOSA (HsO)]
[GdDOSA-butrol (H2O)]
[GdDTPA-BMA(H20)]
[GdDTPA-BMEA(H2O)]
[GdBOPTA(H2O)] 2-
[GdEOB-DTPA (H2O)] 2 -
Brand Name
Magnevist®
Dotarem®
ProHance®
Gadovist®
Omniscan®
OptiMARK®
MultiHance®
Eovist®
Company
Schering
Guerbet
Bracco
Schering
Nycomed-Amersham
Mallinckrodt
Bracco
Schering
Table 4 Contrast agents that are licensed for clinical use
H2O 
[GdDOTA (H2O)]-
/ N'
H2O
[GdHPDOSA (H2O)]
0 H26 HO
[GdDO3A-butrol (H2O)]
2-
O
00,
2-
O
[GdDTPA(H2O)J 
O
\2-
[GdDTPA-BMA(H2O)] 
O
NH^
L_jT 
o o 
[Gd DTPA-BM EA(H2O)]
OCH3
2-
[GdBOPTA(H2O)]2- [GdEOB-DTPA (H2O)]2- 
Figure 6 Contrast agents that are licensed for clinical use
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The development of new MRI contrast agents is currently being investigated 
with the aim of increasing the relaxivity of contrast agents to improve image 
quality, to improve their sensitivity and also to target specific markers within 
the body, i.e. apoptosis. 1417
12
1.4 Magnetic resonance imaging
Magnetic Resonance Imaging (MRI) involves the natural production of net 
magnetization that occurs in the body when a magnetic field is applied. The net 
magnetization causes protons in the human body to align in the direction of the 
magnetic field (Bo). This includes any atom that contains a spin and the one 
commonly used to probe the body is hydrogen ('H). It is found in all tissues in 
the human body as they contain both fats and water with the relaxation of 
protons in these molecules forming the basis of the MRI signal.
The proton can be viewed as a small magnet; because it has spin, and a 
positively charged nucleus, therefore having a local magnetic field. A bar 
magnet has magnitude and orientation to this magnetic field (i.e. north and 
south pole), this is the same for the proton, with its spin having an axis of 
rotation with definite orientation and magnitude, and can be described in terms 
of a vector (figure 7).
Figure 7 Diagram to show the positive charge on the nucleus producing a magnetic field 
orientated parallel to the axis of rotation and its analogy to a bar magnet
MR measurements involve a collection of similar spins. When there is no 
magnetic field applied, the spin vectors in the tissue are orientated randomly, on 
application of a strong magnetic field the spin vectors align themselves parallel 
with the externally applied field BO, thus making the tissue a weak magnet 
(figures).' 8
13
External Magnetic field
I, H I:
J> J> J.
Random orientated protons
Orientated 
protons
Figure 8 Diagram to show the effect of an applied magnetic field B0 on the set of individual 
protons in fluid or tissue
The individual protons are not stationary in one position, and precess about the 
magnetic field. The precession is tilted slightly away from the axis of the 
magnetic field, but the axis of rotation is always parallel to BO, and is defined as 
being in the z direction (figure 9). 19
B/,
Bn ,Y
X
Figure 9 Showing a proton precessing about the magnetic field direction. The precessional axis 
is parallel to the main magnet field B0, in the z direction, with a frequency of precession of W0 
(also known as Larmor frequency), and a net magnetization of M
hi the z component there are spins in two orientations, parallel (spin up), and 
anti-parallel (spin down). Protons can swap between the two by simply gaining 
or losing energy. The energy difference between the two spins is directly
14
proportional to the strength of the external magnetic field. In equilibrium the 
protons are all out of phase with each other, and are either parallel or anti- 
parallel to magnetic field BQ. The vector sum is called the net magnetization 
MO, which is aligned exactly with the main field B0 . The entire field of MRI is 
based on the manipulation of this M value from the longitudinal to the 
transverse component, and allowing it to relax back. MRI involves a short pulse 
of radio frequency (rf) energy that contains many frequencies spread over a 
narrow range or bandwidth, causing protons to absorb the energy at a particular 
frequency. The frequency absorbed is proportional to the magnetic field BO (the 
Larmor equation coo = yBo). Absorption of rf energy frequency (o>o) at a 90° 
pulse, causes M to rotate into the xy plane (Mi), perpendicular to BO (figure 
10). 19
Z Z4 iuM f _v 90°
Figure 10 Diagram to show the effect of a 90° excitation pulse
When the rf pulse stops, the protons start to re-align themselves from MI and 
return to their equilibrium position M. A conducting wire detects the changes in 
the net magnetization M, because protons induce a voltage in the wire due to the 
changing field producing a radio frequency, and therefore producing a MRI 
signal. 18
The process of the net magnetization M, returning to the z plane is known as 
relaxation. Important parameters in MRI are the T/ relaxation times and the 7^ 
relaxation times. Tj relaxation provides the mechanism by which protons give 
up their energy to return to the z-component, and hence get an increase in the 
return in longitudinal magnetization. The excited protons do not transfer their 
energy to another spin, they actually release it to the surrounding lattice, and 
this energy does not contribute to the spin excitation. For these reasons, T/ 
relaxation may also be known as longitudinal or spin-lattice relaxation. T2 
relaxation is the process where the energy of one proton is transferred to a
15
nearby proton and the absorbed energy remains as spin excited. This is also 
known as spin-spin relaxation, or transverse relaxation time. Protons are 
contained in both fats and water with both longitudinal and transverse relaxation 
occurring rather rapidly in fats compared to water. As a result, fat protons have 
short TI relaxation times. In comparison protons in water molecules do not 
decay as efficiently as those in fat protons, because of their high mobility, and 
reduced ability to give up their energy to the lattice as effectively.20 In a MR 
image, you want to relax the water protons, and not fat protons. Contrast agents 
work by improving the MRI image, but do not directly interact with fat 
molecules and therefore will only affect water molecules.
16
1.5 Gadolinium(lll) contrast agents
Contrast agents are used in medical imaging when there is poor contrast 
between healthy and pathological tissues due to small variation in relaxation 
times. Consequently, this has led to improvements in medical diagnosis by 
providing better tissue characterisation with greater sensitivity and specificity. 
Gadolinium(III) acts as a T\ contrast agent by increasing the signal observed 
and resulting in a brighter area of the image where the contrast agent is located. 
Gadolinium(III) is toxic in the body as its ionic radii is very similar to that of 
calcium(II), as a result it can disrupt calcium signalling pathways and hence it 
needs to be chelated by a polydentate ligand. An important feature of 
gadolinium(III) contrast agents is that they should have at least one bound water 
molecule (q) so that it can be relaxed more rapidly and then undergo rapid 
exchange with water molecules in the bulk. This exchange is required to be 
rapid as the image obtained is representative of the relaxivity. Other factors that 
can affect relaxivity are shown in figure 11 and include the number of inner- 
sphere water molecules (q), their residency time (tm) and Gd-H distance (r), the 
2nd-sphere water (q') with its residency time (tm ), and Gd-H distance (r 1); and 
the tumbling correlation rate, (tR.). 2122
H
Figure 11 Illustration of the different parameters that influence relaxivity
Designing gadolinium compounds that are able to accommodate a greater 
number of bound water molecules q, have an optimally short water residence
17
time (Tm), and a slower tumbling rate (TR) should lead to an increase in the 
relaxivity of the contrast agent.
1.5.1 Increase the number of bound water molecules (q)
An increase in the number of bound water molecules (where q > 1) would 
result in a more efficient inner sphere relaxivity and an enhancement in the 
overall proton relaxation rate and image quality. 16 Forming gadolinium(III) 
complexes with 2- to 3- coordinated water molecules, can cause a decrease in 
their thermodynamic stability and lead to leaching of the gadolinium(III) ion 
therefore making it toxic. However, there are some examples of stable 
gadolinium(III) complexes with two bound water molecules, which offer 
comparable stability to current clinical agents and lead to an increase in 
relaxivity.23 24 Raymond and co-workers have reported a family of 
gadolinium(III) agents based on tris-(2-aminoethyl)-amine hydroxypyridinone 
that show a relaxivity of 10.5 mM" 1 s" 1 , while Merbach and co-workers have 
given an account of a dinuclear gadolinium(III) substituted with 
diethylenetriamine -A^Ar ',jV",A^'"-tetraacetate (DTTA) that is linked by the 
formation of a supramolcular complex with iron(III) (figure 12).25 26
r^N^i
Q.NH\ H HNv/0
coo
Figure 12 Gadolinium(III) agents based on hydroxypyridinone (left) and a dinuclear 
gadolinium(III) substituted with DTTA (right)
Raymond and co-workers have further developed the hydroxypyridinone 
(HOPO) complexes by replacing the tris-(2-aminoethyl)-amine (TREN) with 
triazacyclonane (TACN) as the ligand cap. 25 These stable complexes have three 
bound water molecules (q = 3) with relaxation enhancement of 12.5 mM'V. 
These complexes (figure 13) have also been shown to have improved water
18
solubility with over 1000-fold increase compared to the parent TREN series. 
However, such agents have not undergone extensive stability analysis so 
questions might arise about how they will respond under physiological 
conditions .
Figure 13 The molecular structure of Gd- TACN- 1,2-HOPO
Merbach and co-workers have also reported another supramolecular 
gadolinium(III) complex where the number of gadolinium(III) centres has been 
increased from 2 to 6 by switching to a 2,2'-bipyridine (figure 14) from the 
terpyridine used in their previous complex (figure 12), to form a metallostar, 
which results in an increase in the number of inner sphere bound water
i^f i 1
molecules (q) see figure 14." The relaxivity reported is 33.6 mM" s" at 40 
MHz. The increase in relaxivity is also due to the formation on the 
supramolecular structure, that leads to a reduction in the rumbling rate.
Figure 14 The structure of the metallostar molecular framework
Both Raymond and co-workers and Merbach and co-workers have presented 
novel gadolinium(III) complexes which clearly show that altering the number of
19
inner sphere water molecules can lead to significantly higher relaxivity values, 
and will result in brighter and better defined MRI images. Parker and co- 
workers have also investigated a supramolecular structure to alter the number of 
water molecules, however here, the number of outer sphere water molecules (q') 
has also been increased. 27 Here, a medium molecular weight conjugate that 
incorporates a sugar moiety dendritic wedge attached to a central 
gadolinium(III) complex has been synthesised. The compound is known to 
contribute to the 2nd sphere water molecule exchange and has been shown to 
have a relaxivity of 23.5 Mm'V 1 (298 K, pH 7, 20 MHz). This molecule can be 
renally excreted and should be cleared from the blood pool quickly after 
injection due to the presence of the sugar moieties.
1.5.2 Multiple gadolinium(lll) centres
Incorporating a number of gadolinium(III) ions in a molecular system can 
increase the relaxivity of a gadolinium MRI contrast agent and allow a lower 
concentration of gadolinium(III) contrast agent to produce a useful enhancement 
in the MR image.28 There are a number of approaches to tackle this challenge, 
including the metallostar structures that Merbach and co-workers have produced 
(figure 14).26 Alexander and co-workers have formed a tetranuclear Gd-DO3A 
showing a 5.86 times enhancement in relaxivity compared to 
[Gd(DO3A)(H2O)2)8]. 29 While other approaches involve the production of 
multi gadolinium(III) centres by forming micelles and nanoparticles. One such 
approach by Delville and co-workers uses either noncovalent or covalent 
binding of low-molecular weight Gd-DTPA chelates to metal oxide particles 
(SiO2, A12O3 ). 30 This has a relaxivity of 42 mM'V1 (4.7 T) for the silica doped 
nanoparticles, and by incorporating a rhodamine based dye they have shown 
that these agents are able to penetrate the cell membrane. An example has been 
been produced by Cho and co-workers, where a biocompatiable 
polysuccinimide (PSI) derivatives is conjugated with Gd-DTPA to form 
micelles, although no relaxivity data has been published yet. 31 More data is 
required to understand the effect these type of contrast agents will have in vivo, 
as micelle formation might be affected by physiological conditions and this 
could influence the overall relaxivity.
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Another line of approach is to form dendnmer based gadolinium(III) contrast 
agents. 32 There are numerous examples in the literature with a number of 
reviews on such compounds. 33 34 Merbach and co-workers have synthesised a 
DTPA based chelate containing a phosphinate group conjugated to a generation 
5 polyamidoamine (PAMAM) dendrimer via benzylthiourea linkages (figure 
15). 35 36 The relaxivity here was shown to be 26.8 mM'V at 37°C, 4.7 T, but 
this could potentially be increased if a way could be found to fully load the 
PAMAM G5 dendrimer with Gd-DTPA (currently only loading of 49% has 
been achieved).
ooc^.
OOC
Figure 15 Gadolinium(III) based dendritic complex based on PAMAM G5
Brechbiel and co-workers have also formed a dendritic MRI agent based on 
PAMAM G4, which is shown in figure 16. 37 This utilises a fourth generation 
polyaminoamido dendrimer bearing 2-(4-isothiocyanatobenzyl)-6- 
methyldiethylenetriamine pentaacetic acid (1B4M-DTPA) chealator complexed 
with gadolinium(III). Compared to the Merbach and co-workers complex, a 
much greater number of gadolinium(III) complexes are attached to the PAMAM
21
G4 dendrimer with 50 - 57 present per molecule. The compound was shown to 
be a potential vascular contrast agent to target intravascular agents with 
angiogenesis.
-2
O O /50-57 
Figure 16 Gd-B4M-DTPA-functionalized PAMAM G4 dendrimers
Dendritic gadolinium(III) compounds have huge potential as MRI contrast 
agents as they increase the number of gadolinium(III) ions on a single molecule 
which in turn leads to an increase in the relaxivity. 38 They are also known to 
alter the route of excretion and the potential function of the agent. Smaller 
dendrimer based contrast agents of less than 60 kD in molecular weight, are 
found to be excreted from the kidneys and have shown potential as blood pool 
contrast agents. The larger dendrimer based contrast agents are generally 
processed by the liver and have potential as lymphatic imaging compounds. 38
1.5.3 Responsive MRI contrast agents
While relaxivity is one way to expand the potential applications of a 
gadolinium(III) contrast agent, another way is to produce molecules that can 
respond to changes in their environment leading to the variation in the 
relaxivity, thus reporting on their environment. This event could be a change in 
physiological pH, metal ion concentration, enzyme activity or partial pressure of 
oxygen. 13 39"42 The contrast agent will respond to physiological changes by 
either 'switching on' (increase in relaxivity), or by 'switching off (decrease in 
relaxivity) allowing physiological or diseased states to be identified. There are
a number of examples in the literature of pH dependent probes.43 44 The
motivation for these studies stems from the fact that tumour tissue is more 
acidic, with pH values at around 6.8 - 6.9, while with healthy tissue this is 
around pH 7.4. Agents that can differentiate between the two have great
22
potential for pH mapping and locating tumour tissue. A number of approaches 
have been investigated to produce pH sensitive agents, including reversible 
intermolecular and intramolecular anion binding, and changes in water or proton 
exchange rates. Parker and co-workers have formed an agent based on (Gd- 
DOSAala) where to produce a variation in relaxivity due to pH, a reversible 
intermolecular anion binding event occurs as shown in figure 17.45 Here, the 
gadolinium(III) complex is coordinated to seven donors from the ligand and 
possesses two water bound molecules (q = 2). Displacement of the two water 
molecules by endogenous anions, results in a decrease in relaxivity. The Gd- 
DO3Aala showed about a 280% increase in relaxivity between pH 8 and 6 from 
1.9 mM" 1 s" 1 (q = 0) and 7.2 mM" 1 s" 1 (q = 2) at 20 MHz respectively.
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Figure 17 Gd-DO3Aala where R = CH(CH3)CO2" showing intermolecular anion binding on a 
pH sensitive probe
Another approach is a reversible intramolecular anion coordination, such as the 
gadolinium(III) compound Gd-SaDO3A.46 Changes in pH affect the hydration 
state which causes changes in relaxivity. This occurs because the sulphonamide 
group is protonated at lower pH (pH 5.5) and hence is not bound to the 
gadolinium(III) centre, which allows water molecules to complete the hydration 
sphere (q = 2) and leads to a relaxivity of 8.5 mM" 1 s" 1 . While at pH 8, the 
sulphonamide is not protonated and is able to displace the water molecules and 
bind to the gadolinium(III) (q = 0) leading to a decrease in the relaxivity (2.8 
) (figure 18).
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Figure 18 Gd-SaDO3A R = (CH3 )2 CO2', R' = CH3 showing intramolecular anion binding on a 
pH sensitive probe.
Sherry and co-workers have formed a pH activated contrast agent that has a 
response dependent on changes in proton exchange rates.47 Gd-DOTA-4AmP 
(figure 19) has been used to map tissue pH with a relaxivity of 5.3 mM"1 s" 1 at 
pH 6.3 (where q = 1) and 3.4 mM" 1 s" 1 at pH 9 (where q= 0). It is postulated that 
the pH responsive changes are due to protonation of the phosphonates that are 
believed to form a hydrogen bonded network that provides a catalytic pathway 
for the exchange of bound water protons with the bulk water. The compound 
has been shown to target the kidneys and identify the acidic regions.48
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Figure 19 Structure of Gd-DOTA-4AmP
These above compounds have shown that responses to variations in pH can 
result in an alteration of relaxivity. However, these compounds do not show 
sufficient sensitivity to differentiate between healthy and tumour tissue. 
Another area of research is to form MRI agents that can be activated by the
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presence of metal ions such as calcium(II) and zinc(II). Meade and co-workers 
have synthesised a molecule that displays an alteration of relaxation properties 
in response to a physiological changes in calcium(II) concentration (figure 
20). Calcium(II) (which plays an important role in signal transduction) binds 
to the carboxylates from the imidodiacetates allowing water access to the 
gadolinium(III) centres and increasing relaxivity from 3.3 mM" 1 s" 1 to 5.8 mM" 1
0. O O O
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Figure 20 Proposed conformational change of a calcium activated MRI agent
Meade and co-workers have also formed a MRI agent that can monitor enzyme 
activity through changes in relaxivity properties (figure 21). 50 In this case, Gd- 
DO3A bears a pendant /?-glucuronic acid moiety linked to the macrocycle by a 
self immolative linker. In the presence of the enzyme /?-glucuronidase, the /?- 
glucuronic acid is cleaved to allow the water to access the gadolinium(III) ion, 
resulting in a 20% increase in relaxivity. 51
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Figure 21 An enzyme activated MRI contrast agent
Meade's enzyme active contrast agent is irreversible, which may be an issue 
with specific monitoring of enzyme activity, as one /?-glucuronidase enzyme 
could cleave the /?-glucuronic acid linker on multiple gadolinium(III) contrast 
agents.
1.5.4 Targeted MRI agents
Most MRI agents distribute around the intravascular and interstitial space and 
can be classed as non-specific agents. Therefore there is great scope for 
designing agents that can target specific events and detect abnormalities to 
improve diagnostic accuracy. 52 53 "56 Typical target areas or events in the body 
for example include tumours, heart failure and cellular uptake. 57 5 "61 These 
agents could target and locate within a region e.g. cancerous tissue, and allow 
physicians to easily identify the disease. There are many approaches to target 
different tissues within the body including the use of antibodies and 
polypeptides. 54 62 Meade and co-workers have formed a progesterone modified 
DTPA based contrast agent that is able to target over expressed hormone 
receptors in cancers (figure 22). 63 The relaxivity of this molecule was shown to
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be 4.73 mM" 1 s" 1 at 4.7 T and in vivo, was shown to accumulate in the 
intracellular space resulting in a signal intensity increase.
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Figure 22 Structure of the progesterone conjugated MRI contrast agent
Another approach involves exploiting the interaction between avidin and biotin 
to form a supramolecular structure that would give target specific agents for 
angiogenesis (formation of new blood vessels). 64 65 A number of research 
groups have investigated the synthesis of MRI contrast agents that can target 
human serum albumin (HSA) and have the potential to be used as angiography 
contrast agents. 66 67 ' 68 Such an example has been developed by Caravan and 
co-workers where the amphiphilic gadolinium(IH) complex MS-325 
((rrisodium-((2-(R)-[(4,4-diphenylcyclohexyl)phosphonooxymethyl]- 
diethylenetriaminepentaacetato) (aquo) gadolinium(III))) has been produced 
(figure 23). 69 This agent has been shown to assess blockages in arteries by 
targeting HSA in the plasma. This targeting of HSA allows the complex to stay 
in the plasma compartment and extends the circulation time, hence results in 
better image differentiation of the blood vessels. Also by binding to HSA, the 
gadolinium(III) complex increases its relaxivity because of the slow rotation of 
the complex-protein unit, with a relaxivity value of 6.84 mM" 1 s" 1 at 4.7 T.
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Figure 23 Structure of gadolinium(III) MS-325
Significant progress has occurred in the synthesis of novel MRI agents. Current 
investigations include increasing the number of bound water molecules on the 
gadolinium(III) metal centre, an increase in the number of gadolinium(III) metal 
centres (i.e. dendrimers and micelles etc) and the synthesis of responsive and 
targeted gadolinium(III) contrast agents. Presently, the number of new 
gadolinium(III) agents that have been clinically accepted is limited as they must 
be shown to be cost effective and non-toxic.
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1.6 Lanthanide Luminescence
There are many examples of organic luminescent molecular probes that are used 
in imaging applications which are based on heterocyclic dyes such as rhodamine 
and MitoTracker (figure 24). 70
t cr H,N
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MitoTracker Red CMXRos Rhodamine
Figure 24 MitoTracker and Rhodamine luminescent molecular probes
They typically have short lived singlet excited states with lifetimes less than 10 
ns, broad absorption and emission bandwidths in the order of tens of nm, and 
they usually have small Stokes shifts. Luminescent lanthanide complexes have 
the advantage of 'delayed fluorescence' and hence provide an opportunity to 
probe biological systems with the interference from biological chromophores 
removed by time gating. Lanthanide complexes have been exploited for their 
luminescence properties and have shown great potential as materials for liquid 
crystal displays, organic light emitting diodes and as biological probes. 71 
Lanthanides have very low excitation coefficients (< 1 M" 1 cm"1 ) because the f - 
f transitions are Laporte forbidden and the 4f electrons are effectively shielded 
by the 5p and 6s electrons. For this reason, lanthanides need a highly absorbing 
chromophore to be able to act as a luminescent agent. The chromophore 
absorbs the excitation, followed by energy transfer onto the metal centre and 
finally leading to a metal centred sensitised luminescence.
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Figure 25 Schematic to show the energy transfer processes to sensitise emission
Figure 25 gives a very simple model of what occurs to allow lanthanide 
emission via sensitisation, this can also be shown in terms of the energy levels 
i.e. Jablonski diagram. The sensitisation pathway involves absorption of energy 
by the antenna into its excited singlet state (Si). This is followed by intersystem 
crossing of the chromophore to its triplet states, then energy transfer onto the 
lanthanide(III) metal ion and finally results in the metal ion sensitised 
luminescence when the transition to the ground state occurs. Figure 26 shows 
the typical process for an europium(III) ion. The triplet state of the antenna 
transfers its energy onto the 5Do followed by the internal conversion to the 
ground states 7Fy (J = 0 - 4) resulting in emission. As a consequence typical 
europium(III) emission bands are observed at about 580, 595, 615, 655 and 700 
nm.
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Energy
Intersystem 
.crossing
- 5D,Energy 
transfer
Excited triplet 
state
Excitation Emission
-7F6
-7F5
- 7/4
Ground state Eu3+
Figure 26 The sensitisation pathway of lanthanide luminescence for europium(III)
The wavelengths of the lanthanide emissions are relatively long with 
europium(III) emitting in the red and terbium(III) in the green region of the 
visible spectrum, while neodymium(III) and ytterbium(III) emit in the near
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infra-red region. They also have excited state lifetimes that occur in the milli or 
sub-microsecond for europium(IIl) and terbium(III) while neodymium(III) and 
ytterbium(III) are micro or submicro second range. These lifetimes are much 
longer than most organic chromophores, with singlet excited state (Si) lifetimes 
within 10 ns. As a result of this, the lanthanide emission can be distinguished 
from fluorescence emission because of this 'delayed fluorescence' by using a 
time-gated luminescence microscope. During a time gated luminescence 
experiment (figure 27), the short lived background fluorescence decays to 
negligible levels during an appropriate 'delay time'. These experiments 
therefore record after a 'x' gated time, leaving just lanthanide metal centre 
emission and removing the scattered light and short lived fluorescence from 
organic chromophores. 72
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Figure 27 Principles behind time-resolved long-lived luminescence
Time-gated experiments can be used to probe biological environments with 
lanthanide probes, as the lanthanide luminescence allows for the fluorescence 
from biological chromophores to be removed, hence offering greater reliability 
in monitoring biological systems with more clearly defined images. 8 I0
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1.7 Luminescent lanthanide complex design
To design luminescent lanthanide complexes for imaging, the number of bound 
water molecules ideally should be zero (q = 0) to prevent the loss of energy by 
non-radiative transfer processes (quenching) and the sensitising antenna has to 
be close to the lanthanide metal centre to allow for fast and efficient energy 
transfer. The luminescence from lanthanide excited states can be quenched by 
radiative or through non-radiative deactivation to the ground state. Non- 
radiative processes are promoted by high frequency vibration modes of nearby 
or coordinated solvent molecules (X-H). The quenching is therefore increased 
(i.e. decrease in luminescence) by the co-ordination of water molecules (when q 
> 0). This is because of the abundance of O-H oscillators that result in the 
overlap of energy levels and stretching vibrations. Other vibrational overtones 
that are known to quench luminescence include N-H, C-H and C=O, although 
not as efficiently as O-H. While deuterated oscillators (i.e. O-D, C-D, N-D) are 
less effective at quenching luminescence as they are of lower frequency and 
require more energy to interact with excited states of the lanthanide metal ion. 
Another issue is the choice of chromophore, it needs to absorb light efficiently 
at a suitable wavelength and possess a fast intersystem crossing to the triplet 
state (Si to TI) to allow for efficient energy population of that state. The energy 
of the chromophore has to be higher than the energy of the lanthanide excited 
state for the sensitisation process to be thermodynamically favourable. 73 For 
europium(III) and terbium(III) the energy acceptor levels are at 581 nm and 490 
nm respectively, which means the triplet energy state should be higher then 455 
nm preventing thermally activated energy back energy transfer onto the 
chromophore interfering with lanthanide luminescence. Therefore, the 
chromophore needs to have a high triplet energy and a small Sj - TI energy gap 
to allow for excitation to occur in the range of 300 - 430 nm.74
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1.7.1 Sensitisation of lanthanide luminescence by a 
chromophore
As shown in section 1.5, a chromophore can be incorporated onto a lanthanide 
chelator to sensitise the luminescence of the lanthanide metal to result in long- 
lived emission. A number of approaches to form novel luminescent lanthanide 
complexes involve the attachment of the chromophore to either a polydentate 
ligand such as DTPA, or a macrocyclic ligand such as DOTA (figure 2).75 76 
Attachment of the chromophore, can influence the excitation properties and may 
lead to a more efficient overlap between the lanthanide metal ion excited state 
and chromophore triplet state. Couchet et al. have formed a europium(III) 
complex based on a bis(pyridine) DTPA structure (figure 28).4 The 2,2'- 
bipyridine chromophore does not co-ordinate to the metal centre and acts purely 
to sensitise the europium(III) metal centre. The system produces quantum 
yields (O) of 2.8% and emission lifetimes (T) of 0.58 ms both in water 
(excitation at 285 nm, pH 8.6, 295 K). While Werts et al. have synthesised a 
system, again based on DTPA, and incorporated fluorescein, with a 
ytterbium(III) metal ion (figure 28). 74 Ytterbium(III) is known to emit in the 
near-infrared region and is much lower in energy. Emission lifetimes (T) of 
1.91 ms in water were observed after excitation at 510 nm.
o
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Figure 28 Structures of europium(III) 2,2'-bipyridine DTPA (left) and ytterbium(III) DTPA 
fluorescein (right)
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There are numerous examples in the literature of molecules based upon DOT A 
as the chelating ligand. 77 78~80 One example involves the incorporation of 
azaxanthone sensitising chromophores with europium(III) and terbium(III) 
complexed to DO3A (figure 29).81 The emission lifetimes are reported as 0.57 
ms and 1.82 ms, with quantum yields of 6.9% and 24% for europium(III) and 
terbium(III) respectively. Thus showing that with azaxanthone as the 
chromophore, the terbium(III) shows greater sensitisation and leads to an 
enhanced luminescence.
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Figure 29 Azaxanthone DO3A sensitising ligand (where Ln = europium(III) and terbium(III))
The chromophore unit can also have a dual function, as it is able to sensitise and 
encapsulate the lanthanide metal ion. 82 Raymond and co-workers have been 
involved in synthesising a range of octadentate ligands that form luminescent 
lanthanide complexes. 24 Carrying on the work based on l-hydroxypyridine-2- 
one (1,2-HOPO) derivatives, a europium(III) H(2,2) (N,N,N',N"-teti:akis-(2- 
aminoethyl)-ethane-l,2-diamine)-l,2-HOPO that has a emission lifetime of 738 
(is and quantum yield of 3.6% has been reported (figure 30). 83 The molecule 
contains no bound water molecules and this leads to an improvement in its 
luminescent properties. Another lanthanide metal ion complex is again based 
on H(2,2), however this time it contains four 2-hydroxyisophthalamide 
chelating groups (H221AM), with the europium(III) and terbium(III) complexes 
formed (figure 30). 84 The emission lifetimes have been found to be 1271 us 
(Tb(III)) and 784 us (europium(III)) while the quantum yields are 63% 
(terbium(III)) and 2.3 % (europium(III)). This ligand architecture is able to 
sensitise the different lanthanide ions, with a strong preference for terbium(III), 
probably due to the energy gap between the chromophore and metal centre 
being the best match.
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Figure 30 Two chelating ligands of H(2,2)-1,2-HOPO (left) and H221AM (right)
1.7.2 Lanthanide luminescence sensitised by transition metal 
complexes
Ruthenium and chromium complexes have been used as chromophores for 
lanthanide sensitisation as they are known to possess intense, low energy and 
tunable charge transfer absorption bands making them a good alternative to 
organic based chromophores like fluoroscein. 85 86
Gunnlaugsson and co-workers have produced a mixed-lanthanide-transition 
metal (f-d) complex based on a cyclen-ruthenium coordination conjugate (figure 
31). 87 The cyclen unit bears a 1,10-phenanthroline moiety that is complexed to 
a Ru-bipyridine (bipy), with both the ytterbium(III) and neodyium(III) 
complexes formed.
+5
Yb1Ru-Ln = 
Nd1Ru-Ln =
Figure 31 Structures of ytterbium(III) and neodyium(III) complexes of the Ru(bipy)2 conjugate
35
Complexation of the Ru(bipy)2 conjugate leads to lanthanide luminescence in 
the NIR through excitation by metal to ligand charge transfer (MLCT) 
transitions through the chromophore. These complexes lead to intense emission 
bands as the lanthanide metal centre can effectively be sensitised by the 
chromophore or by the MLCT band. 87 Another approach is to use transition 
metals to form supramolecular structures, which will in turn enhances the 
luminescence because of the increase in the number of lanthanide metal ions. 
Nagano and co-workers have developed a luminescent lanthanide sensor for 
zinc(II) based on a europium(III) DTPA unit with a quinoyl moiety as the 
antenna (figure 32). 88
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Figure 32 Structure of europium(III) N-[N-(2-N,N -bis(2-pyridylmethy\)-aminomethylqumolin- 
6-yl)carbamoylmethyl]-./V,N ',7V ",N" '-diethylenetriaminetetraacetic acid
Upon addition of zinc(II), changes occur in the time delayed emission (8.5 fold 
increase upon addition of 1.0 equivalents of zinc(II) with a large Stokes shift of 
> 250 nm), absorbance (3 peaks of 330, 318, and 249 nm change to 2 peaks of 
320 and 253 nm) and fluorescence spectra [increase of fluorescence intensity up 
to 1.0 equivalents of zinc(II)]. These changes occur because there is a 
photophysical change in the quinoyl moiety upon addition of zinc(II), which in 
turn leads to a decrease in the number of bound water molecules from 1.42 to 
1.22, and results in a change luminescence decay (T) in D2O from 2.03 to 2.23 
ms.
1.7.3 Multinuclear lanthanide complexes
Multinuclear lanthanide f-f architectures have shown great promise as 
luminescent complexes. 89 90 ' 91 Gunnlaugsson and co-workers have formed a 
bis-cyclen dinuclear lanthanide complex with lanthanum(III), europium(III) and
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terbium(III), see figure 33. 92 However here, the chromophore is a less effective 
para-xylene unit, which weakly sensitises the lanthanide metal ion. To enhance 
the lanthanide emission, carboxylate anions are added e.g. pimelic acid, that can 
cause a displacement of the metal bound water molecules. The displacement 
causes the formation of a self assembly ternary complex between the 
carboxylate and lanthanide metal ion. Upon coordination of pimelic acid it was 
shown that a 13% luminescent enhancement occurs with the terbium(III) 
complex.
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Figure 33 Structure of the bis-cyclen lanthanide complex where Ln = europium(III), 
terbium(III), lanthanum(III)
A more interesting approach is to form mixed lanthanide complexes. Tremblay 
and co-workers have done this by producing a cocktail of terbium(III) and 
europium(III) complexes based on DTPA and containing the chromophore
carbostyril 124 (figure 34). 93
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Figure 34 Structure of the Ln-DTPA carbostyril complex, where Ln = europium(III) or 
terbium(III)
Faulkner and co-workers have produced a mixed luminescent lanthanide 
complex that bears two DO3A and one DTPA ligands as shown in figure 35.94 
This trinuclear complex contains two terbium(III) ions that are sensitised by the
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ytterbium(III) ion. The two terbium(III) ions are coordinated to DO3A, and the 
ytterbium(III) binds to the DTPA unit.
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Figure 35 Structure of the ytterbium(III)/terbium(III) complex
The near-IR emission from ytterbium(III) gave lifetimes of 1.8 (water) and 5.2 
p,s (deuterium oxide). This system is luminescent in both the visible 
(terbium(III) emission) and near-IR (ytterbium(III) emission) region. 
Ytterbium(III) is excited at 488 nm and results in near-IR emission at 980 nm 
with lifetimes of 4.2 |us in
1.7.4 Responsive luminescence lanthanide agents
Lanthanide complexes that can modulate lanthanide emission by external inputs 
such as pH, '02 partial pressure and presence of selective ions have great 
potential to act as sensors for environmental and biological sensing. This will 
allow for monitoring of environmental or biological stimuli by effectively 
switching 'on' or 'off the luminescence. 95 % Parker and co-workers have 
formed a Eu-DO3A based unit containing a 2-methyl quinoline moiety that acts 
as both a chromophore and receptor (figure 36). 9y In basic conditions the 
lanthanide emission is 'switched off while in acidic conditions the emission is 
'switched on'. The emission starts to decrease when the pH gets to above 4.5 
and leads to a significant decrease at pH 9, above which the emission is 
completely quenched. This is believed to be associated with the deprotonation 
of the quinoline nitrogen. The complex has been incorporated into a hydrogel
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and has been shown to retain its properties, and shows promise as a fluorescent 
pH sensor. 98
— N
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Figure 36 A pH sensor based on Eu-DO3A based unit containing 2-methyl quinoline
Yuan and co-workers have produced a europium(III) complex of the ligand [4'- 
(10-methyl-9-anthryl)-2,2' :6 ',2' '-tetrpyridine-6,6 '-diyl]bis(methylenenitrilo) 
tetrakis(acetate), (MTTA- europium(III)) which is able to probe singlet oxygen 
('02) concentration (figure 37)." Singlet oxygen is important as a probe for 
biological sensors because it is a toxic species that is associated with cell 
signalling cascades, and the destruction of malignant cells. This complex can 
specifically react with 'Ch and form an endoperoxide [EP-MTTA- 
europium(III)] that is accompanied by an increase in luminescence quantum 
yield of 0.9 to 13.8% and lifetime of 0.8 to 1.29 ms. The variation in emission 
properties in the presence of singlet oxygen suggests it could be applied as a 
sensor for biological changes e.g. apoptosis.
-1
Figure 37 The singlet oxygen sensor based on a europium(III) complex
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A number of research groups have investigated lanthanide complexes that show 
an alteration in the luminescent properties upon binding of an anion.' 00 
Faulkner and co-workers have reported a series of ytterbium(III) and 
neodymium(III) complexes of DO3A that can interact with a carboxylate or 
phosphonate containing molecule that acts as a chromophore and results in 
'switching on' of the lanthanide emission (figure 38). 101 This is a very similar 
system to Gunnlaugsson and co-workers bis-cyclen complex discussed in 
section 1.6.3, where an increase in luminescence occurs upon the interaction of 
an anion (figure 33).92
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Figure 38 Self assembly of the DO3A based complex where upon interaction of a anion can 
lead to lanthanide emission, where Ln = ytterbium(III) and neodymium(III)
1.7.5 Targeted luminescent lanthanide agents
For imaging biological systems and sensing applications, it is a major advantage 
to understand cellular localisation and to be able to target cells in vivo with 
lanthanide complexes. Parker and co-workers have produced numerous 
lanthanide complexes that can used for cellular imaging (figure 39). l02 One 
such example is based on cyclen and bears a tetraazatriphenylene chromophore, 
it is taken up by mouse fibroblasts (NIH 3T3) cells. The europium(III) complex 
has an absorbance maximum at 340 nm and emits with a millisecond lifetime in
the range of 480 to 720 nm. 103 104
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Figure 39 The lanthanide complex bearing a tetraazatriphenylene chromophore synthesised by 
Parker and co-workers 104
Romieu and co-workers have formed an aminopropargyl derivative of the 
terpyridine-bis(methyl-enarnine) tetraacetic acid chelate (Eu(TMT)-AP3) that 
has been used for fluorescent labelling of proteins and peptides. 105 It contains a 
capase-3 enzyme substrate dye that is able to detect capase-3 (a component 
known to be involved in apoptosis) (figure 40). In the presence of caspse-3, 
(Eu(TMT)-AP3)capase-3 enzyme substrate conjugate is cleaved and results in 
an increase in lanthanide luminescence. However, it has been shown that after 
cleavage, (Eu(TMT)-AP3) does not maintain its original photophysical 
properties, and more work will be needed to improve the properties of these 
compounds.
H03S
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Figure 40 Structure of (Eu(TMT)-AP3)capase-3 enzyme substrate
,H
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1.8 Multimodal imaging agents
Development of multimodal lanthanide imaging agents that can be imaged by 
both MRI and by fluorescence microscopy, and target cellular function are a 
major target for development in the area of biological imaging agents. 
Multimodal imaging agents will help in the understanding of disease states by 
allowing targeting units to localise in diseased tissue, and through simultaneous 
MRI visualizing the body and high resolution fluorescence imaging, the 
mechanism of diseases may be understood.
There are a number of contrast agents that show the potential to be able to target 
specific tissues or cell types and be visualised by either MRI or luminescence 
spectroscopy.' 73 ' l06 However, there are a limited number of compounds that 
are able to do all three. Mishra et al. have formed a Gd-DO3A-ethylenediamine 
complex that bears a fluorescent dye (figure 41).' 07 In this design, the 
gadolinium(III) unit acts as an MRI contrast component, while the fluorescein 
unit allows the complex to be detected by fluorescence microscopy when it is 
taken up by cells. The compound has a relaxivity value of 5.36 s^mM" 1 at pH 
7.4, and has been shown to be taken up by cells (3T3 mouse fibroblasts) using 
fluorescence microscopy and labelled cell pellet MRI experiments.
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Figure 41 Structure of the Gd-DO3A fluorsecein complex
Bornhop and co-workers have gone for a different approach in forming
i nsmultimodal lanthanide agents. Here, a 'cocktail' of 
europium(III)/gadolinium(in) peripheral benzodaiezpene receptor (PER) 
mediated cyclen agents (PK11195) have been produced (figure 42). PER is a
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protein that is located in the mitochondria and is associated with a number of 
biological functions including immunomodulation and apoptosis. PBR has been 
identified as a factor in Alzheimers and Huntingtons disease. A 'cocktail' 
solution of 40% Eu-PKl 1195 and 60% Gd-PKl 1195 has been shown to localise 
within the mitochondria in the cells (glioblastoma cells) using fluorescence 
microscopy, and an increase in the relaxivity is observed in cell pellet MRI 
experiments, also showing cellular uptake has occurred. The Gd-PKl 1195 
complex has relaxivity of 5.94 mM" 1 s" 1 , which is comparable to the known 
contrast agent Magnevist (6.45 mM" 1 s" 1 , 4.7 T) with the added ability to target 
cells.
-1
Ln = Gd(lll), Eu(lll)
Figure 42 Structure of Ln-PKl 1195
Meade and co-workers have published an interesting compound Gd(DTPA)- 
tetramethyl rhodamine amine dextran (GRID), that has been show to track stem 
cell transplants (figure 43). 109 This is a similar design to a compound used in 
the work of Mishra et al. as the gadolinium(III) component can be used to 
image through MRI, the rhodamine unit can be detected using fluorescence 
microscopy, and cell targeting is achieved via the dextran unit. 107 This 
compound has been shown to accumulate in cells (MHP36) by the use of 
fluorescence microscopy and a MRI cell pellet experiment. Further studies 
have also indicated that GRID is able to locate within cells and remain
detectable for up to 7 days. 109
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Figure 43 Structure of GRID
Cell grafts of GRID loaded cells have been inserted into an animal brain. MRI 
has shown that the grafted region can easily be located, with histology studies 
carried out using fluorescence microscopy also matching the grafted regions.2
An interesting method exploited in the formation of multimodality agents is the 
use of lipids with annexin A5 to form supramolecular structures. Annexin A5 is 
known to detect the expression of phospholipid phosphatidylserine (PS) which 
is associated with apoptosis. Nicolay and co-workers have formed a Gd-DTPA- 
bis(stearylamide)lipid that contains a lipid biolayer of pegylated liposomes to 
form micelles with annexin A5 covalently coupled (figure 44). 6 Also 
incorporated into the bilayer are fluorescent lipids that allows for fluorescent 
imaging. The study showed that these annexin A5 lipid nanoparticles have the 
ability to target and locate in apoptotic cells as detected using MR and 
fluorescent imaging experiments. Strijkers and co-workers have formed 
annexin A5 conjugates with quantum dots that contain a paramagnetic lipid 
coating (figure 44). The quantum dots act as a fluorescent dye, annexin A5 
targets apoptotic cells, the lipid bilayer makes it water soluble and the Gd-
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DTPA incorporated into the bilayer allows for MRI image contrast. The agent 
has been shown to target apoptotic cells by MRI and fluorescent imaging.
I Annoxm A5-qrs
Gd-DTPA-BSA
M]\fO= Mal-PEGMOO-CSPE
PEG2DOO-DSPE
O= DSPC
o$j> Cktesterol
•= P6-cart»)cyflijofescein
Figure 44 Structures of the annexin A5 supramolecular structures, Nicolay and co-workers 
complex (left) and Strijkers and co-workers (right) 110 6
It is clear from the number of publications in the area of lanthanide contrast 
agents as imaging probes that it is an area of major current interest. Important 
developments have been made in the performance of gadolinium(III) contrast 
agents in MRI and luminescent lanthanide metal ion compounds for use as dyes 
in fluorescence microscopy. Multimodal contrast agents that have the potential 
to target biological tissue and provide the opportunity to do simultaneous 
visualisation (MRI and luminescence) also show great promise. There is still a 
long way to go before they could be accepted for clinical trials and commercial 
applications. Comprehensive in vivo and in vitro pharmacological and 
toxicological analyses must firstly be undertaken to assess safety and efficacy of 
potential contrast agents.
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1.9 Purpose of work
The overall aim of the work presented in this thesis is the design, synthesis and 
characterisation of multimodality lanthanide imaging agents. The research 
involves the synthesis of a series of lanthanide chelators based on DO3A (31) 
(chapter 4) bearing a benzimidazole derivative (7) (chapter 2) that can act as 
both a chromophore unit and a linking group for conjugation and that has 
functionality to couple to an optical dye (either rhodamine or BODIPY 
derivatives as discussed in chapter 3). The role of the DO3A chelator is to 
successfully bind the lanthanide ion to prevent release of this toxic metal centre. 
The benzimidazole derivative was developed as it can act as a chromophore to 
sensitise the lanthanide metal ion. Simultaneous work was performed on an 
alternative to the benzimidazole derivatives in their role as a 
chromophore/linker group, the benzyl derivative (4-nitrobenzylbromide) that 
has previously been characterised. 78 Optical dyes based on rhodamine and 
BODIPY have been designed to efficiently conjugate to the chromophore/linker 
groups, and to function as a highly fluorescent dyes and to influence localisation 
within the cell.
Other researchers have successfully exploited DO3A-based chelators in the 
preparation of lanthanide imaging agents, however DO3A benzimidazole 
chelators have not been previously investigated. Benzimidazole has a number 
of highly appropriate properties for use in lanthanide chelators. It can 
coordinate to the metal centre via the N-donor, act as a sensitising chromophore 
and be functionalised through the N-H group to attach targeting biomolecules or 
optical dyes. Benzimidazole synthesis is well known in the literature, although 
limited research has been carried out to prepare precursors that allow for the 
linkage of two molecules, for example DO3A and the further attachment of a 
fluorescent dye [rhodamine and boron dipyromethenes (BODIPY)] (figure 45). 
In this work, lanthanide complexes of DO3A bearing a benzimidazole precursor 
have been prepared and characterised, and further investigations to form 
complexes bearing a fluorescent dye to produce multimodal contrast agents for 
MRI and luminescence imaging have also been carried out.
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Linker
Lanthanide 
chelator
V 
Optical dye
Figure 45 A proposed multimodal lanthanide complex (Ln-DO3A (chelator) in red, 
benzimidazole precursor in blue (linking unit), and BODIPY (optical dye) in purple
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2. Synthesis of benzimidazole derivatives
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2. 11ntroduction
For a luminescent lanthanide contrast agent to function efficiently and emit 
fluorescence of a detectable intensity, a chromophore group is required to 
sensitise the lanthanide metal centre. In the literature, there are many reported 
examples of different organic chromophores that can efficiently absorb and 
transfer energy to sensitise lanthanide metal centres, for example 1,10- 
phenanthroline and anthracene as shown in figure 46. 87 ''' The benzimidazole 
group can also be used as a sensitising chromophore (figure 47) with the 
additional advantage that it can be N-substituted at the 1-position and C- 
substituted at the 2-position to allow for further functionality to be incorporated.
1,10-phenanthroline anthracene
Figure 46 Structure of typical organic chromophores used to sensitise the emission of 
lanthanide ions, 1,10-phenanthroline and anthracene
This chapter focuses on discussion of the methodology used to synthesise 
benzimidazole derivatives that can be used as both a chromophore unit to 
sensitise lanthanide metal ions and as a linker group to allow for conjugation to 
optical dyes (discussed in chapter 3).
2.1.1 Benzimidazole
A benzimidazole unit consists of a phenyl ring fused to an imidazole ring as 
shown in figure 47. This unit has the potential to be used as an organic 
chromophore for lanthanide sensitisation due to the highly conjugated n system 
and well characterised procedures for functionalisation to facilitate 
incorporation into a chelating ligand.
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Figure 47 Molecular structure of benzimidazole
Benzimidazole containing compounds are present in nature and one of the most 
well known systems is (5,6-dimethyl-l-(a-D-ribofuranosyl)benzimidazole, 
which is an integral part of the structure of vitamin B ]2 . More recently 
benzimidazole based compounds have been incorporated into pharmaceutical 
agents and have been used as DNA intercalators. 112 " 3 For example, 2-[(4- 
diarylmethoxy)phenyl]-benzimidazole has been identified as a potential 
inhibitor for the infectious disease hepatitis C, and other substituted 
benzimidazoles have shown promise as DNA intercalating chemotherapeutic 
agents for the treatment of cancer. 114 115 ' 116
Benzimidazoles have been used as components of metal chelating ligands and 
more specifically in ligands used to form luminescent lanthanide complexes. 
This has been successfully exploited by Yang et al. in a study where a series of 
tripodal Hands based on bis(2-benzimidazolylmethyl)(2-pyridylmethyl)amine 
and bis(2-pyridylmethyl)(2-benzimidazolemethyl)amine (figure 48) were 
synthesised and the gadolinium(III), praesodymium(III), ytterbium(III), 
europium(III) and terbium(III) complexes prepared. 117
Figure 48 Structure of two tripodal ligands; bis(2-benzimidazolylmethyl)(2- 
pyridylmethyl)amine (left) and bis(2-pyridylmethyl)(2-benzimidazolemethyl)amine (right)
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2.2 Strategy for the preparation of multi-functional 
benzimidazole derivatives
The advantage of the benzimidazole unit is that it has the potential for multi- 
functionalisation. It can act as a sentising chromophore unit but it can also be 
used as a linking group to attach optical dyes to a chelating ligand, which will 
either be directly detected or offer alternative wavelengths for lanthanide 
sensitisation. To prepare a benzimidazole that can act as a dual functional 
component, a number of key synthetic steps are needed. These steps include: 1) 
attachment of the benzimidazole to the chelating ligand via the carbon at the 2- 
position to allow for the formation of a 5-membered chelate ring on 
coordination of the metal centre, 2) attachment of additional functional groups 
at the 1-position for linking an optical dye and 3) coordination of a metal centre 
with binding via the N-donor at the 3-position.
Nitrogen to coordinate 
to lanthanide
Substitute at 2-position to 
attach to chelator
Attach benzyl amine to 
conjugate to optical dye
X=CI, Br
R = NO2 , NHCOCH3
Link to optical dye unit
Figure 49 Target multi-functional benzimidazole derivative
A target multi-functional benzimidazole is depicted in figure 49. Each of these 
reactions is considered in turn. A key step in this process is the initial 
attachment of either a nitro benzyl or amide benzyl group onto the N at the I - 
position. The nitro or amide functionality can be converted to an amine at a 
later stage (see chapter 4). Substitution of the carbon at the 2-position can be 
facilitated via the formation of a methyl halide that will react with the secondary 
amine on the DO3A chelator (31). Formation of the benzimidazole derivative
51
can be achieved using chloroacetic acid (modified Philips method) or 
orthoesters as reagents. 118 The remaining nitrogen at the 3 -position will 
ultimately coordinate to the lanthanide metal ion, potentially allowing for 
efficient sensitisation via the benzimidazole chromophore as it will be directly 
bound to the metal centre.
2.2.1 Synthetic methodology to produce multi-functional 
benzimidazole derivatives
The synthesis of benzimidazole derivatives that are functionalised at both the 1- 
and 2-position (figure 48), can involve a two-step process with either a 
cyclisation step to form the benzimidazole unit carried out first, or the initial 
attachment of a nitro or amide benzyl group onto the nitrogen at the 1 -position. 
Previous work has shown that either step can be undertaken first, and the two 
proposed methods are shown in figure 50. Method 1 involves the mono 
substitution of one of the amines on the phenylenediamine, followed by the 
cyclisation to yield the benzimidazole compound. While method 2 carries out 
the cyclisation first, followed by a nucleophilic substitution of the amine at the 
1-position. Both of these methods have been exploited in the literature in the 
synthesis of benzimidazole derivatives with the desired functional groups. 119 12°
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o*. Method 1
-NH2
-MH XCH2R'
Method 2
Figure 50 Two potential strategies to synthesise benzimidazole precursors (where R = 
NHCOCH3 or NO2 , R' = CNHOCH3 , or COOH, X = OH, Cl or Br,)
Methods to synthesise benzimidazoles substituted at the 1-position are well 
documented in the literature. This can involve nucleophilic substitution at the 
nitrogen with either an alkyl halide or an acid chloride. 121 122
2.2.2 Strategy for the cyclisation step to form benzimidazole 
derivatives
In the literature a variety of different routes are reported for the synthesis of 
benzimidazole derivatives that have been functionalised at the 2-position, 
including the formation of the 5-membered ring using carboxylic acids, solid-
phase routes, nitroanilines, and orthoesters. 
of these reactions are summarised in figure 51.
123 124-128 Representative examples
53
Aldehydes Orthoesters
NH,
NHR'
™'
O
*
Carboxylic acids
K2C03
HCI
NH,
NHR'
NH2
O
Solid-phase
RC(OMe)3
Nitroanilines
Figure 51 Summary of reactions to synthesis benzimidazole derivatives
While both the nitroaniline and the solid-phase route provide interesting 
alternatives in the synthesis of benzimidazoles, in this case they are not suitable. 
The solid-phase route would give products that do not contain the desired 
functionality and both methods involve multi-step reactions with expensive 
precursors. The synthesis of benzimidazoles using aldehydes was considered. 
Das et al. have reported the synthesis of a series of benzimidazole derivatives 
that were obtained by treating 1,2-phenylenediamine with substituted aldehydes 
in the presence of (bromodimethyl)sulfonium bromide at room temperature, 
with percentage yields of 72 - 91% (figure 52). 129 Similarly Gogoi et al have 
combined a series of substituted aldehydes with 1,2-phenylenediamine in water 
in the presence of potassium carbonate, iodine and potassium iodide (figure
52). 130
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o(Me2SBr)Br 
MeCN
rt, 4-8 h
I2 , Kl, K2C03 , 
H20
Figure 52 Synthesis of benzimidazoles using (bromodimethyl)sulfonium bromide (top), and 
potassium carbonate, iodine and potassium iodide (bottom)
A search of the available chemicals database did not reveal any suitable 
substituted aldehyde derivatives that were commercially available. As a result, 
this was not investigated further. Efforts then focused on the carboxylic acid 
and orthoester routes.
Section 2.3-2.5 details the results obtained using method 1 and section 2.6 
contains the results obtained using method 2. A discussion of the synthesis of 
benzimidazole precursors is also presented.
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2.3 Synthesis of benzimidazole derivatives - method 1
Method 1 involves the mono alkylation of 1,2-phenylenediamine with a benzyl 
derivative, where R2 is an aldehyde (imine formation followed by reduction) or 
an alkyl bromide group, followed by the cyclisation to form the benzimidazole 
derivative by reaction with either a carboxylic acid or orthoester. The general 
synthetic scheme for method 1 is shown in figure 53.
R1
Figure 53 Synthetic route to a benzimidazole derivativised at Nl (where R 1 = NHCOCH3 or 
NO2 , R2 = CH2Br or CHO(needs to be reduced before cyclisation), R3 = CNHOCH3 , or COOH 
and X = Cl or Br)
Herault et al. have employed this strategy in the synthesis of 2-ferrocenyl-Ar-n- 
butylbenzimidazole by functionalising the phenyl unit first, then treating the 
molecule with ferrocene carboxaldehyde to form the benzimidazole 
compound. 121 The reaction involves aromatic nucleophilic substitution of n- 
butyl amine onto 2-bromonitrobenzene, followed by reduction of the nitro group 
to form an amine and finally condensation with ferrocene carboxaldehyde to 
give the benzimidazole functionalised ferrocene in 63% overall yield. The 
reaction is shown in figure 54.
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n-butylamine 
DMSO
ferrocene carboxaldehyde 
oxone
DMF, H2O, rt
n-Bu
H2 , Pd/C(10%) 
MeOH, rt
n-Bu
Figure 54 Synthesis of 2-ferrocenyl-7V-n-butylbenzimidazole
The next stage in the synthetic scheme involves the cyclisation of the 
substituted phenylenediamine to form the benzimidazole precursor. The 
proposed method involves a modification of the Phillips synthesis where the 
benzimidazole precursor is condensed with either chloroacetic acid or 
chloroacetimidate orthoesters. 131 132
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2.4 Synthesis of amide bearing benzimidazoles
The initial strategy involved the use of an amide derivative that can be readily 
converted to an amine at a later stage by acid hydrolysis. This would be carried 
out after the attachment of the benzimidazole to the DO3A chelator (31), thus 
both the acid arms and amine site can be deprotected at the same time. This 
offers an advantage over the route using the nitro compound because there are 
fewer steps in the overall synthetic scheme (the nitro group must be reduced in a 
separate step to the deprotection of the acid arms).
2.4.1 Attempted synthesis of 1-(4-acetamidobenzyl)-2- 
chloromethyl benzimidazole (3)
The synthetic scheme for the preparation of l-(4-acetamidobenzyl)-2- 
chloromethyl benzimidazole (3) is shown in figure 55. The amide group is 
sensitive to acidic conditions, and so the use of carboxylic acids to form the 
imidazole ring would lead to early deprotection of the amide. The use of 
orthoesters (such as methyl chloroacetimidate hydrochloride) was investigated 
due to the milder conditions for benzimidazole synthesis.
-NH, xv^ rf^ N-—i"no
.. . NaBH4 f if
r^^NH2 n^^, ^-N ————1* ^JL
l*%tx;1--NH2 ^^kirrvu
2 ^^ NCOCHs // \N )T'%
NCOCH3 ^^^NCOCH3 CICH2CNOCH3 NCOCH3
Figure 55 Synthetic scheme for the synthesis of the benzimidazole unit l-(4-acetamidobenzyl)- 
2-chloromethyl benzimidazole (3)
The first step in the synthesis of l-(4-acetamidobenzyl)-2-chloromethyl 
benzimidazole (3), involved the mono-alkylation of 1,2-phenylenediamine with 
4-acetamidobenzaldehyde to form 1 -(4-acetamidomethylene)phenylenediamine
(1).
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2.4.2 N-substitution reactions of 1,2-phenylenediamine
The potential problem associated with the N-substitution reactions of 1,2- 
phenylenediamine is the possibility that multiple alkylation may occur, resulting 
in the formation of secondary, tertiary or quaternised amines on either one or 
both of the nitrogens. Some possible multiple alkylation products are shown in 
figure 56.
NH2
2RX
B1
B2
B2 (a NHR NHR
NR2 
NHR
NR2 
NR2
C1
C2
C2
NR2 
NR2
RX NR3 
NR2
D1
D2
Figure 56 Possible reactions leading to multiple alkylation of the amines on 1,2- 
phenylenediamine
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The presence of a small excess of the alkylating agent, can result in the 
formation of a mixture of the alklylated amines (B-D). To prevent multiple 
alkylation, an excess of the 1,2-phenylenediamine can be used, which 
encourages the formation of the mono-alkylated product (Bl) over the multi- 
alkylated products. 133
2.4.3 N-substitution reactions of 1,2-phenylenediamine with 4- 
acetamidobenzaldehyde (2)
The initial attempt to prepare l-(4-acetamidomethylene)phenylenediamine 
involved adding 4-acetamidobenzaldehyde to a 3-fold excess of 1,2- 
phenylenediamine and stirring for 4 hours at room temperature, followed by 
heating at reflux for 20 minutes. The !H NMR spectrum was not consistent 
with the desired product, instead showing a mixture of products alongside the 
starting material. Imine bonds are known to be susceptible to hydrolysis, either 
upon heating to reflux or due to the presence of water, and so it was thought that 
the desired product was degrading during the reaction. Therefore, the reaction 
conditions were altered to avoid heating and the mixture was stirred with 
molecular sieves to remove any water formed in the reaction. The reaction was 
monitored by thin layer chromatography (t.l.c.) and the optimum conditions 
were found to be stirring for 72 hours with 3A molecular sieves, followed by 
removal of the solvent and maintaining the temperature below 40°C. The 
compound was then recrystallised from the minimum amount of ethanol, and 
the resulting yellow solid was collected in a 69% yield. The presence of the 
desired product was confirmed by 'H NMR spectroscopy, and the key feature 
was the characteristic imine proton observed at 6.86 ppm. The reduction of the 
imine bond to an amine bond to form l-(4-acetamidomethyl)phenylenediamine 
(2), was achieved using sodium borohydride. The ! H NMR spectrum confirmed 
the disappearance of the imine proton at 6.86 ppm and showed the formation of 
a CH2 peak at 4.51 ppm.
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2.4.4 Cyclisation of the benzimidazole using substituted 
orthoesters
A known synthetic procedure used to produce benzimidazole containing 
compounds involves using orthoesters as precursors. For example, Musser et 
al. have utilised othoesters in the development of benzimidazoles as 
incorporation into pharmaceutical agents used for inhibitors of leukoriene D4 
antagonists. 131 This reseach group treated 7V-methyl-2-phenylenediamine with 
chloroacetamidate to produce benzimidazole precursors in ca. 70% yield (figure 
57). Alternatively, Yasui et al used methyl 2,2,2-trichIoroacetimidate to form 
4,4'-dibromo-6,6'-dimethyl-2,2'-bisbenzimidazole in ca. 80% yield (figure 
57). 134
NH2 CICH2CNHOCH3
NH
MeQC(=NH(CCI3)
cat. HCI 
K2C03
Figure 57 The synthesis of benzimidazoles using orthoesters by Musser et al. (top) and by 
Yasui et al. 131 134
Orthoesters such as methyl chloroacetimidate hydrochloride are also known to 
form benzimidazoles on reaction with 1,2-phenylenediamine. 135
2.4.5 Preparation 
benzimidazole (3)
of (4-acetamidobenzyl)-2-chloromethyl
To form l-(4-acetamidobenzyl)-2-chloromethyl benzimidazole (3) using the 
orthoester route, methyl chloroacetimidate hydrochloride is required, which can 
be readily synthesised by a variety of methods. 135 The two routes that were 
investigated are identified in figure 58.
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Ck Cl
II HCI
N or NH 
Na, MeOH
Figure 58 The proposed synthesis of methyl chloroacetimidate hydrochloride
The initial route explored was that reported by McElvain et al., where dry 
hydrogen chloride gas was bubbled through an ice cooled solution of 
chloroacetonitrile in dry ethanol, followed by the addition of diethyl ether, 
which resulted in the formation of a white precipitate. 136 The second method 
published by Schaefer et al. involves sodium methoxide being stirred with 
chloroacetonitrile overnight. 137 In both cases the l-(4- 
acetamidomethyl)phenylenediamine (2) was then added to the reaction mixture 
and heated at reflux overnight, under an inert atmosphere. The literature 
reported yields of 30% and 71% yields respectively, however, with these 
starting materials neither method produced the desired product according to 
analysis by proton and carbon NMR spectroscopy and mass spectrometry 
(electrospray). Instead the analytical data suggests that 2-chloro-acetimidic acid 
methyl ester hydrochloride has possibly hydrolysed leaving (2) to react with the 
chloride and form unwanted by-products. Therefore, the synthesis of nitro 
benzyl ring benzimidazole derivatives was investigated.
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2.5 Synthesis ofnitro benzyl benzimidazoles
As the synthesis of benzimidazole derivatives with an appended benzylamide 
group were problematic, efforts were concentrated on synthesis of the nitro 
benzyl benzimidazoles. The strategy involved the preparation of the 
phenylenediamine precursor l-(4-nitrobenzyl)phenylenediamine (5) with the 
attachment of either 4-nitrobenzylbromide, or 4-nitrobenzaldehyde (which 
forms an imine linkage that is then reduced to an amine) to phenylenediamine. 
This can then be converted to a benzimidazole derivative that contains a 
reactive moiety at the 2-position. The research focused on the preparation of 
the chloromethyl benzimidazole derivative (7).
2.5.1 Synthesis of 1-(4-nitrobenzyl)phenylenediamine (5)
Synthesis of the nitro-functionalised benzyl benzimidazole l-(4-nitrobenzyl)-2- 
chloromethyl benzimidazole (7) was investigated using a number of routes. The 
synthetic routes utilised are shown in figure 59.
CICH2COOH
N02 
NaBH4 \HOCH2COOH
Figure 59 Scheme showing the synthesis of l-(4-nitrobenzyl)-2-chloromethyl benzimidazole 
(7)
The initial aim was to form l-(4-nitrobenzyl)phenylenediamine (5) either by a 
Schiff s base condensation with 4-nitrobenzaldehyde followed by the reduction
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or a single step reaction with 4-nitrobenzylbromide. Using the optimised 
protocol for the amide compounds, 4-nitrobenzaldehyde in methanol was added 
to 1,2-phenylenediamine in methanol in the presence of 3 A molecular sieves 
and allowed to stir for 72 hours at room temperature. The solution was filtered 
and the solvent removed, to yield a red solid. To remove unwanted starting 
material, the compound was re-crystallised from ethanol, and the precipitated 
solid was collected to give 1 -(4-nitrophenylmethylene)phenylenediamine (4) in 
71% yield. The ! H NMR spectrum corresponds to the desired product with the 
aromatic protons observed in the range 6.81 - 8.32 ppm and integrating to 8 
protons. The imine proton (C/fN) appears as a singlet at 6.81 ppm with an 
integration value of one. The imine was then reduced to the amine by the 
addition of an excess of sodium borohydride in small portions to a solution of 
(4), followed by heating at reflux for 4 hours. The reaction was quenched with 
water and then the product extracted into dichloromethane. A white solid was 
isolated in 48% yield. Successful reduction was confirmed by *H NMR 
spectroscopy, which showed the loss of the imine peak at 6.81 ppm and the 
formation of a CHa peak at 4.46 ppm (integration value of 2). The aromatic CH 
peaks are in the range of 6.46 - 8.19 ppm. The overall yield of the two steps 
was 60%, taking a total of five days to synthesise (5). As an alternative to using 
4-nitrobenzyaldehyde in the reaction with phenylenediamine, 4- 
nitrobenzylbromide was used to form (5) in a single step reaction. In this 
reaction, 4-nitrobenzylbromide was added dropwise in methanol to a 5-fold 
excess of 1,2-phenylenediamine and the reaction mixture allowed to stir for 4 
hours, the solvent was removed and the product recrystallised from the 
minimum amount of ethanol. The recrystallised product was purfied using flash 
column chromatography on silica with dichloromethane as the eluent to give a 
red/orange solid in yields of ca. 60%. Attempts were made to perform flash 
column chromatography directly on the crude reaction material, but it was 
found that the recrystallisation removed starting material that was not easily 
separated by chromatography alone due to its similar r.f. value to the product. 
The electrospray mass spectrum contained the molecular ion peak of (5). In the 
'HNMR spectrum, the singlet peak at 4.38 ppm arises from the CITjNH, and a 
double doublet at 6.39 ppm and a multiplet at 6.65 ppm correspond to the 
aromatic protons on the phenylenediamine component. The two triplets at 7.49
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ppm and 8.0 ppm correspond to the aromatic protons on the other phenyl ring. 
Single crystal X-ray crystallographic analysis was carried out on samples of 1- 
(4-nitrobenzyl)-2-chloromethyl benzimidazole and the structure determined. An 
ORTEP plot of the structure of l-(4-nitrobenzyl)phenylenediamine (5) is shown 
in figure 60.
Figure 60 The molecular structure of l-(4-nitrobenzyl)phenylenediamine, showing the atom 
labelling and 50% probability ellipsoids for non-H atoms
Bond length (A)
C1-N1
C2-N2
C7-N1
C11-N3
N3-O2
N3-O1
1.3961 (18)
1.3998(19)
1.4570(19)
1.4678(18)
1.2242(18)
1.2268(17)
Bond and torsion angles (°)
Cl -Nl -C7
N1-C7-C8-C13
C6-C1 -Nl -C7
119.22(11)
-64.36(17)
-9.2 (2)
Table 5 Selected bond lengths and bond and torsion angles of l-(4- 
nitrobenzyl)phenylenediamine
The crystal structure of l-(4-nitrobenzyl)phenylenediamine is characterised by 
the hydrogen-bonded dimers (Nl - H14-O1 1 and N2 - H16-O21) as indicated 
in table 5. This dimer locks the secondary amine group containing the Nl atom 
into a chiral form, and it contains both the enantiomeric forms of the molecule. 
The hydrogen bonding is combined with n-n stacking, and results in one- 
dimensional chains running parallel to the b axis. This n-n stacking occurs 
between the benzene ring (mean plane-plane distance = 3.29 A) of the 
nitrobenzyl groups of dimers in adjacent unit cells (figure 61 and 62).
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Figure 61 The hydrogen bonded (dashed lines) dimers and n-n stacking between dimeric 
units of 1 -(4-nitrobenzyl)phenylenediamine
D-H-A
N1-H14-O1 1
N2-H16-O2'
D-H
0.92 (2)
0.91 (2)
H-A
2.43 (2)
2.62 (2)
D-A
3.3005(18)
3.4277(19)
D-H-A
158.3(15)
148.0(18)
Table 6 Hydrogen-bond geometry (A, °) of l-(4-nitrobenzyl)phenylenediamine, where the 
symmetry code: (i) —x +1, -y + 2, -z
Figure 62 The crystal packing, viewed along the b axis of 1 -(4-nitrobenzyl)phenylenediamine
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2.5.2 Cyclisation to form benzimidazoles using carboxylic 
acids
There is a great deal of interest in the use of carboxylic acids to form 
benzimidazoles under acidic conditions. 138 A large number of publications have 
reported the use of substituted acetic acid derivatives in reactions with 1,2- 
phenylenediamine using 5 M HC1 as the solvent. 121 The solution is heated at 
reflux, followed by an alkaline work up at 0°C that causes precipitation of the 
desired compound. In particular, Wilson et al. have used this method to form a 
series of substituted benzimidazoles in ca. 80% yield (figure 63). 132
NH2 
NH2
RCOOH
2 -5 h, 5M HCI
Figure 63 Synthesis of substituted benzimidazoles using carboxylic acids
All of these literature methods are based on modifications of the Philips method. 
The proposed mechanism for the formation of the benzimidazole unit using this 
method is shown in figure 64.
Figure 64 Proposed mechanism for the reaction of substituted 1,2-phenylenediamine with a 
carboxylic acid R=CH2C6H4NHCOCH3, X = Cl, Br or OH
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The role of the acid is to act as a catalyst, activating the carbonyl group by the 
protonation of the oxygen to form a carboniurn ion. With the electron 
deficiency at the carbon ion on the acetic acid moiety, the lone pair on the 
nitrogen is able to attack the carbonium ion resulting in a dehydration reaction 
to form the benzimidazole compound.
2.5.3 Synthesis of 1-(4-nitrobenzyl)-2-chloromethyl 
benzimidazole (7)
Initial efforts to synthesise l-(4-nitrobenzyl)-2-chloromethyl benzimidazole (7) 
involved using the modified Philips procedure. There are numerous reports of 
phenylenediamine derivatives being converted to a chloromethyl benzimidazole 
group using chloroacetic acid. 139 122 ' 132> 14° These procedures describe heating a 
mixture of 1,2-phenylenediamine and chloroacetic acid to reflux in 5N HC1 with 
reaction times varying from 4 to 24 hours. The product is then precipitated out 
with aqueous ammonia solution in an ice bath. While there is the extensive 
literature suggesting that this procedure works for a variety phenylenediamine 
analogues, all attempts to form the nitrobenzyl benzimidazole derivative (7) 
proved unsuccessful. Numerous efforts were made, with variations in reaction 
times and the molarity of the HC1 solution. However, after several attempts it 
became apparent from the 'H NMR spectrum that a mixture of products was 
isolated on each occasion. The mass spectral (electrospray) data showed a peak 
at m/z = 302, corresponding to the desired product (7), and another peak at 282. 
It is proposed that the work up itself was causing the problem rather than the 
reaction. In the work up, aqueous ammonia solution was partially displacing 
the chloride causing the formation of l-(4-nitrobenzyl)-2-aminomethyl 
benzimidazole (peak of 282). The reaction was repeated using sodium 
hydroxide solution, and instead of the amine displacing the chloride, this time a 
mixture of the chloromethyl and the hydroxymethyl benzimidazole was formed. 
The mass spectrometry data again showed that the desired compound had been 
formed, with a peak at m/z = 302 corresponding to product (7) but there was 
also a peak at m/z = 283 representing the hydroxyl product. The literature does 
suggest that the work up needs to be kept below 15°C, and the reaction was
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performed cold by placing the vessel in an ice bath. In practice, however, it was 
difficult to maintain the reduced temperature in solution as the work up involves 
the neutralisation of the acid, therefore a lot of heat was generated and this 
might have led to the formation of the by product. To avoid the problems 
encounted in the work up, an alterative route was investigated that involved 
using glycolic acid instead of chloroacetic acid. Thionyl chloride could then be 
used to convert the hydroxymethyl group to the chloromethyl equivalent. A 
number of research groups have used this type of route to produce chloro 
derivatives, possibly due to the same issue that was encountered in this work. 139
The method used to form l-(4-nitrobenzyl)-2-hydroxymethyl benzimidazole 
(6) is virtually the same as that used in the attempted preparation of (7), 
however in this case glycolic acid was used and slightly longer reaction times 
were required, resulting in a yield of 77%. The 'H NMR spectrum clearly 
shows the Ct^OH singlet peak at 4.83 ppm, and the Ctb benzyl peak located at
5.69 ppm. The aromatic CH peaks are in the range of 7.29 to 8.1 ppm, but not 
all individual peaks are distinguishable due to overlap forming a large multiplet 
at 7.29 ppm with an integration of 5 [(the other two peaks are at 7.6 ppm 
(doublet with an integration of 1) and 8.1 ppm (double triplet, integration of 2)]. 
The 13C NMR spectrum contains 13 carbons, with the peaks at 46.9 ppm and
57.0 ppm corresponding to the two CH? peaks.
The hydroxyl group was then readily converted to the chloride to give l-(4- 
nitrobenzyl)-2-chloromethyl benzimidazole (7) by stirring (6) with thionyl 
chloride for 24 hours. The resulting cream solid was isolated in a yield of 68%. 
There is a clear difference in the 'H NMR spectrum of (7) compared to (6) with 
the shift of the CH2 peak from 4.83 ppm to 6.32 ppm, because the hydroxide has 
been displaced by a chloride causing an increase in the electron withdrawing 
character and resulting in the CH2 shifting down field. The I3C NMR spectrum 
shows a shift in the CH2 peak to 32.9 ppm. The X-ray crystal structure has also 
been obtained. An ORTEP plot of the structure of l-(4-nitrobenzylmethyl)-2- 
chloromethyl benzimidazolium chloride (7).HC1 is shown in figure 65.
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Figure 65 The molecular structure of l-(4-nitrobenzylmethyl)-2-chloromethyl benzimidazolium 
chloride (7).HC1, showing the atom labelling and 50% probability ellipsoids for non-H atoms.
In the crystal structure of l-(4-nitrobenzylmethyl)-2-chloromethyl 
benzimidazolium chloride (7).HC1, there are no hydrogen-bonded dimers as 
were observed in the phenylenediamine structure (7).HC1. As shown in table 7, 
the bond lengths are very similar to those observed in the phenylenediamine 
structure, with some slight variation in bond angles due to the formation of the 
benzimidazole unit.
Bond length (A) Bond and torsion angle (°)
1.345(3) 109.8 (2)
1.328(4) 123.3 (3)
C(2)-N(2) 1.384(3) 126.8 (3)
1.390(3) 110.15(18)
1.481 (4) N(1)-C(3)-C(2) 106.3 (2)
1.801 (3) N(1)-C(3)-C(4) 132.6 (2)
Table 7 Selective bond length and bond and torsion angle for l-(4-nitrobenzylmethyl)-2- 
chloromethyl benzimidazolium chloride (7).HC1
A view of the crystal packing is shown in figure 66, in this case no ^-stacking or 
edge to face phenyl interactions are observed.
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Figure 66 The crystal packing view along the b axis for l-(4-nitrobenzylmethyl)-2- 
chloromethyl benzimidazolium chloride (7).HC1
2.5.4 The attempted preparation of 1-(4-nitrobenzyl)-2- 
iodomethyl benzimidazole (8)
A number of research groups have shown that a chloroalkyl group can be 
readily converted to an iodoalkyl group. The reason for converting the chloro to 
an iodo, is that it will be a better leaving group. This should make (8) more 
effective at undergoing nucleophilic substitution reactions with DO3A 
compared to (7). The reaction conditions reported by Charmant et al. were 
used. 141 The chloro derivative was added to a solution of sodium iodide in 
acetone and heated at reflux for 6 hours. The reaction mixture was then cooled 
to room temperature and washed with water, after which the organic layer was 
collected and the solvent removed. The reaction scheme is shown in figure 67.
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Figure 67 Attempted synthesis of l-(4-nitrobenzyl)-2-iodomethyl benzimidazole (8)
The product (8) was not isolated as a single species using this procedure 
according to analysis of the 'H NMR spectrum, which suggested a mixture of 
compounds had formed. As the iodide ion is such a good leaving group, the 
reaction shown in figure 67 could be reversible, thus giving a mixture of (7) and 
(8). Therefore, no further efforts were made to isolate (8).
2.5.5 The synthesis of 1-(4-nitrobenzyl)-2-methylpyridine 
benzimidazolium chloride (9)
The potential of (7) to undergo a nucleophilic substitution reaction with an 
amine was investigated by reaction with pyridine. The nitrogen atom in the 
pyridine is planar and trigonal with the lone pair in the plane of the ring. This is 
nucleophilic because the lone pair of electrons cannot be delocalized around the 
ring. However, pyridine is less nucleophilic then the secondary amine position 
on DO3A, therefore if the reaction with pyridine was successful, the reaction 
between (7) and DO3A (31) should occur. A modified version of the procedure 
reported by lemura et al. was used, where (7) was dissolved in pyridine and 
heated at reflux for 30 min. 142 The solvent was removed under reduced 
pressure, and the resulting cream solid was recrystallised from methanol to give 
l-(4-nitrobenzyl)-2-methylpyridine benzimidazolium chloride (9) as a white 
solid in 52% yield. The reaction scheme is shown in figure 68.
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Figure 68 Synthesis of 1 -(4-nitrobenzyl)-2-methylpyridine benzimidazolium chloride (9)
The *H NMR spectrum showed two singlets at 6.14 and 6.97 ppm (each having
an integration value of 2) that represent the two CHa groups. In the aromatic 
region there are 5 peaks from 7.3 - 9.67 ppm and with a total integration of 13 
protons. The 13C NMR spectrum shows 13 peaks, with those at 46.83 and 56.03 
ppm assigned to represent the CH2 peaks, and the other 1 1 peaks in the region 
of 110.33 - 146.65 ppm representing the CH and C peaks. The electrospray 
mass spectrometry data shows the molecular ion peak, and the X-ray crystal 
structure was also obtained. An ORTEP plot of the structure of l-(4- 
nitrobenzyl)-2-methylpyridine benzimidazole is shown in figure 69.
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Figure 69 The molecular structure of l-(4-nitrobenzyl)-2-methylpyridine benzimidazolium 
chloride, showing the atom labelling and 50% probability ellipsoids for non-H atoms.
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The crystal structure of l-(4-nitrobenzyl)-2-methylpyridine benzimidazolium 
chloride shows no clear n-stacking or edge to face phenyl interactions, similar to 
the crystal structure for (7).HC1. The bond lengths in the two structures are 
similar, however, there is variation in some bond angles. N2-C1-N1 is 109.8° 
for (7).HC1 and 114.1° for (9), and N2-C1-C15 is 123.3° for (7).HC1 and 125.4 
for (9). An even larger difference can be seen for the angle N1-C1-C15 as this 
decreases from 126.8 for (7).HC1 to 120.4° for (9). These differences may be 
due to the steric bulk of the pyridyl group.
Bond length A
C(1)-N(1)
C(1)-N(2)
C(2)-N(2)
C(3)-N(1)
C(1)-C(15)
C(15)-N(4)
1.366(5)
1.306(4)
1.388(5)
1.388(5)
1.486(5)
1.472(6)
Bond and torsion angle °
N(2)-C(1)-N(1)
N(2)-C(1)-N(15)
N(1)-C(1)-C(15)
C(1)-C(15)-N(4)
N(1)-C(3)-C(2)
N(1)-C(3)-C(4)
114.1(3)
125.4(4)
120.4(3)
111.5(3)
110.4(3)
130.9(4)
Table 8 Selected bond lengths and bond and torsion angles for l-(4-nitrobenzyl)-2- 
methylpyridine benzimidazolium chloride
Figure 70 Packing diagram for the crystal structure of l-(4-nitrobenzyl)-2-methylpyridine 
benzimidazolium chloride
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This section detailed the preparation and characterisation of benzimidazole 
derivatives using method 1. This route was successfully used to prepare the 
desired compound l-(4-nitrobenzyl)-2-chloromethyl benzimidazole (7). The 
next section (2.6) contains a discussion of the attempted synthesis of 
benzimidazole derivatives using method 2.
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2.6 Synthesis of benzimidazole derivatives - method 2
The previous sections (2.4-2.5) described the synthesis of benzimidazole 
precursors by initial functionalisation of the 1,2-phenylenediamine followed by 
a cyclisation reaction to form the benzimidazole molecule (method 1). This 
section contains a discussion of an alternative method to form benzimidazole 
molecules (method 2). This will initially use a cyclisation reaction to form the 
benzimidazole compound, for example, a condensation reaction between 1,2- 
phenylenediamine and an acetic acid derivative (chloroacetic acid), followed by 
substitution, (e.g. with nitrobenzyl bromide), at the benzimidazole amine.
NH2 CICH2R' f^W^CI ^ [^VN<
L II .
NH2 "^ ~N ^^N
n
Cl
Figure 71 Proposed synthetic strategy to produce novel benzimidazole precursors using method 
2 (where R' = CNHOCH3 , or COOH)
2.6.1 Synthetic methods used to produce benzimidazole 
derivatives using method 2
A number of research groups have investigated the substitution of groups 
directly onto the Nl position on the benzimidazole (method 2). Raban et al. 
have attached a 2,4-dinitrobenzenesulfenyl chloride onto the benzimidazole unit 
in about 95% yields (figure 72). l22 An alternative method is reported by Li et 
al where they have reacted methyl iodide with benzimidazole in the presence of 
potassium carbonate using DMF as solvent, giving the product in yields greater 
than 70% (figure 72). l43
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Figure 72 Direct functionalisation of the the benzimidazole nitrogen: Raban et al. (a), Li et al. (b) 122' 143
Wang et al. have attached a methyl group to the Nl-position as part of a route to 
alkylate both of the nitrogen positions, the N-3 position was subsequently 
reacted with ethyl 6-(trifluoromethylsulfonyloxy)hexanoate in 87% yield (figure
73). 144
Figure 73 Functionalisation of the the benzimidazole nitrogen at both the Nl and N3 position
A related approach has been employed by Li et al where 1,2-phenylenediamine 
and 3-phthalimidopropionic acid were suspended in polyphosphoric acid to 
form 2-[2-(lH-benzoimidazol-2-yl)-ethyl]-isoindole-l,3-dione, which could 
then be reacted with a variety of reagents allowing substitution to occur at the 
N-l position on the benzimidazole. 145 Using this methodology, this group has 
shown that a number of novel benzimidazole compounds can be synthesised. 
For example, 4-methylbenzoyl chloride, 4-methylbenzyl chloride and p-
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toluenesulfonyl chloride (tosyl chloride) were reacted to form benzimidazole 
derivatives using dry dichloromethane as solvent, and 4-(dimethyl- 
amino)pyridine (DMAP) as a base, see figure 74.
0
1 N-
-COOH
Figure 74 Reaction scheme showing the synthetic routes investigated by Li et al. 14S
The wealth of reactions show that this route is well characterised and potentially 
could be used to produce the target benzimidazole derivative for this work. 
This section includes the discussion of the synthetic procedures used in the 
synthesis of 2-chloromethyl benzimidazole and the attempts to attach a 4- 
nitrobenzyl group onto the Nl-position.
2.6.2 Synthesis of 2-chloromethyl benzimidazole (10)
The synthesis of l-(4-nitrobenzyl)-2-chloromethyl benzimidazole (7) involves 
the initial preparation of 2-chloromethyl benzimidazole (10), using either 
chloroacetic acid, or methyl chloroacetimidate hydrochloride (figure 75). 132 
This intermediate can then be treated with the nitrobenzyl bromide in the
_£., 146presence of base.
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jj^V-NH2 CICH2COOH
CICH2CNHOCH3 H 10
Figure 75 The attempted synthesis of l-(4-nitrobenzyl)-2-chloromethyl benzimidazole (7) using 
method 2
The synthesis of (10) was initially attempted by using a modified version of the 
procedure employed by Bloom et al., where 1,2-phenylenediamine and 
chloroacetic acid were suspended in 5 N hydrochloric acid, and heated at reflux 
for 18 hours. 138 The solution was cooled to 0°C using a salt ice bath and the pH 
adjusted with ammonium hydroxide solution to cause formation of a precipitate 
that was collected by filtration. As with previous attempts to synthesise (7) 
using method 1, this reaction failed to yield any pure product. The 'H NMR 
spectrum appeared to show a mixture of products had been formed, which is 
likely to be a combination of (10) and 2-aminomethyl benzimidazole (due to the 
basic work up). Attempts were also made to exploit the orthoester route using 
methyl chloroacetimidate hydrochloride. 137 The procedure was the same as was 
used in the attempted synthesis of (3), where methyl chloroacetimidate 
hydrochloride is formed in situ, and then allowed to stir for 24 hours with 1,2- 
phenylenediamine under an atmosphere of nitrogen. Again, this route did not 
produce the desired compound, as was shown by analysis of the !H NMR 
spectrum. This was unexpected as 2-chloromethyl benzimidazole (10) can be 
purchased from Aldrich and should be relatively easy to produce.
2.6.3 Synthesis of 2-chloromethyl benzimidazole derivatives 
(7)
Numerous attempts were made to synthesise (7) from purchased (10) by 
substituting 4-nitrobenzyl bromide onto the Nl-position. Initial efforts involved 
the use of triethylamine (TEA) as the base, and varying the reaction conditions, 
with 4-nitrobenzylbromide dissolved in dichloromethane and added dropwise to 
a solution of 2-chloromethyl benzimidazole in dichloromethane with a drop of
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TEA. This mixture was allowed to stir for 24 hours at room temperature. The 
solvent was then removed, which resulted in the formation of a brown solid. 
Analysis showed that the desired product had not been formed using this 
procedure. This was believed to be the result of using conditions that were not 
sufficiently forcing to cause the formation of the desired compound and 
therefore the procedure was repeated.
On this occasion, the reaction mixture was heated at reflux for 3 hours after 
being stirred for 24 hours, and the solvent was changed to tetrahydrofuran, since 
this is more polar and should favour the substitution reaction. A similar method 
has been used by Raban et al. (figure 72), where 2,4-dinitrobenzenesulfenyl 
chloride was treated with 1,2-phenylenediamine in the presence of TEA and 
tetrahydrofuran to form 7V-[(2,4-dinitrophenyl)thiol]-2-chloromethyl)-5(6)- 
chlorobenzimidazole with a crude yield of 96%. 122 In an analogous manner, 2- 
chloromethyl benzimidazole and 4-nitrobenzylbromide were mixed in 
tetrahydrofuran with a drop of TEA and reaction mixture was stirred at room 
temperature for 24 hours, followed by heating at reflux for 3 hours. The solvent 
was removed and purification attempted by flash chromatography 
(dichloromethane with an increasing gradient of methanol from 0% to 10%). 
Chromatography proved unsuccessful in isolating the desired compound, 
possibly because once again the resulting solid was a mixture of materials that 
had similar r.f. values. One explanation for the difficulties in forming the 
desired compound is that the TEA might be reacting with the starting material 
i.e. at the methyl chloride position, and preventing the reaction from going to 
completion. 2-Chloromethyl benzimidazole is not very soluble in 
tetrahydrofuran, and while the TEA increased the solubility it may also have 
caused formation of by products.
Therefore, an alternative option involved using an even higher polarity solvent 
such as dimethylformamide that will fully dissolve the 2-chloromethyl 
benzimidazole, and changing the base to potassium carbonate, which will 
remove the possibility of an amine base reacting with the chloromethyl group. 
Thomas et al. have used a related procedure to form methyl 4'-[(butyl-1H- 
benzimidazol-l-yl)methyl]biphenyl-2-carboxylate. 147 This procedure involved
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reacting 2-butylbenzimidazole with a slight excess of methyl 4- 
(bromomethyl)biphenyl-2-carboxylate and potassium carbonate in 
dimethylformamide with heating at 100°C. Dichloromethane was then added, 
and the insoluble material removed, resulting in 45% yields after further 
purification by flash chromatography. The modified procedure used herein 
involved reacting 2-chloromethyl benzimidazole, 4-nitrobenzylbromide (in a 
slight excess) and potassium carbonate dissolved in dimethylformamide while 
heating to reflux for 3 hours. 147 Upon addition of dichloromethane, a precipitate 
resulted which was then removed by filtration, and the filtrate was evaporated to 
dryness to give a solid. Analysis by ]H NMR spectroscopy suggested that the 
desired compound had not been synthesised in a pure form and a mixture of 
products had been isolated.
Alternative strategies were then considered, Yu et al. have managed to attach a 
number of alkyl groups to the N-1 position on 2-hydroxymethyl benzimidazole 
by using sodium hydride as base with dimethylformamide as the solvent. 148 A 
modified version of this procedure was attempted. Sodium hydride was added 
in small portions to a solution of 4-nitrobenzylbromide and 2-chloromethyl 
benzimidazole in dimethylformamide over a period of 30 minutes. The reaction 
was allowed to stir for 1 week at room temperature and the progress of the 
reaction monitored by t.l.c. After a week stirring, no compound was separated 
on the t.l.c. plate that might correspond to possible product formation and so the 
reaction was heated at reflux for 3 hours. The elevated temperature resulted in 
the formation of a number of new compounds that were observed by t.l.c. The 
resultant solid did not appear to consist of the desired compound (7) based on 
!H NMR spectrscopy. It appears that leaving the reagents to stir at room 
temperature is not sufficient to cause a reaction, however heating to reflux 
causes the formation of multiple products. The reaction was repeated, varying 
the conditions, using potassium carbonate as the base (a less powerful base), 
and acetone as the solvent (a less polar solvent). 4-Nitrobenzylbromide and 2- 
chloromethyl benzimidazole were reacted under these conditions with heating at 
reflux for 24 hours. Following the removal of the solvent, the 'H NMR 
spectrum again showed that a mixture of products had formed with no 
identifiable peaks that could be assigned to the desired compound (7).
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Further investigations were conducted, this time employing lithium 
diisopropylamide, (LDA), as the base, since it will react at low temperatures and 
should readily deprotonate the amine on the benzimidazole to allow for the 
reaction with the 4-nitrobenzylbromide. The first attempt involved using 2- 
chloromethyl benzimidazole dissolved in dry tetrahydrofuran with the reaction 
mixture cooled to -30°C under in an inert atmosphere. While (10) does not 
dissolve fully in tetrahydrofuran, the product does, so it was anticipated that if 
the reaction occurred, the product could easily be separated from the starting 
material and other reagents at the work up stage. LDA was then added 
dropwise over 5 minutes, and the reaction mixture allowed to stir at -30°C for 
15 minutes, during which time the solution became clear. After 15 minutes, 4- 
nitrobenzylbromide was added dropwise in dry tetrahydrofuran, and the reaction 
mixture was allowed to warm to room temperature and stirred over night under 
a nitrogen atmosphere, which led to formation of some precipitate. Following 
the removal of the solvent, the *H NMR spectrum indicated that the reaction had 
not gone to completion, with a mixture of starting material and product being 
obtained, probably due to the lack of solubility of (10) in tetrahydrofuran. 
Attempts to purify the material by re-crystallisation, or washing with 
tetrahydrofuran proved to be unsuccessful. The reaction was repeated, using the 
same conditions as before, except this time LDA was stirred with 2- 
chloromethyl benzimidazole for 2 hours instead of 15 minutes to allow 
abstraction of the proton on the amine. Further analysis showed that a mixture 
of products was present that could not be identified or purified.
The aim of this approach was to provide a more reactive alkyl halide (4- 
nitrobenzylbromide) compared to the chloromethyl group on the benzimidazole 
and hence in the presence of base the reaction at Nl would occur with the 
nitrobenzyl reagent rather than this 'self reaction' to give a polymeric 
compound. However, it is likely that the 'self reaction' did occur when stirring 
with LDA for 2 hours. The other problems with this synthetic strategy appeared 
to be the low solubility of the benzimidazole starting material, leading to 
incomplete reaction, and the fact that the Nl nitrogen position was not as 
reactive as expected. The choice of solvent seemed to be very important to the 
reaction with polar solvents such as pyridine and dimethylformamide preferred
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due to improved solubility, however, the starting material is partially soluble in 
less polar solvents such as tetrahydrofuran and dichloromethane in the presence 
of TEA. It is likely that deprotonation of the starting material was increasing 
the solubility. The reaction to form the desired product produces acid, which, if 
insufficient base was present, could have reprotonated unreacted starting 
material causing it to precipitate and preventing the reaction from going to 
completion. A further by-product that could have formed is the bis-alkylated 
compound where the N2 position on the imidazole ring is quatemised resulting 
in a mixture of starting material and mono and di-substituted products. Wang et 
al. have observed such reactions, see figure 73. 144
As discussed already it is possible that reaction could occur between two 
molecules of starting material (alkyl chloride reacting at the Nl position). One 
way to prevent this would be to use an alternate starting material in the 
substitution reaction with nitrobenzyl bromide, such as 2-hydroxymethyl 
benzimidazole. Attempting this reaction would clarify the role of the 'self 
reaction' in the unsuccessful synthesis. The resulting compound could be 
converted to (7) by treatment with thionyl chloride. However, as method 1 was 
used successfully to produce the desired benzimidazole compound l-(4- 
nitrobenzyl)-2-chloromethyl benzimidazole (7), method 2 was not investigated 
further.
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2.7Conc/£/s/ons
Two methods were investigated to synthesise l-(4-nitrobenzyl)-2-chloromethyl 
benzimidazole (7). While issues were encountered with both methods, the 
formation of the 7V-alkylated benzimidazoles was more successful using the 
cyclisation of alykylated diaminobenzene (method 1) rather than alkylation of 
the pre-formed benzimidazole (method 2). Method 1 was used to successfully 
produce the target compound (7). It proved to be much more challenging to get 
method 2 to proceed cleanly and isolation of a single product was not achieved.
Initial attempts to synthesise l-(4-aminobenzyl)-2-chloromethyl benzimidazole 
(3) using method 1, were carried out using an amidobenzyl group which can 
subsequently be converted to the amine compound by acid hydrolysis. The 
precursor l-(4-amidobenzyl)phenylenediamine (2) was accessible from the 
Schiffs base condensation reaction between 1,2-phenylenediamine and 4- 
acetamido benzaldehyde to form (1), followed by the reduction of the imine to 
the amine to give (2). However, difficulties then arose in finding a suitable 
method to convert it to the benzimidazole derivative (3). The use of methyl 
chloroacetimidate hydrochloride resulted in unwanted by products, possibly due 
to the hydrolysis of the starting material. Efforts were then focused on the 
synthesis of l-(4-nitrobenzyl)-2-chloromethyl benzimidazole (7). The precursor 
compound l-(4-nitrobenzyl)phenylenediamine (5) can be synthesised using a 
related procedure by reacting 1,2-phenylenediamine and 4-nitrobenzylaldehyde, 
followed by reduction of the imine to the amine using sodium borohydride. 
However an improved synthesis was investigated and optimised, reacting 1,2- 
phenylenediamine and 4-nitrobenzylbromide to give the formation of (5) in a 
single step.
The cyclisation reaction to form benzimidazole compound (7) was initially 
attempted by treatment of (10) with chloroacetic acid in 5 N hydrochloric acid, 
but this led to a mixture of by-products due to partial displacement of the chloro 
group with either an amino or hydroxo group in the work up. Therefore, an 
alternative route to synthesise this compound from l-(4-nitrobenzyl)-2-
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hydroxymethyl benzimidazole (6) was investigated (6) was synthesised by the 
treatment of (5) with glycolic acid in 5 N hydrochloric acid solution, followed 
by the conversion of the hydroxide to the chloride by reaction with thionyl 
chloride. Overall, the characterisation of an efficient route to produce, l-(4- 
nitrobenzyl)-2-chloromethyl benzimidazole (7) with full characterisation was 
achieved. This compound is a key precursor in the synthesis of dual 
functionalised benzimidazole containing chelators.
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3. Synthesis of optical dyes
86
3.1 Introduction
There are many examples of organic optical dyes that are frequently used to 
study biological function. Examples of some widely used fluorescent dyes 
include ethidium bromide, Alexa Fluor dyes, and fluorescein. The structures of 
these compounds are given in figure 76.
/C2H5
Ethidium bromide Fluorescein
HO3S
Alexa Fluor 350
Figure 76 Structures of widely used fluorescent dyes
Such dyes function by undergoing a process of fluorescence, where the 
molecule becomes excited to a higher energy state (excited state) via the 
absorption of light i.e. excitation. The molecule undergoes a decay process 
back to the lowest energy excited state. This is followed by the return of the 
optical dye to the ground state and results in the emission of light, as shown in 
figure 77.
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Excited state
Excitation
Absorption of light
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Loss of energy
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Emission of light
Figure 77 The process of fluorescence for an optical dye
The emitted light is of lower energy and of longer wavelength than the absorbed 
light, hence the colour of the light that is emitted can be different from the 
colour of the light that has been absorbed. Optical dyes can undergo this 
process repeatedly, and are commonly used in the study of biological function. 
However, they are susceptible to photobleaching where a high intensity 
illumination can cause structural instabilities and may lead to degradation of the 
molecule over time. 69
Common dyes used for this application include those based on rhodamine and 
boron dipyrromethenes (BODIPY). They can both be used to obtain optical 
images of biological systems, as they are known to be taken up into cells and 
are relatively non- cytotoxic. Rhodamine based agents are hydrophobic cationic 
dyes that can penetrate cell membranes. In particular, dyes of this type have 
been shown to target functional mitochondria. Rhodamine dyes are attracted to 
the mitochondria as they have a negative membrane potential and can be used to 
study mitochondrial function i.e. their role in the apoptotic cascade. When the 
membrane potential is lost (a result of apoptosis), the dye is no longer localised 
and this change can be observed using confocal microscopy. 149 150- 151 
Structurally, BODIPY dyes are based on the complexation of dipyrrins with 
boron. They have high fluorescence quantum yields, with tunable emission
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maxima wavelengths and have good photochemical stability which has resulted 
in their uses for biological staining, see figure 78 for general structures. 152 
5 o 4
Rhodamine BOOIPY 
Figure 78 The general structures of rhodamine (left), and BODIPY (right) based dyes
The aim of this work is to attach such dyes to a DO3A chelator derivative. This 
is motivated by the fact that they could aid the ability of the contrast agent to 
enter the cell, due to the intrinsic properties of the rhodamine and BODIPY 
dyes. 153 154 As well as their cellular uptake properties, it is hoped that with the 
gadolinium(III) complexes the resulting dye conjugate would function as a dual 
modality imaging agent [i.e. detectable by both fluorescence microscopy 
(optical dye) and MRI contrast properties (paramagnetism of gadolinium(III)]. 
Alternatively, with a luminescent lanthanide ion, the dye conjugate can 
potentially act to sensitise the lanthanide metal ion through energy transfer 
processes. This would be advantageous in optical imaging as lanthanide 
luminescence is longer lived and allows for gating out of background 
fluorescence from biological systems.
This chapter contains a discussion of the attempted syntheses to produce 
rhodamine (sections 3.2-3.4) and BODIPY (sections 3.5-3.8) derivatives that 
have the potential to be conjugated to the chelators, l,4,7-tris(carboxymethyl)- 
10-(4-aminobenzyl)-l,4,7,10-tetraazacyclododecane (40) and 1,4,7- 
tris(carboxymethyl)-10-( 1 -(4-aminobenzyl)-2-methyl benzimidazole)-1,4,7,10- 
tetraazacyclododecane (36).
For the rhodamine derivatives, two strategies have been employed. Initially 
work by Nguyen et al was followed to synthesise a rhodamine B derivative 
bearing a piperazine ring (this was to prevent the formation of the non- 
fluorescent lactam derivative) that could then be functionalised with an alkyl
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halide. 155 This unit could potentially be directly coupled to the chelator 
derivatives. The second strategy involved the preparation of a rhodamine 
derivative bearing an alkyl amine that could either be converted to an 
isothiocyanate group to facilitate conjugation to an amino bearing chelator, or 
used without modification for coupling to an isothiocyanate bearing chelator. 
The target rhodamine molecules are shown in figure 79.
O
J^—jr
,NH2
x^/^\ /* 
X = Cl, Br
Et2N NEt7
Figure 79 The two target rhodamine derivatives
The synthesis of BODIPY compounds initially involved the formation of a 
phenyl amine substituted at the 8-position (meso) that could be converted to an 
isothiocyanate group for conjugation at a later stage. As an alternative route, 
the addition of an alkyl amine functionality on the phenyl ring at the 8-position 
was investigated due to possible issues with the reduced nucleophilicity of the 
aromatic amine in the initial design. The target BODIPY molecules are shown
in figure 80.
R
R = NH2 , NCS,
NHCO(CH2)3NH2
F F
Figure 80 Target molecules for BODIPY derivatives
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3.2 Rhodamine optical dyes
The effectiveness of rhodamine as a fluorescent probe to study biological 
function has encouraged efforts to further functionalise these structures. 
Currently, purchasing functionalised rhodamine dyes is expensive, for example 
to purchase rhodamine B isothiocyanate (with the functional group on one of 
the phenyl ring positions) from Aldrich (2007-2008) will cost £79.20 for 500 
mg. When this is compared to the cost of rhodamine B base (£25.40 for 25g), 
there is a noticeable difference in price and clearly a premium is being charged.
A number of strategies are reported in the literature for synthesising rhodamine 
derivatives. Methods employed by Minta et al. and Lippard and co-workers, 
involve starting from a xanthone derivative to add functionality at the 12- and 
13-positions respectively and a benzophenone derivative to add functionality at 
the 3-position. 151 156 Here, the functional groups are added by the complete 
synthesis of a rhodamine derivative from a non-fluorescent precursor, however, 
this can involve multi step reactions and starting from expensive precursors. 
Other common approaches utilise a rhodamine compound, such as rhodamine 
B, and attach other groups on to the carboxylic acid. Therefore, to keep costs 
down and to allow for synthesis of reasonable amounts of the rhodamine dyes, it 
was decided to functionalise the rhodamine B base at the carboxylic acid group 
(figure 81).
Et2N
Functionalisation 
at the carboxylic acid
Figure 81 Functionalisation of the rhodamine B base
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Analogues of rhodamine have previously been synthesised to act as sensors to 
measure oxygen concentration, metal ion concentration and temperature. Some 
examples are described in the following sections along with the synthetic 
strategies that could be applied to this work.
3.2.1 Rhodamine analogues as oxygen sensors
Ribou and co-workers have reported the synthesis of rhodamine functionalised 
with a pyrene unit to form (l'-pyrene butyl)-2-rhodamine ester (figure 82). 
This was prepared by the coupling of 1-pyrenebutanol and rhodamine 110 by a 
DCC coupling reaction in a 17% yield. This compound was designed to 
measure oxygen concentrations in the mitochondria of living cells. The oxygen 
concentrations can be measured by either fluorescence intensity variation or by 
fluorescence lifetime changes of the pyrene unit, while the rhodamine unit 
targets the mitochondria.
H,N
Figure 82 Structure of (1 '-pyrene butyl)-2-rhodamine ester
Another example is from the work of Koide et al. where they have synthesised a 
rhodamine derivative bearing either a 4-amino- or 4-hydroxyphenyl ether 
moiety that can detect highly reactive oxygen species in the mitochondria of 
living cells (figure 83). 157 Normally this is not fluorescent, but in the presence 
of reactive oxygen species (peroxide), the phenyl group is cleaved to form a 
highly fluorescent molecule.
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Non-fluorescent 
R = NH2 , OH
Figure 83 Structure of a reactive oxygen sensor based on rhodamine
3.2.2 Rhodamine analogues as metal ion sensors
Rhodamine derivatives have also been shown to act as sensors for a number of 
metal ions including iron(III), zinc(II) and mercury(II). Xiang et al. have 
synthesised an iron(III) selective rhodamine derivative based on rhodamine B 
and diethylenetriamine. 158 The molecule was prepared by the addition of 
diethylenetriamine to two equivalents of rhodamine 123 to form a lactam 
derivative that is non-fluorescent. The fluorescence increases in the presence of 
iron(III) due to the opening of the spirocyclic ring on complexation with 
iron(III), and the resulting fluorescent complex can then be detected.
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-Fe(lll) Fe(lll)
Non-fluorescent
Fluorescent
Figure 84 Structure of the iron(III) selective probe synthesised by Xiang et al. 158
Yang et al. have reported the synthesis of an optical-electrochemical sensor for 
mercury(II) based on rhodamine B bearing a ferrocene substiruent and an 8- 
hydroxyquinoline moiety. 159 This compound is synthesised by the coupling of 
an amine on the ferrocene unit to the carboxylic acid on the rhodamine unit 
resulting in a lactam derivative that is non-fluorescent. The ferrocenyl group 
was incorporated to act as a reversible redox-active group, while 8- 
hydroxyquinoline acts as a coordinating site for the metal ion. Changes in the 
UV/visible absorption spectrum, fluorescence emission spectrum and 
electrochemical properties have been observed upon binding with mercury(II), 
while confocal microscopy has demonstrated the application of this conjugate to 
monitor mercury(II) levels in living cells.
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Hg(H)
Non-fluorescent
Figure 85 Reaction between a rhodamine B derivative, with a ferrocene unit and 8- 
hydroxyquinoline, with mercury(II)
3.2.3 Rhodamine analogues as temperature sensors
A polymer based on TV-isopropylacrylamide and rhodamine that is sensitive to 
changes in temperature has been prepared (figure 86). 160 The polymer was 
shown to exhibit a selective emission enhancement in the temperature range of 
25 - 33°C in acidic media. This change in optical properties is thought to be 
caused by polymer aggregation. At temperatures below 25°C, the polymer 
chain forms a non-fluorescent coil, while an increase in temperature to above 
25°C causes the coil to form fluorescent globules of 1 - 200 um due to polymer 
aggregation. At temperatures greater than 35°C, the globules become so large 
(>200 um) that there is a reduction of fluorescence due to a decrease in the 
amount of incident light absorbed.
/^O 
HN
Y
Figure 86 Structure of a temperature sensing polymeric rhodamine derivative
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3.3 The attempted synthesis of rhodamine B piperazine 
amide derivatives
To be able to conjugate these optical dyes to the chelators (36) and (40) that 
contain a benzyl amine, the rhodamine molecule needs to have a reactive 
functional group available. Nguyen et ol. have reported a practical synthetic 
route to produce functionalised rhodamine dyes that can be coupled to proteins, 
providing materials for biomolecule modification. 155 This strategy has been 
followed here using the routes shown in figure 87.
Et,N
Et,N
13
15
NEt,
Figure 87 The synthetic scheme used to produce functionalised rhodamine B derivatives
The advantage of this route, apart from the use of the inexpensive rhodamine B 
starting material, is that the cyclisation to a non-fluorescent species (lactam) is 
avoided due to the formation of a tertiary amine on addition of the piperazine 
unit. Generally, functionalising at the carboxylate group to form an amide bond 
can lead to a rapid cyclization that results in the non-fluorescent lactam (figure 
88). The loss of fluorescence means that the rhodamine derivative is no longer 
useful for biological imaging.
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CT ^ NEt2 
Figure 88 Cyclization of the rhodamine amide (right) to form a lactam (right)
Nguyen et al. have reported that the piperazine unit can subsequently be further 
functionalised at the secondary amine with either an acid chloride or an alkyl 
halide. 155 This could be coupled onto the secondary amine group on DO3A (31) 
or at the aromatic amine position on (36) and (40).
The first step is to convert rhodamine B to the lactam derivative known as 
rhodamine B base (11). This is readily done by partitioning the compound 
between aqueous 1M sodium hydroxide solution and ethyl acetate with the 
organic layer collected. The solvent was then removed from the organic layer 
to leave a pink foam. The yield achieved was 93%, which was the same as that 
quoted in the literature method. 155 The synthesis of (11) was confirmed by 
analysis of the *H NMR spectrum, which corresponded to the published data.
3.3.1. The synthesis of rhodamine B piperazine amide (12)
Rhodamine B piperazine amide (12) was synthesised from (11). The first step 
was the dropwise addition of trimethylaluminium in toluene to a solution of 
piperazine in dry dichloromethane over 1 hour. A solution of (11) in 
dichloromethane was then added, and the resulting reaction mixture heated at 
reflux for 24 hours. After allowing the reaction mixture to cool to room 
temperature, the aluminium reagent was quenched with 0.1 M of hydrochloric 
acid solution. This was then filtered to remove any solids formed, washed with 
dichloromethane and methanol, followed by removal of the solvent. The 
compound was purified by using a simple extraction work up. The de- 
protonated product (12) has a much greater water solubility than (11), and 
therefore was extracted selectively into the basic aqueous solution when 
partitioned with ethyl acetate. The aqueous solution was then saturated with
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sodium chloride followed by acidification with 1 M hydrochloric acid solution, 
and (12) was extracted from the aqueous layer with propan-2-ol and 
dichloromethane. The product was isolated as a dark purple solid in 57% yield. 
From the 'H NMR spectrum, the triplet at 1.32 ppm can be assigned to the CH3 , 
with the multiplet at 3.69 ppm to the CH2 on the diethylamine moiety. The key 
marker is the broad singlet at 3.33 ppm that has an integration of four and can 
be assigned to the piperazine ring protons. The 13C NMR spectrum contains 17 
peaks as expected, and the electrospray mass spectrum has a peak that 
corresponds to the molecular ion. The literature preparation reports a higher 
yield than was obtained in this work (70% compared to 57%). This may be due 
to insufficient extraction in the work up resulting in the loss of product or it is 
possible that salts could have been retained in the reported procedure that 
artificially increased their yield.
3.3.2 The synthesis of a rhodamine B piperazine amide 
derivative containing an alkyl halide
The next step, involves a nucleophilic substitution reaction at the secondary 
amine position on the piperazine ring to form a functionalised rhodamine B 
derivative. The literature contains reports of a number of different substitutions, 
using reagents such as succinic anhydride, chloroacteyl chloride and 3- 
bromopropanol, see figure 87. 155 In this work, chloroacetyl chloride was 
initially used. The attempted synthesis of rhodamine B 4-(2- 
chloroacetyl)piperazine (13) was carried out by dissolving (12) in 
dichloromethane and then cooling this solution to 0°C. Chloroacetyl chloride 
was then added to the reaction mixture, followed by the addition of pyridine (to 
act as a base). The reaction mixture was warmed to room temperature and then 
allowed to stir for 4 hours. The literature quotes a yield of 95%, however, the 
desired product was not isolated. 155 The reaction was repeated using the same 
procedure but replacing chloroacetyl chloride with bromoacetyl chloride to form 
rhodamine B 4-(2-bromoacetyl)piperazine (14), but once again the desired 
product was not isolated. It was initially thought that the acid chloride had been 
hydrolysed to give the analogous carboxylic acid and hence did not react. 
Therefore, an alternative route using 3-bromopropanol was investigated.
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The attempted synthesis of rhodamine B 4-(propoxy)piperazine (15) involved 
the addition of 3-bromopropanol and diisoethylpropylamine to a solution of (12) 
in dimethylformamide under an atmosphere of nitrogen followed by stirring the 
reaction mixture for 24 hours. At this point, further amounts of 3- 
bromopropanol and diisoethylpropylamine were added and the reaction mixture 
was left to stir for a further 2 hours. The solution was then concentrated and the 
extraction procedure carried out, however the desired product was not isolated. 
This suggests that the issue may be with the secondary amine group on (12) and 
that it could be deactivated, preventing the substitution reaction of either the 
acid chloride/bromide or alkyl bromide. This reaction was not investigated 
further and alternative routes were pursued.
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3.4 The synthesis of rhodamine B ethylenediamine 
derivatives
Kirn and co-workers have reported the synthesis of two different rhodamine 
based sensors for which the fluorescence is selectively 'turned on' in the 
presence of mercury(II) (figure 89). 161 The two derivatives have slightly 
different structures, however they both work on a similar principle where upon 
binding of mercury(II) the molecule is converted from the non-fluorescent 
cyclised lactam to the non-cyclised fluorescent structure. One of these 
compounds is Ar-(rhodamine-6G)lactam-A^ '-phenylthiourea-ethylenediamine 
where the mercury(II) causes a desulfurization reaction, and the other is based 
on rhodamine B and bears both a tris(2-aminoethyl)amine and two 
sulphonamide groups. In the latter compound, the mercury(II) binds to oxygen 
donor of the rhodamine amide group and the N-donor groups of the two 
deprotonated sulfonamide groups. 162
Hg(li)
Non-fluorescent fluorescent
Hg(H)
NEt2 Et,N
Non-fluorescent fluorescent
Figure 89 Structures of the two compounds reported by Kim and co-workers 7V-(rhodamine- 
6G)lactam-A^'-phenylthiourea-ethylenediamine (top), and a rhodamine B derivative containing 
both a tris(2-aminoethyl)amine and two sulphonamide groups (bottom) 162161
These compounds were synthesised in a similar fashion from either rhodamine 
6G, or rhodamine B by treatment with ethylenediamine. A related approach
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was exploited in this work by adopting the ethylenediamine as a linking group 
to join the dye to the chelator.
3.4.1 The synthesis of rhodamine B base ethylenediamine (16)
The formation of the rhodamine B ethylenediamine complex offers the potential 
for the ethylenediamine primary amine group to be coupled to an isothiocyanate 
group. The proposed synthetic scheme is shown in figure 90.
OH
ethylenediamine
Figure 90 Reaction scheme of the preparation of rhodamine B base ethylenediamine (16)
A major issue with this synthetic route is that the rhodamine derivatives 
produced are not fluorescent due to the lactam formation. However, such 
molecules do hold the potential to act as mercury(II) sensors.
The synthesis of (16) was carried out by dissolving rhodamine B into hot 
ethanol, adding a 5-fold excess of ethylenediamine, and heating the mixture at 
reflux for 6 hours. The solution was then concentrated to a volume of around 5 
ml and cooled to below 0°C. A precipitate formed that was collected by 
filtration and then recrystallised from a minimum amount of acetonitrile to give 
an orange/pink solid in a 38% yield. In the ! H NMR spectrum, the aromatic 
region is very complex and individual peaks cannot be fully assigned, however 
in the alkyl region there are peaks at 2.32 ppm that 3.11 ppm that are both 
triplets representing the 2 CH2 environments and are characteristic for 
ethylenediamine. The BC NMR spectrum shows 17 different carbon 
environments representing 1 CHa, 3 CHa, 7 CH, and 6 C carbons.
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3.4.2 The synthesis of 
ethylenephenylthiourea (18)
rhodamine B base
To confirm that the alkyl amine would be reactive towards phenyl 
isothiocyanates, a test reaction was undertaken to form the thiourea compound 
(18). The reaction scheme is presented in figure 91.
SCN-
Et,N NEt2
18
Figure 91 Reaction scheme for the synthesis of rhodamine B ethylenephenylthiourea (18)
Phenylisothiocyanate was added to a solution of (16) in dry dichloromethane 
and the resulting mixture was stirred for 48 hours at room temperature under an 
atmosphere of nitrogen. The solvent was then removed, and the crude material 
recrystallised from a minimum amount of acetonitrile to give a light pink solid. 
The peaks in the 'H NMR spectrum overlap and are difficult to fully assign, 
however the integration values do equate to what is expected, and the 13C NMR 
spectrum contains peaks representing 22 unique carbon environments. The 
electrospray mass spectrum contains the expected molecular ion peak. This test 
reaction confirms that the alkyl amine can undergo reaction with an 
isothiocyanate moiety.
A rhodamine unit, (16), has been synthesised that can be conjugated to DOS A 
derivatives containing a phenylisothiocyanate group, however the dye is not in a 
fluorescent form. There are potential applications of this system, such 
conjugates could still show promise as mercury(II) sensors and the rhodamine 
moiety will cause localisation at the mitochondria in cellular systems. Hence, 
such a conjugate coupled with a luminescent lanthanide ion may still be useful 
as an optical sensor in biological systems.
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3.5 BODIPY derivatives as optical dyes
Boron dipyrromethenes (BODIPY) have been exploited as fluorescent probes in 
life science applications. 163 This is due to their attractive photophysical 
properties as characterised by a tunable emission spectral profile in the 500-650 
nm range, high fluorescence quantum yields, low rates of intersystem crossing, 
large molar absorption coefficients, and excellent photostability. 164 The general 
structure of the BODIPY molecule is shown in figure 92, however, this does 
have the limitation of small Stokes shifts (around 600 cm" 1 ) and hence requires 
specific excitation wavelengths. Different approaches have been employed to 
tune the optical properties including functionalisation at the meso position i.e. 8- 
position, substitutions at the 3- and 5- position and replacement of the fluorine 
atoms on the boron. 165166
Functionalisation 
at 8-position
Functionalisation 
at 5-position
Functionalisation 
at 3-position
Replacement 
of fluoride atoms
Figure 92 Diagram illustrating the different approaches used to functionalise BODIPY
3.5.1 Synthesis of BODIPY derivatives with substitution at the 
3-and 5-position
Rohand et al. have investigated substituting BODIPY dyes at the 3 and 5 
position to synthesise 3,5-dichloro-BODIPY. 166 The synthesis started from 4- 
methylbenzaldehyde and pyrrole to form the dipyrromethane. This is followed 
by chlorination with jV-chlorosuccinimide, then oxidation with />-chloranil and 
complexation with trifluoroboronetherate giving the product in overall yields of 
20% (figure 93).
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o W-chlorosuccinimide
)>
Figure 93 Reaction scheme to synthesise 3,5-dichloro-BODIPY
From the chloro BODIPY derivative, they have prepared a selective potassium 
binding BODIPY chemosensor via linkage to an azacrown ether. 166 The 3,5- 
dichloro-BODIPY compound was selectively substituted by a methoxy group 
upon addition of sodium methoxide, and the second chloride substituted by an 
aza-18-crown-6 in 40% overall yield (figure 94).
NaOMe
MeO MeO F ' > V fc
Figure 94 Reaction scheme to synthesise 3-[(4,7,10,13,16)-pentaoxa-l-aza-cyclooctadecane]- 
3a,4a-diaza-4,4-difluoro-5-niethoxy-8-phenyl boron dipyrromethene
3.5.2 Synthesis of fluorine substituted BODIPY derivatives
Ziessel and co-workers have optimised the properties of the BODIPY analogues 
by replacing the fluoride ions with aryl, ethynaryl, ethynylthienyl or 
ethynylpolypyridine to form a library of compounds. 164 The synthesis involves 
the use of organometallic reagents (RLi or RMgBr) to displace the fluoride ion, 
with yields of around 30 - 40%. The compounds remain strongly fluorescent, 
with a slight increase in the fluorescence relative to the fluoride substituted 
analogues (figure 95).
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MgBr
F F
Figure 95 Reaction scheme to synthesise an aryl substituted compound
3.5.3 BODIPY compounds as sensors
BODIPY compounds can be exploited as fluorescent sensors. Baruah et al. 
have synthesised a BODIPY based hydroxyaryl derivative that shows 
fluorescence enhancement with the decreasing pH (pKa values ranging from 7.5 
to 9.3) (figure 96). 167 While Sunahara et al have reported the synthesis of a 
switchable fluorescent BODIPY derivative that is sensitive to its environment 
and can detect local polarity changes in biological samples including proteins,
membranes and receptors (figure 96). 168
Cl
F F F F
Figure 96 Structures of the pH probe (left), and the polarity probe (right) based on the BODIPY 
framework
Qi et al. have published the synthesis of an interesting tripodal fluorescent 
system that contains a triazine core and can combine three different functional 
moieties such as a signalling (BODIPY), a binding and an auxiliary subunit 
(figure 97). 169 Such a compound has the potential to be used in tagging of 
biological substrates to give fluorescent chemosensors, and a component of
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functionalised nanomaterials. The initial study involved the synthesis of the 
compound and analysis of its photophysical properties, however, more work is 
needed to exploit the full potential of this approach.
H,CO,
F F
Figure 97 Structure of a novel BODIPY-triazine based tripodal fluorescent compound
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3.6 Synthesis of a BODIPY functionalised at the 8- 
position
The preparation of BODIPY analogues that contain functionality for further 
conjugation to DO3A derivatives, can be achieved by substituting at the meso 
position (8-position), with a secondary amine that could be converted to a 
isothiocyanate group. Numerous research groups have investigated routes to 
introduce functionality at the 8-position to improve the optical properties of the 
BODIPY dye. 170 The addition of a further aromatic group e.g. a phenyl ring can 
lead to improved fluorescence. There are a number of methods to synthesise 
such BODIPY analogues. A strategy employed by Pena-Cabrera et al. involves 
substitution with a derivatised boronic acid onto 8-thiomethylBODIPY using 
Pd(0) and Cu(I)-2-thienylcarboxylate in overall yields of greater than 70% 
(figure 98). 154
SMe
+ 3R-B(OH)2
2.5% Pd2(dba)2 
7.5% TFP
SCuTC
Figure 98 Reaction scheme showing the use of boronic acids to produce 8-substituted BODIPY 
derivatives
Porres et al. reported the reaction of a substituted aldehyde with 2,4-dimethyl-3- 
ethylpyrrole to form a multichromophoric BODIPY analogue (figure 99) 171 The 
synthetic strategy employed here involved 2,4-dimethyl-3-ethylpyrrole 
undergoing a condensation reaction with a substituted benzaldehyde ((!,!'- 
biphenyl)-4,4'-dicarboxaldehyde). The dipyrromethane was converted to a 
dipyrromethene using DDQ (dichlorodicyanoquinine) oxidation, and then 
treated with trifluoroboronetherate, to give the desired product in overall yields 
of 42%.
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CHO
CHO
1)TFA
2)DDQ
3) BF3-Et2O
Figure 99 Reaction scheme for the synthesis of a multichromophoric BODIPY analogue
Ulrich and co-workers have reported the synthesis of 4,4-difluoro-4-bora-3a,4a- 
diaza-s-indacene derivatives bearing an isothiocyanate or isocyanate functional 
group (figure 100). 172 They started from 2,4-dimethyl-3-ethylpyrrole which was 
treated with nitrobenzoyl chloride, followed by conversion to the boron 
complex using trifluoroboronetherate, and finally the nitro group was reduced to 
an amine with 5% Pd/C in yields over 50%. The amine group can then be 
converted to an isothiocyanate or isocyanate group ready for conjugation to 
biomolecules.
0 ci
H i) DCM
N^ II) BF3OEt2 , EtjN
F F F F
Figure 100 Reaction scheme for the synthesis of an aminophenyl BODIPY.
3.6.1 The synthesis of 5-(4-isothiocyanatophenyl) boron 
dipyrromethene (21)
The method chosen for the synthesis of 5-(4-isothiocyanatophenyl) boron 
dipyrromethene (21) was developed by Boyle and co-workers. 173 The reason 
for using this route is that the amide functionalised benzaldehyde reacts
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efficiently and the amide group in the resulting product can readily be converted 
to the desired amine. The synthetic scheme used is shown in figure 101.
o NH,
H i) TFA, DCM 
N ii) DDQ, DCM i) HCI, MeOHii) BF3OEt2 , Et3N, DCM
20
F F
TOP, DCM
NCS
21
F F
Figure 101 Synthetic scheme used to prepare 5-(4-isothiocyanatophenyl)BODIPY (21)
The reason for using the 3-ethyl-2,3-dimethylpyrrole rather than pyrrole is to 
restrict the rotation of the 5-phenyl ring, which leads to a ten-fold increase in 
fluorescence quantum yield. The synthesis of (19) involved the reaction of 4- 
acetamidobenzaldehyde and 3-ethyl-2,3-dimethylpyrrole in dry 
dichloromethane, with the addition of a catalytic amount of trifluoroacetic acid 
(TFA) and stirring at room temperature overnight. The dipyrromethane 
derivative was converted to the dipyrromethene by DDQ oxidation (stirred for 1 
hour at room temperature). The reaction mixture was washed with water, and 
then the organic layer was collected and the solvent removed. The mixture was 
then purified by flash chromatography on silica gel with a solvent gradient from 
100% dichloromethane to 10% methanol in dichloromethane. This gave (19) as 
a purple solid in 37% yield, which was higher than the reported yield in the 
literature. 173 'H NMR spectroscopy was used to analyse the product, giving a 
complex spectrum with a number of overlapping peaks. However, the
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integration values and peak positions are consistent with the previously reported 
data.
To convert the amide to the amine, 1 M hydrochloric acid was added to a 
solution of (19) in methanol and the reaction mixture was heated at reflux for 1 
hour. It was then cooled to room temperature and neutralised with a solution of 
2 M sodium hydroxide, followed by an extraction into dichloromethane. The 
compound was used crude to form the boron complex. The crude solid was 
dissolved into dry dichloromethane, triethylamine and trifluoroboronetherate 
and then stirred at room temperature for 3-4 hours under nitrogen. The reaction 
mixture was washed with water and brine, and the crude material was purified 
by flash column chromatography using 2:1 dichloromethane:hexane as the 
eluent. The product elutes with an r.f. of 0.36, to give (20) as a red solid in 36% 
yield. The 'H NMR spectrum highlights the loss of the amide peak to suggest 
that the deprotection step had occurred, with the electrospray mass spectrum 
confirming the identity of the BODIPY complex (20).
To allow for conjugation of (20) onto the DO3A derivatives, the primary amine 
was converted to an isothiocyanate group to form (21) by the use of TDP in dry 
dichloromethane. The solution was stirred under nitrogen for 4 hours and was 
purified by flash chromatography with a 2:1 mixture of hexane:dichloromethane 
as eluent to give a red solid in 75% yield. The 'H NMR spectrum highlights the 
shift in position of the aromatic CH peaks upon conversion to the isothiocyanate 
from 7.37-7.39 ppm in (20) to 7.0-7.02 ppm in (21).
3.6.2 Attempted synthesis of 5-(4- 
phenyl(thioureaphenyl))borondipyrromethene (22)
Boyle and co-workers have already demonstrated that the isothiocyanate 
BODIPY (21) can be coupled to proteins bearing alkyl amines (lysine side 
chains). 173 To test the reactivity of the isothiocyanate group towards aromatic
110
amines, an attempt was made to react (21) with phenylamine as shown in figure 
102.
NCS
21
F F ' ' F F 
Figure 102 Attempted synthesis of 5-(4-phenyl(thioureaphenyl))borondipyrromethene (22)
The reaction mixture was stirred under nitrogen at room temperature for 7 days. 
The progress of the reaction mixture was monitored by t.l.c., and showed that no 
reaction had occurred. This suggests that the aminophenyl group is unreactive 
with the isothiocyanate or the reaction is only proceeding very slowly. A slow 
reaction would be problematic as hydrolysis of the isothiocyanate may compete. 
The delocalisation of electron density on the amine group into the aromatic 
system probably accounts for its reduced reactivity.
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3.7 Synthesis of boron dipyrromethane complexes 
bearing an alkyl amine
There are a number of options available in the synthesis of alkyl amine bearing 
BODIPY derivatives. These derivatives offer an alternative to the aromatic 
amine BODIPY analogues, in which the alkyl amine may react with the 
isothiocyanate group more readily then its aromatic amine counterpart. The 
target BODIPY analogue is shown in figure 103.
Figure 103 Target BODIPY analogue bearing an alkyl amine, where R = CH2NH(CH2)2NH2, or 
(CH2) 3NH2
The three synthetic strategies that have been investigated are depicted in figure 
104. Methods 1 and 2 involve the use of a Boc-protected aminobutyric acid 
with ethyl chloroformate used to activate the carboxylic acid. In method 3, 5- 
(4-aminophenyl)BODIPY (20) is treated with bromoacetyl chloride followed by 
the reaction with an excess of ethylenediamine.
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BrCHoCOCI
Method 3
NH2CH2CH2NH2
Method 1
o /
NHBoc
HN v v /1)4MHCI/dioxane 1)TFA"•"' 2)BF3 OEt2)TFA
CICOOEt
Method 2
Figure 104 Routes to prepare BODIPY analogue bearing an alkyl amine, where R = 
CH2NH(CH2)2NH2, or (CH2)3NH2
3.7.1 The synthesis of BODIPY derivatives using methods 1 
and 2
In the literature, there are a number of examples of the addition of an alkyl 
amine onto aromatic amine bearing compounds. An example investigated by 
Perillo et al, involves 2-bromoethylamine hydrobromide being substituted onto 
an arylamine. 174 This relies on the arylamine being more reactive than the 
amine on 2-bromoethylamine hydrobromide. Poindexter et al. coupled 2- 
oxazolidinones onto an aromatic amine, which results in an alkyl amine
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extending from the phenyl ring. 175 An interesting method investigated by Biron 
et al. involved the preparation of a cationic porphyrin that bears an amino acid 
derivative (figure 105). 176 This was synthesised by the coupling of a porphyrin 
to a Boc protected glutamic acid via an amide bond through the activation of the 
carboxylic acid in 80% yield. The removal of the Boc protecting group was 
performed quantitatively by stirring in a solution of 4 M HC1 in dioxane.
COOH
Boc.
N COOCH3
CICOOEt
4M HCI/dioxane
•COOCH3 
NHBoc
COOCH3 
NH2
Figure 105 Synthetic scheme to react a porphyrin with a modified amino acid reported by Biron 
etal.
3.7.2 Synthesis of 4-Boc aminobutyric acid (23)
A modified method based on the synthesis reported by Biron et al was followed 
in the preparation of an alkyl amine bearing BODIPY compound (25). 
176Initially, the Boc protected aminobutyric acid (23) was prepared following 
the method reported by Itoh et al.. 111 This involved reacting 4-aminobutyric 
acid and /er/-butyloxycarbonyl in a mixture of triethylamine and dioxane, which 
was stirred for 4 hours at 0°C. The solution was then concentrated to give a 
white solid, which was dissolved into water and washed with ethyl acetate. 
Collection of the aqueous layer followed by removal of the solvent gave a clear 
oil in 49% yield. The 'H NMR spectrum confirmed the presence of the Boc 
group with a singlet at 1.30 ppm representing the three CH3 groups, and the
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peaks at 1.63, 2.16, and 2.97 ppm representing the three CH2 groups with the 
expected splitting pattern of a quintet, triplet and triplet respectively.
3.7.3 Synthesis of 5-(4-aminobutylamidophenyl) boron 
dipyrromethene (25)
The carboxylic acid group on (23) was activated by stirring with 
ethylchloroformate and triethylamine in dry dichloromethane. The mixture was 
allowed to stir for 30 minutes at room temperature under nitrogen and the acyl 
chloride derivative of (23) was isolated. The compound was dissolved into dry 
dichloromethane, the solution was cooled to 0°C, followed by the addition of 
(20) and then the reaction mixture was left to stir for 1 hour under nitrogen. The 
resulting crude solid was purified by flash column chromatography with a 
solvent gradient from 100% dichloromethane to 2% methanol in 
dichloromethane to give a red solid with a yield of 85%. The 1 H NMR 
spectrum shows two peaks in the aromatic region at 7.21 and 7.78 ppm. In the 
alkyl region, the triplet at 0.97 ppm is from one of the CH3 groups on the 
BODIPY, while the other peaks are overlapping with two broad multiplets 
between 1.2-2 ppm, and 2.3 - 2.5 ppm with a total integration of 21 protons. 
The electrospray mass spectral data shows the expected molecular ion peak. 
The reaction scheme is shown in figure 106.
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^O Boc-ON 
XOH
CICOOEt
23 OH NH2
20
NHBoc
FF
F F
1)4MHCI/dioxane
2)TFA
Figure 106 Reaction scheme showing the synthesis of 5-(4-aminobutylamidophenyl) 
borondipyrromethene (25)
Initial efforts to deprotect the boc-protected amine involved following a 
modified method based on the synthesis reported by Biron et al.. 176This 
involved dissolving (24) into a mixture of 4 M hydrochloric acid and dioxane, 
and then stirring for 4 hours at room temperature while monitoring by t.l.c. the 
reaction. After 4 hours, there were no signs of Boc deprotection and so an 
alternative method was then investigated. This procedure was repeated with 
dissolving (24) in trifluroracetic acid and dichloromethane and stirred for 20 
minutes at room temperature. However, the addition of the trifluoroacetic acid 
caused a colour change of the solution from bright red to purple that is 
characteristic of the uncomplexed dipyrrin compound. The t.l.c. had a number 
of spots at r.f values that are not characteristic of the polar boron complexes. 
This suggests that the trifluoroacetic acid had reacted with the BODIPY unit 
and possibly caused the decomplexation of the boron.
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3.7.4 Synthesis of 5-(4-aminobutylamidophenyl) 
borondipyrromethene (26) (method 2)
Method 2 involved starting from 5-(4-aminophenyl) dipyrromethene and 
coupling to the acyl chloride derivative of (23) with the reaction scheme shown 
in figure 107. The activated 4-boc aminobutyric acid (23) was dissolved into 
dry dichloromethane and 5-(4-aminophenyl) dipyrromethene was added. The 
reaction mixture was stirred for 1 hour at 0°C, followed by 1 hour at room 
temperature. The resulting solid was purified by flash column chromatography 
eluting with a solvent gradient of methanol in dichloromethane to form a purple 
solid (26) in 45% yield. The 'H NMR spectrum was very broad, with two 
aromatic peaks at 7.24 and 7.88 ppm, and the alkyl region from 0.84 and 2.44 
ppm. The broadening of the NMR signals may be due to the restricted 
molecular rotation of the compound.
NHBoc
1)TFA 
o 1)CICOOEt, TEA || J 26 2) BF3OEt, TEA
23 OH 2) "H2
F F
Figure 107 Attempted synthesis of 5-(4-aminobutylamidophenyl) borondipyrromethene (25)
3.7.5 The synthesis of 5-(4-aminobutylamidophenyl) 
borondipyrromethene (25)
Attempts were made to deprotect the amino Boc group on (26) to give (25). 
(26) was dissolved in a mixture of trifluoroacetic acid and dichloromethane and 
allowed to stir for one hour at room temperature. The solvent was removed, and 
the solid was re-dissolved into ethyl acetate and washed with sodium hydrogen 
carbonate. The resulting crude solid, isolated from the organic layer, was 
complexed to boron by the reaction with trifluoroboronetherate in the presence 
of triethylamine. The reaction mixture was stirred for four hours at room 
temperature under an atmosphere of nitrogen. After work up, t.l.c. analysis was
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performed on the reaction mixture, which indicated the presence of two polar 
compounds that may contain boron. It was proposed that a mixture of (25), and 
the starting material (26) had been isolated. This was not investigated further 
due to the small amount of product obtained.
3.7.6 Synthesis of 5-(4-bromomethylamidophenyl) 
borondipyrromethene (28) (method 3)
An alternative method to form an alkyl amine appended on a BODIPY complex 
was investigated where bromoacetyl chloride was treated with 5-(4- 
aminophenyl)borondipyrromethene to form 5-(4-bromomethylamidophenyl) 
borondipyrromethene (28). Ethylenediamine can be reacted with (28) to form 
5-(4-ethylenediaminomethylamidophenyl)borondipyrromethene (29). The 
reaction scheme is shown in figure 108.
F F
BrCHjCOCI
F f
Figure 108 The reaction scheme used to prepare 5-(4-ethylenediaminomethylamidophenyl) 
borondipyrromethene (29)
The first attempt to synthesise (28), involved dissolving 5-(4-aminophenyl) 
dipyrromethene into dry dichloromethane in the presence of triethylamine and 
cooling the reaction mixture in an ice bath to 0°C. Bromoacetyl chloride was 
added and the reaction mixture was stirred for 24 hours. The compound was
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purified by preparative t.l.c. using 10% methanol in dichloromethane as eluent 
to give a red solid in 82% yield. The analytical data from the !H NMR and 13C 
NMR spectroscopy and electrospray mass spectrometry showed that instead of 
(28), the triethylamine BODIPY derivative (27) had been formed by reaction 
with triethylamine. Triethylamine acted as a nucleophile to react with the alkyl 
bromide group on the BODIPY moiety. The 'H NMR spectrum contains two 
doublets at 7.21 and 7.85 ppm that represent the two aromatic proton 
environments, and a triplet at 0.94 ppm, quintet at 2.26 ppm and two singlets at 
1.37 and 2.5 ppm that were assigned to BODIPY protons. The singlet at 4.62 
ppm represents the CH2 next to the amide group. The two peaks at 1.44 ppm 
and 3.74 ppm (triplet and a quintet) represent the Ctk groups of the 
triethylamine. The electrospray mass spectral data shows a molecular ion peak 
that corresponds to (27). While it is not possible to couple this compound to the 
DO3A chelators, it may have potential as a dye compound for cellular imaging 
studies. The quatemarised amino group will improve water solubility of the 
BODIPY derivative and the positive charge may aid cellular uptake of the 
compound. This route is also generally applicable to the formation of other 
quaternised amino derivatives of BODIPY and incorporating different alkyl 
chains or functionality may influence cellular localisation. The cellular uptake 
of this compound was studied using fluorescence microscopy and the results are 
presented in chapter 5.
To produce (28), the reaction was repeated and 5-(4-aminophenyl) 
dipyrromethene was washed with sodium hydrogen carbonate solution to make 
the phenyl amine more susceptible to undergo nucleophilic substitution by 
deprotonating the amine. The compound was then re-dissolved in dry 
dichloromethane and cooled in an ice bath to 0°C under nitrogen. Bromoacetyl 
chloride was added, and the reaction mixture was allowed to stir for 4 hours, no 
triethylamine was added. The solvent was removed, and the compound was 
purified by preparative t.l.c. using dichloromethane as eluent. The product was 
isolated as a red solid in 77% yield. Analysis by 'H NMR, 13C NMR 
spectroscopy and electrospray mass spectrometry confirmed the formation of 
(28).
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3.7.7 Synthesis of 5-(4-ethylenediaminemethylamidophenyl) 
borondipyrromethene (29)
The synthesis of the alkyl amine containing compound (29) was achieved by 
dissolving (28) into acetonitrile, adding ethylenediamine and stirring the 
reaction mixture overnight under nitrogen. The solvent was removed, and work 
up yielded a red solid. To purify the crude material, a preparative t.l.c was 
performed to give a red solid in 13% yield. The } H NMR spectrum, showed the 
neighbouring CHa next to the amide shifted to 2.21 ppm, and two multiplets at 
2.72 and 2.83 ppm that represent the two CH2 groups on the ethylenediamine. 
The electrospray mass spectrum contained the expected molecular ion peak at 
493 for (29).
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3.8 Synthesis ofzinc(ll) (di-5-(4-aminophenyl)) 
dipyrromethene (30)
The use of transition metal complexes with dipyrromethene ligands in 
fluorescence imaging applications is limited by quenching processes associated 
with a metal centre that reduce the quantum yield. However, the combination of 
a diamagnetic metal centre and restricted internal rotation of the phenyl group 
can be used to increase these quantum yields. 178 Attempts were made to 
produce the zinc(II) (di-5-(4-aminophenyl))dipyrromethene complex (30). The 
two equivalents of ligand form a four coordinate tetrahedral environment 
around the metal centre. The complex has two primary amine groups available 
to react with isothiocyanate functionalised DOS A chelators (figure 109). 
Ultimately this could be used to form a trimetallic species with two 
gadolinium(III) ions, e.g. Gd2ZnL2, that could function as a multimodaliry 
imaging agent. The quantum yield for the fluorescence process will still be 
lower than that observed for BODEPY derivatives but an increase in the number 
of gadolinium(III) ions will improve the properties as an MRI contrast agent 
relative to the BODIPY analogue.
NH2
1)1MHCI
2) Zn acetate
Figure 109 Synthetic scheme to show the preparation of zinc(II) (di-5-(4-aminophenyl)) 
dipyrromethene (30)
The method used to synthesise the zinc(II) complex was a modified version of 
that reported by Dolphin and co-workers, where zinc(II) acetate in methanol
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was added to the solution of 5-(4-aminophenyl) dipyrromethene in methanol 
under nitrogen, and the reaction mixture heated at reflux overnight. 179 The 
reaction was worked up and resulted in a green solid in 83% yield. The 'H 
NMR spectrum was very similar to the dipyrrin starting material and therefore 
could not be unequivocally assigned to the formation of the zinc(II) complex. 
High resolution mass spectrometry confirmed the formation of (30). Further 
evidence was obtained from the UV-vis spectrum, where the mean absorbance 
peak for the starting material 5-(4-aminophenyl) dipyrromethene was at 461 nm, 
shifted to 504 nm upon zinc(II) complexation. The zinc(II) complex could 
theoretically be coupled to a DOS A chelator derivative, but this was not 
attempted as similar issues with reactivity of the amino group exist as were 
encounted for the BODIPY derivatives (see chapter 4).
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3.9 Conclusions
This chapter contains discussion of the synthesis of optical dyes that contain 
appropriate functionality for conjugation to a DO3A derivative. The two optical 
dyes investigated were based on rhodamine and boron dipyrromethene 
(BODIPY).
The rhodamine synthesis involved following the method reported by Nguyen et 
al where a piperazine ring was coupled onto rhodamine B base using 
trimethylaluminium. 155 The piperazine ring will prevent the cyclisation reaction 
to form a non-fluorescent lactam. Efforts were made to attach appropriate 
functionality for conjugation to a DO3A chelator by reacting chloroacetyl 
chloride, bromoacetyl chloride and 3-bromopropanol at the secondary amine on 
the piperazine unit (13). However, this proved unsuccessful, possibly due to 
inhibition of the reactivity of the amine on piperazine by protonation.
The preparation of a rhodamine derivative bearing an alkyl amine was 
investigated, as this would readily undergo nucleophilic substitution with an 
isothiocyanate group to form a thiourea link. The compound (16) was formed 
by the reaction between rhodamine B and ethylenediamine. However, 
compound (16) forms a non-fluorescent lactam that will limit its use as an 
optical dye. It may still have cellular uptake and localisation properties that are 
of interest and could potentially be used as a sensor for mercury(II).
BODIPY analogues have been synthesised using the method developed by 
Boyle and co-workers. 173 This method involved the reaction between 3-ethyl- 
2,3-dimethylpyrrole and 4-acetamidobenzaldehyde to form the dipyrromethane, 
with DDQ oxidation to convert it to the dipyrromethene (19). The amide was 
then removed using HC1, followed by complexation with boron to form a 
BODIPY derivative containing an aromatic amine (20). The isothiocyanate 
derivative (21) can then be synthesised by reaction with TDP.
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To form a BODIPY molecule containing an alkyl amine, efforts initially 
involved the coupling reaction between the Boc protected amine group (23) 
with the amino BODIPY (20). The carboxylic acid unit in this compound was 
activated using ethylchloroformate to form the acyl chloride. While this 
reaction worked, attempts to deprotect the Boc group with TFA resulted in the 
decomplexation of the boron. The reaction was repeated using 5-(4- 
aminophenyl) dipyrromethene to form the compound 5-(4- 
Bocaminobutylamidophenyl)dipyrromethene (26). Attempts to deprotect the 
Boc group, and complex the compound to boron without isolating the 
intermediates led to the formation of a number of side products.
An alternative method was investigated where 5-(4-aminophenyl) 
dipyrromethene was coupled to bromoacetyl chloride in the presence of 
triethylamine, however, instead of forming the desired compound (28), the 
triethylamine reacted with the alkyl halide to form (27). This compound is of 
interest as a fluorescent probe due to its improved solubility properties and 
potential for cellular uptake. The reaction was repeated where the 5-(4- 
aminophenyl) dipyrromethene was washed with base to deprotonate the phenyl 
amine, and then coupled with bromoacetyl chloride to result in the formation of 
(28). This in turn was treated with ethylenediamine to produce a BODIPY 
derivative with an alkyl amine (29).
A number of optical dyes that have the potential to be conjugated to a DO3A 
chelator derivative have been prepared, including a rhodamine derivative 
containing an alkyl amine(16), and BODIPY analogues with either an aromatic 
amine (20), an alkyl amine (29) or an isothiocyanate group (21).
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4. Synthesis of macrocyclic chelators for 
lanthanides
125
4.11ntroduction
With the development of biomedical applications for metal ions, such as 
gadolinium(III) complexes as MRI contrast agents, there has been a growing 
interest in the synthesis of functionalized polydentate ligands that can complex 
lanthanide metal ions. For polydentate chelators to be used in biomedical 
applications, the complexes formed need to have high thermodynamic stability 
and be kinetically inert. Dissociation of the lanthanide ion is undesirable, as the 
free lanthanide metal ion is toxic. The equilibrium between the complexed 
lanthanide ion and other competing endogenous metal ions or anions can lead to 
dissociation of the metal ion. Common ligands utilised for lanthanide 
complexation in biological systems include 1,4,7,10-tetraazacyclododecane- 
1,4,7,10-tetraacetic acid (DOTA), a macrocycle incorporating a cyclen ring and 
diethylenetriaminepentaacetatic acid (DTPA), a branched acyclic chelator, as 
shown in figure 2. The DOTA ligand is known to form more 
thermodynamically stable lanthanide(III) complexes than the DTPA ligand. 
This is due to the macrocyclic effect. This means that complexes of 
macrocyclic ligands are more thermodynamically stable than linear polydentate 
analogues with the same number and type of donor atoms. Macrocyclic ligands 
are in a preorganised conformation that requires minimal reorganisation on 
metal ion complexation. The stability constant KML is defined by the equation 
below.
K - 
~
Figure 110 Stability constant
The equilibrium lies towards the lanthanide complex. At physiological pH, the 
ligand can be protonated, which will lower the stability constant. This is 
defined as the pH dependent stability constant K'ML- The table below shows 
typical stability constants for common lanthanide(III) chelators (see also figure 
6 for ligands forming gadolinium(III) complexes). 9
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Ligand
DTPA
DTPA-BMA
DTPA-BMEA
DOTA
DO3A
HP-DO3A
BOPTA
Log KML
22.46
16.85
16.84
25.3
21.0
23.8
22.59
Log K'ML
17.70
14.9
-
18.6
14.97
17.21
-
Table 9 Stability constants for selected lanthanide(III) complexes (K*ML is the stability constant 
for the protonated complex)
The data shows that DOTA has the highest thermodynamic stability constant. 
However, there are no simple methods to attach further functional groups to 
DOTA. Modified chelators e.g. HP-DO3A, generally have lower stability than 
DOTA, but are still sufficiently stable for biological applications.918°
This chapter is split into two parts, the first part (sections 4.1 - 4.5) presents 
discussion of the synthetic strategy to produce a chelator that has an appropriate 
functional group for coupling to an optical dye. The second section (4.6) 
contains discussion of the synthetic strategies used to produce multimodality 
imaging agents. The chelator unit used in the multi-modal lanthanide contrast 
agents is based on cyclen, DO3A (31). This allows for attachment of a further 
chelating arm by reaction with either l-(4-nitrobenzylmethyl)-2-chloromethyl 
benzimidazole (7) or 4-nitrobenzylbromide, which can be used to conjugate to 
other molecules. These chelators complex lanthanide ions and after conversion 
of the nitro group to an amine, an optical dye such as BODIPY or a rhodamine 
analogue can be attached. A target molecule is depicted in figure 111. Here, 
the DO3A chelator bears a benzimidazole linker that is coupled to the optical 
dye BODIPY.
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Optical dye
J
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ON N X)
o
Lanthanide chelator
Linker
Figure 111 A target multi-modality contrast agent
This chapter focuses on the synthetic strategy and methodology used in the 
preparation of multi-modality contrast agents that contain a lanthanide(III) 
chelator (DO3A), a linker group (benzimidazole or benzyl) and an optical dye 
(BODIPY or rhodamine).
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4.2 Synthetic strategy to produce a functionalised 
chelator bearing an amine
Chelating ligands based on cyclen form thermodynamically stable lanthanide 
complexes.2 The desired chelator precursor is based on cyclen, with three 
acetate arms, and the remaining N-position functionalised with a benzimidazole 
unit (7). The structure of this molecule is shown in figure 112.
Linker group - benzimidazole
.OR
O,N
Nitro group to convert to 
an amine
acetate arms for 
Ln complexation 
(R=H (unprotected, 
or C(CH3 )3 )(protected))
Cyclen
Figure 112 Chelator functionalised with a benzimidazole group
Methods for the synthesis of such functionalised chelators for lanthanide 
imaging agents include initial coupling of the functionalised arm (i.e. with a 
benzimidazole or benzyl unit), followed by attachment of the three acetate arms 
(method 1), or performing the two steps in reverse order (method 2)
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Method 1
CO N
R'O
N O
OR'
t
b
OR 1
,NH
ON N
R'O
>-*'
Method 2
Figure 113 Synthetic method to produce the functionalised chelators, X = Cl, Br, and R' 
C(CH3 )3 or H
The preparation of functionalised chelators using method 1 has been 
investigated by Balogh et al. to produce monopropionate analogues of DOTA4"
^101
and DTPA ". They investigated and compared two routes to synthesise these 
analogues. One route involved using an excess of the cyclen to selectively 
mono-alkylate, while the second route involved bridging the cyclen with 
glyoxal, that allows controlled mono-alkylation of the cyclen. The glyoxal 
bridge can be removed using hydrazine. The route is shown in figure 114.
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Figure 114 Two routes to produce DOS A chelator derivatives investigated by Balogh et al. 181
To make their target compound via the bis-aminal route, cyclen is bridged using 
glyoxal and then mono-alkylated with 3-iodopropionic acid. The removal of the 
glyoxal bridge is performed by refluxing in hydrazine, and this is followed by 
alkylation at the remaining secondary amine position with chloroacetic acid in 
overall yields of 80%. The other route involves three steps and includes an 
initial selective mono-alkylation of cyclen with ethyl-3-bromopropionate, 
followed by the quantitative alklyation of the three amines with 
ethylbromoacetate, and then hydrolysis in 6 M HC1 to give the product in 85% 
overall yield. When compared to method 2, these routes will either increase the 
number of steps, or lead to an excess use of cyclen that cannot be recovered.
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Method 2 is therefore more advantageous because the 3-armed chelator (DO3A 
(31)) can be synthesised readily in reasonable yields to give a generally 
applicable precursor. The synthesis involves the initial preparation of DO3A 
(31) and then the remaining secondary amine is alkylated with the selected alkyl 
halide benzimidazole (7) or 4-nitrobenzyl bromide (figure 115).
02N
Figure 115 Proposed routes to produce a functionalised chelator with an appended amine 
moiety
The initial strategy involved the formation of the DO3A ligand by following a 
literature method using three equivalents of terf-butylbromoacetate to one 
equivalent cyclen. 77 The next step involved the attachment of the functional 
group, e.g. (7), by stirring the two together with base and heating to reflux. Li 
et al have synthesised a functionalized 1,4,7-triazacyclononane bearing 
benzimidazole groups, and numerous other groups have also reported the 
attachment of various alkyl halides to DO3A suggesting such reactions should 
readily occur. 143 Many literature reports have shown that the nitro group can be 
converted to an amine by a palladium on carbon catalysed hydrogenation, 
however there are potential issues with debenzylation of the functional arm. 182 
183 Sections 4.3 - 4.5 contains discussion of the synthesis of benzimidazole or 
benzyl amine bearing D03A chelators
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4.3 Synthetic strategy to produce chelators bearing a 
benzimidazole group
The coupling of the chelator DO3A (31) to the benzimidazole, l-(4- 
nitrobenzyl)-2-bromomethyl benzimidazole (7) will form the compound 1,4,7- 
tris(ter/-butoxycarbonylmethyl)- 1 0-( 1 -(4-nitrobenzyl)-2-methylbenzimidazole)- 
1,4,7,10-tetraazacyclododecane (32). The nitro group can then be converted to 
the amine by reduction and the lanthanide complexes formed for both the nitro 
(34a-d) and the amine bearing benzimidazole D03A chelators (37a-d). The 
routes to form the benzimidazole chelator DO3A derivatives and the lanthanide 
complexes are shown in figure 116.
33 N. 34a-d
N•
ON No
Figure 116 Synthetic scheme to produce the benzimidazole derivatives
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4.3.1 Synthesis of 1,4,7-tris(fe/f-butoxycarbonylmethyl)- 
1,4,7,10-tetraazacyclododecane (31)
The synthesis of the tri-substituted cyclen (31) involves the selective alkylation 
of the cyclen ring. The initial attempt used 3 equivalents of the tert- 
butylbromoacetate dissolved in chloroform, which was added dropwise to a 
mixture of potassium carbonate and cyclen in chloroform. The solution was 
stirred for 72 hours and filtered to remove the inorganic material. The filtrate 
was then concentrated to leave a cream solid, which was purified by flash 
column chromatography, with a gradient elution of 100% dichloromethane to 
5% methanol in dichloromethane. The resulting solid was washed with diethyl 
ether to yield a white solid in 56% yield. An alternative method was 
investigated where acetonitrile was used as the solvent instead of chloroform. 
This led to an increase in the yield to 60%. This compares well with the 
literature, with reported yields ranging from 42 - 73%. 184
4.3.2 Synthesis of 1,4,7-tris(terf-butoxycarbonylmethyl)-10-(1- 
(4-nitrobenzyl)-2-methylbenzimidazole)-1,4,7,10- 
tetraazacyclododecane (32)
l-(4-Nitrobenzyl)-2-chloromethyl benzimidazole (7) was substituted onto 
DO3A (31) to form l,4,7-tris(fer/-butoxycarbonylmethyl)-10-(l-(4- 
nitrobenzyl)-2-methylbenzimidazole)-1,4,7,10-tetraazacyclododecane (32). A 
number of reaction conditions were investigated to form (32), which are 
described in this section, the synthetic scheme is shown in figure 117.
O2N
^ O(H3)3
C J ———————— L J N02 ( 
NH HN ON Nn ———————*• ^ ^
31 32
Figure 117 The synthetic route used to form (32)
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The initial method attempted involved adding (31) to a mixture of (7) and three 
equivalents of potassium hydrogen carbonate in dry acetonitrile and then 
heating to reflux for 3 days. The reaction mixture was concentrated, and the 
residue purified by flash column chromatography on silica with an increasing 
gradient of methanol in dichloromethane to give the desired product in a 30% 
yield. However, attempts to repeat this reaction were unsuccessful. Therefore, 
efforts turned to improving the reactivity of the benzimidazole unit by the use of 
potassium iodide to replace the chloro group with an iodo group.
Attempts had been made to isolate the iodo derivative of the benzimidazole 
[attempted synthesis of (8)]. This route involved in situ generation of (8) by 
heating a solution of chloro benzmidazole (7) and potassium iodide and then 
performing the coupling reaction in acetonitrile with (31). Analysis of the 'H 
NMR spectrum, suggested that no reaction occurred, with t.l.c. analysis showing 
no products formed. The reaction was repeated, with no base and the use of a 
catalytic amount of potassium iodide in dry tetrahydrofuran. The first attempt 
resulted in (32) as a white solid in 78% yield after purification by flash column 
chromatography with a solvent gradient of 100% dichloromethane to 2% 
methanol in dichloromethane for the eluent. However, the reaction was not 
reproducible.
The issue is most probably with the protonation of the secondary amine on (31) 
and so conditions were altered to deprotonate this amine. Conditions 
investigated involved using either a two-fold excess of sodium hydride or 
lithium diisopropylamide. Analysis suggested that both bases caused reaction 
of the ester groups. Milder reaction conditions using potassium hydrogen 
carbonate as the base were investigated with dimethylformamide as the solvent. 
Analysis by *H NMR spectroscopy and t.l.c. suggested that no reaction had 
occurred. In a further attempt to deprotonate the amine, (31) was washed with a 
solution of sodium hydrogen carbonate and extracted into dichloromethane. 
The base wash removed the slight yellow colour to form a white solid. A *H 
NMR spectrum was recorded that showed the compound was intact after the 
base wash. The compound was then re-dissolved into acetonitrile with an eight­ 
fold excess of the base sodium hydrogen carbonate and a slight excess of (7)
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and was heated to 60°C for 24 hours. The solvent was removed and the product 
purified by flash column chromatography with an increasing gradient of 
methanol in dichloromethane to give a white solid in 76% yield. The *H NMR 
spectrum shows the typically broad peaks for cyclen based compounds with the 
CH3 peaks at 1.42 ppm, and a broad multiple! from 2.2 - 3.5 ppm representing 
the other protons on the cyclen unit. A characteristic peak at 3.94 ppm 
represents the CHa group on the benzimidazole unit and the peak at 5.43 ppm 
was assigned to the Ch^ group on the nitro benzyl group. The expected peaks 
were identified in the 13C NMR spectrum although the CH2 group on the 
benzimidazole was masked by broadened CH2 cyclen peaks. The identity of the 
compound was confirmed by high resolution mass spectrometry. The X-ray 
crystal structure of the sodium complex formed with (32) was obtained. The 
crystals were grown by slow evaporation of a dichloromethane solution over a 
period of two weeks, resulting in the formation of colourless blocks.
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C24
Figure 118 The molecular structure of the sodium bromide complex 1 ,4,l-tris(tert- 
butoxycarbonylmethyl)-10-( 1 -(4-nitrobenzyl)-2-methylbenzimidazole)-1,4,7,10- 
tetraazacyclododecane (32) showing the atom labelling and 50% probability ellipsoids for non- 
H atoms
The X-ray structure revealed a sodium ion coordinated to the neutral ligand with 
a bromide counter anion to balance the charge and a water molecule also present 
in the asymmetric unit. As shown in figure 119, the sodium ion is 8-coordinate 
sitting above the plane of the tetraazamacrocyclic cyclen ring and is 
encapsulated by the pendant arms, bonding to all four macrocyclic ring N- 
donors, three pendant ester arm O donors and to the N-3 position of the 
imidazole ring. The ionic radius of sodium metal (132 pm), is very similar to 
that of the lanthanides (gadolinium(III) = 119.3 pm, and europium(III) = 120.6 
pm) and therefore the structure should be analogous to the lanthanide ion 
complexes that have not been structurally characterised. A selection of bond 
lengths and angles describing the coordination environment of the sodium ion 
are presented in table 10.
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The Cambridge crystallographic database was searched to locate some relevant 
published structures for comparison of bond lengths and angles. Particularly 
relevant to this structure are the sodium complexes of the 1,4,7,10- 
tetra(ethoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane and 1,4,7,10- 
tetra(teA-/-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane ligands. Each 
of these structures have four pendant ester arms that are coordinated to form 8 
coordinate sodium complexes. A third structure that is highly appropriate for 
comparison has sodium coordinated to a cyclen ligand with three pendant ester 
arms and a fourth arm with a coordinating pyridyl group, l,4,7-tns(tert- 
butoxycarbonylmethyl)-10-(6-(bis(2-pyridylmethyl)aminoethyl)-2- 
pyridylmethyl)-1,4,7,10-tetraazacyclododecane.' 84
The sodium-cyclen N distances show some variation for [Na32]+ in the range 
2.487(4) to 2.649(4) A, which is in contrast to the two tetraester structures 
where the bond lengths were in the ranges, 2.523(2) A to 2.557(2) A and 
2.532(5) A to 2.580(6) A, respectively for the ethoxy and tert-butoxy ester 
complexes. The unsymmetrical nature of the pendant arms may account for this 
deviation as the triester monopyridyl cyclen sodium complex shows greater 
variation with Na-N(cyclen) bond lengths in the range 2.551(2) to 2.665(2) A. 
The Na-N benzimidazole distance in [Na32]+ is 2.498(4) A. This is a longer 
distance than is observed for the Na-N bond lengths in other less sterically 
constrained sodium imidazole complexes, ca. 2.36(3) to 2.39(4) A, but it is 
shorter than the Na- N(pyridyl) distance of 2.797(4) A in the related 
unsymmetric Na cyclen structure, possibly explaining the greater distortion of 
the other Na-N bond lengths in [Na32] +. 184 m
In [Na32]+ the sodium is bonded to the carbonyl oxygen of all three pendant 
arms with bond lengths in the range 2.451(4) to 2.681(3) which are consistent 
with the known structures. The angles N(cyclen)-Na-O/N(attached pendant) are 
in the range 64.38(13) to 68.41(12)° for [Na32]+ which is comparable to the 
other known structures. However, the largest angle in the structure is the 
N(cyclen)-Na-N(benzimidazole) in[Na32]+, again suggesting that the chelator is
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distorting slightly to optimise the favourable bonding interaction between the 
sodium and the imidazole.
The space filling diagram, figure 119(b), shows that access to the metal centre is 
blocked by the tert-butyl groups which limits the potential for a further ligand to 
bind, preventing the formation of species with higher coordination numbers. 
However, the tetra-ethoxyester cyclen structure still has an 8 coordinate metal 
centre despite reduced steric bulk. It is also relevant to note that the nitrobenzyl 
group protrudes in an appropriate orientation for attachment of other molecules 
without interfering with binding of the chelator to the metal centre. This is 
important for the formation of functional lanthanide complexes.
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a)
b)
c)
Figure 119 Ball and stick representations of [Na32]+ (a) view from above, (b) space filling view 
from above and (c) view from the side
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Figure 120 Packing diagram for the X-ray structure of the sodium complex with [Na32]+ (unit 
cell shown in yellow)
The packing diagram shows layers of bromide anions and layers of complex 
cations, see figure 120. In contrast to the crystal structures of the benzimidazole 
precursors (5) and (7), no short intermolecular 7i-stacking or edge to face phenyl 
interactions are present.
Bond length A
N(l)-Na(l)
N(2)-Na(l)
N(3)-Na(l)
N(4)-Na(l)
N(6)-Na(l)
O(2)-Na(l)
O(4)-Na(l)
O(6)-Na(l)
2.632(4)
2.649(4)
2.596(4)
2.487(4)
2.498(4)
2.594(4)
2.451(4)
2.681(3)
Bond and torsion angles °
O(4)-Na(l)-N(4)
O(4)-Na(l)-N(6)
N(4)-Na(l)-N(6)
O(4)-Na(l)-O(2)
N(4)-Na(l)-O(2)
N(6)-Na(l)-O(2)
O(4)-Na(l)-N(3)
N(6)-Na(l)-O(6)
N(3)-Na(l)-O(6)
152.64(13)
127.29(14)
68.41(13)
75.01(12)
87.35(13)
81.13(13)
123.40(12)
80.95(11)
64.74(11)
N(l)-Na(l)-O(6)
N(4)-Na(l)-N(3)
N(6)-Na(l)-N(3)
O(2)-Na(l)-N(3)
O(4)-Na(l)-N(l)
N(4)-Na(l)-N(l)
N(6)-Na(l)-N(l)
O(2)-Na(l)-N(l)
N(3)-Na(l):N(l)
O(4)-Na(l)-N(2)
N(4)-Na(l)-N(2)
N(6)-Na(l)-N(2)
O(2)-Na(l)-N(2)
N(3)-Na(l)-N(2)
N(l)-Na(l)-N(2)
O(4)-Na(l)-O(6)
N(4)-Na(l)-O(6)
0(2)-Na(l)-0(6)
N(2)-Na(l)-O(6)
151.99(13)
73.13(12)
90.55(14)
160.46(14)
82.51(12)
70.93(13)
127.02(13)
64.38(12)
108.58(13)
64.50(12)
109.66(14)
158.37(14)
120.50(13)
68.86(12)
68.60(11)
80.06(11)
126.96(12)
130.31(13)
84.09(11)
Table 10 Selected bond lengths [A] and angles [°] for sodium complex of [Na32] +
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4.3.3 Synthesis of lanthanide complexes of 1,4,7- 
tris(carboxymethyl)-10-(1 -(4-nitrobenzyl)-2- 
methylbenzimidazole)-1,4,7,10-tetraazacyclododecane (34a-d)
The lanthanide complexes of the nitrobenzyl benzimidazole DO3A chelator (32) 
were synthesised. The gadolinium(III) complex is of interest as these highly 
paramagnetic compounds can act as MRI contrast agents. The europium(III) 
and terbium(III) complexes are expected to be luminescent and could have 
appropriate properties for optical imaging. Lanthanum(III) is diamagnetic and 
the resulting complex can be analysed by NMR without the paramagnetic shifts 
that would be observed for the other lanthanide ions.
"
o N r o
~\ HO' 'OH 
32 33 34a-d
Figure 121 The synthesis of the lanthanide complexes of the ligand (L) 1,4,7- 
tris(carboxymethyl)-10-( 1 -(4-nitrobenzyl)-2-methylbenzimidazole)-1,4,7,10- 
tetraazacyclododecane (34a - d) where (34a) = EuL, (34b) = TbL, (34c) = GdL and (34d)=LaL
The tert-butyl ester groups were removed from the acetate arms using cone, 
hydrochloric acid. The solution was concentrated, the residue re-dissolved into 
water and filtered through a 0.2 um syringe filter to remove any insoluble 
material. After removal of the solvent, a yellow solid was isolated. The 'H and 
13C NMR spectra contain broad peaks making assignment difficult, however the 
peaks that represented the tert-butyl group are no longer present. High 
resolution mass spectrometry showed the identity of the molecular ion peak.
The lanthanide metal ions used to prepare complexes were europium(III), 
gadolinium (III), lanthanum(III) and terbium(III). The complexation reactions 
were carried out in water using either the triflate or chloride metal salts. A base 
was used to deprotonate the HC1 salt of the ligand. Care was taken to avoid 
formation of lanthanide hydroxide salts, which tend to be less soluble and
142
precipitate from solution. The reaction mixture was heated at reflux overnight 
in each case. The solution was concentrated, and the product was purified using 
size exclusion chromatography on LH-20 sephadex. The europium(III) 
complex (34a) formed as a yellow solid in a yield of 68%. The *H NMR 
spectrum was recorded for the paramagnetic europium(III) complex as 
information about the coordination geometry can be obtained from the shifted 
spectrum. The peaks were observed in the range of-18 to 30 ppm, the spectrum 
is shown in figure 122.
It has been shown that two isomers are present for lanthanide(III) DOTA 
complexes in aqueous solution, a square antiprism and a twisted square 
antiprism. The exchange process between the two isomers is slow enough to be 
observed on the NMR timescale, where two sets of six resonances are observed 
for the diastereotopic CtbCO and ring NCtbCF^N protons. Aime and co- 
workers have identified these isomers and have shown that the major isomer in 
solution adopts the square antiprism shape, where there is a shift to higher 
frequency of the closest axial ring protons, with the minor isomer generally
1 OC 1 Qf.
forming less shifted proton resonances. ' The ratio of these isomers varies 
depending on the size of the lanthanide, concentration and counterion. Aime 
and co-workers have also performed NMR structural studies on the 
lanthanide(III) complexes of 1,4,7,10-tetraazacyclododecane-4,7,10-triacetic-l- 
(tLtDOSA-P). 187 Here it was shown that there was a higher abundance of the 
fast-exchanging twisted square antiprism compared to the square antiprism. 185 
Using the information from these papers, identification of the isomers present 
for the europium(III) complex (34a) was attempted. The peaks representing the 
square antiprism can be identified between 30.9 - 28.82 pprn (as these peaks are 
more shifted), while the exchanging twisted square antiprism is located around 
10.62 - 9.5 ppm. The ratio is in favour of the square antiprism at around 2:1.
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The terbium(III), gadolinium(III) and lanthanum(III) complexes (34b-d) were 
prepared in yields of greater than 70%. The identity of the compound was 
confirmed by high resolution mass spectrometry. The 'H NMR spectrum of the 
lanthanum(III) complex (34d) is shown in figure 123.
in o ff>m rn in
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Figure 123 ( H NMR spectrum of the lanthanum(III) complex (44d)
Both the alkyl and aromatic regions are broad making complete assignment 
difficult. However, the peaks at 4.2 and 5.3 ppm can be assigned to the CH2 on 
the benzimidazole, and the CH2 peak on the nitro benzyl group respectively. 
13C and DEPT NMR studies were also performed and the spectra are shown in 
figure 124.
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The blue graph represents the I3C NMR spectrum, the purple graph represents 
the DEPT 135° spectrum, the red graph represents the DEPT 45° spectrum, and 
the green graph represents the DEPT 90° spectrum. Varying the degree of the 
pulse will alter the orientation of the peaks on the plot, and allow assignment of 
the number of directly attached protons on each carbon. The DEPT 135 
spectrum can be used to assign the CH and the CHi peaks as they point up on 
the graph, and the CH2 peaks point down, with the C peaks suppressed. While 
the DEPT 90 spectrum will only show the CH peaks, and the dept 45 spectrum 
contains the CH, CH2 and CH3 peaks (point up) with the C peaks suppressed. 
Using this data, the 13C NMR spectrum is shown to contain 6 C peaks, 6 CH 
peaks and a CHa peak. Complete assignment of the CH2 peaks is challenging 
because they are broad and overlapping.
The proton-carbon correlation spectrum is shown in figure 125. The alkyl 
region between 2.02 - 4.23 ppm correlates with the CH2 region between 46.51 - 
60.72 ppm. The aromatic proton peaks at 7.48 and 7.84 ppm correlate with the 
carbon peaks at 118.79 and 123.99 ppm respectively. These peaks can be 
assigned to the benzimidazole unit.
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4.4 Synthesis of a chelator bearing an aminobenzyl 
benzimidazole
The next stage in the synthesis involves the conversion of the nitro group to a 
primary amine. An example of this reaction was investigated by Sircar et ol. 
where a nitro benzyl substituted imidazole based compound was converted to an 
amine by the use of a palladium on carbon catalyst under a hydrogen 
atmosphere in a yield of 78% yields (figure 126) m
5 % Pd/C, H2 
EtOH
Figure 126 Hydrogenation reaction carried out by Sircar et al. 188
In the literature, palladium on carbon is commonly used to remove benzyl 
groups from the macrocycle, cyclen and cyclam, and Nwe et al. have shown that 
using it with cyclohexane can remove 4-nitrobenzyl groups from cyclen. 189 
However, the nitrobenzyl substituted imidazole compound in figure 126 is 
similar to the benzimidazole compound (7), the first method investigated was 
the use of palladium on carbon.
4.4.1 Synthesis of 1,4,7-tris(fert-butoxycarbonylmethyl)-10-(1- 
(4-aminobenzyl)-2-methylbenzimidazole)-1,4,7,10- 
tetraazacyclododecane (35)
The initial method employed, involved a solution of (32) dissolved in methanol, 
to which 5% palladium on carbon was added and the solution stirred for 24 
hours under a hydrogen atmosphere. Analysis suggested that a reaction 
occurred, however, the isolated compound was not the desired product (35) or 
starting material (32). This suggested that debenzylation of either the
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nitrobenzyl group from the benzimidazole unit, or the benzimidazole unit from 
DO3A had occurred.
Lalancette et al. have reported the use of a selective reducing agent, sulfurated 
borohydride, that can reduce a nitro group to the corresponding amine, without 
interfering with halogens, esters, nitriles, olefins or ethers. 190 The proposed 
synthetic route to convert the nitro compound (32) to the corresponding amino 
compound (35) using this sulfurated borohydride is shown in figure 127.
H,N
NaBH2S3
Figure 127 Reaction scheme for the preparation of the aminobenzyl benzimidazole DO3A 
derivative (35)
The sulfurated borohydride was prepared in situ by stirring sodium borohydride 
and sulphur in dry tetrahydrofuran under nitrogen for one hour. During this 
time, an evolution of hydrogen gas occurs as the sulfurated product forms 
(NaBHaSa). The addition of the nitro benzimidazole DO3A chelator (32) was 
added as a solution in dry tetrahydrofuran and the reaction mixture heated at 
reflux for 24 hours. The product was purified by flash chromatography on 
alumina with an increasing gradient of methanol in dichloromethane to form a 
yellow solid in 65% yield. Analysis by *H NMR spectroscopy, confirms the 
formation of the amine product by the shift of the relevant aromatic peaks to 
6.52 and 6.75 ppm and a decrease in the coupling constant to 8.0 Hz. In the 13C 
NMR spectrum, there is a shift in peak position of the carbon coupled to the 
amine to 115.25 ppm.
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4.4.2 Synthesis of the lanthanide(lll) complexes of 1,4,7- 
tris(carboxymethyl)-10-(1 -(4-aminobenzyl)-2- 
methylbenzimidazole)-1,4,7,10-tetraazacyclododecane (37a-d)
The lanthanide(III) complexes of the aminobenzyl benzimidazole DO3A 
chelator (35) were prepared after removal of the tert-butyl groups from the 
acetate arms by reaction with the appropriate metal salt (37a-d). The reaction 
scheme for the synthesis of the lanthanide(III) complexes (37a-d) is shown in 
figure 128.
O
C j HCI
Q N N o o >N N - o —— — - 0-'- N-
N
-o w-^- H0- -OH
35 36 37a-d
Figure 128 Proposed reaction scheme for the synthesis of the lanthanide complexes (37a-d) 
where (37a) = EuL, (37b) = TbL, (37c) = GdL and (37d) = LaL
The deprotection of (35) gave a yellow solid in 93% yield with the identity of 
the compound confirmed by 'H NMR spectroscopy, 13C NMR spectroscopy and 
high resolution mass spectrometry
The lanthanide complexes (37a-d) were prepared in yields of greater than 60%. 
The identity of the compounds were confirmed by high resolution mass 
spectrometry. The *H NMR spectrum for the europium(III) complex is shown 
in figure 129.
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The peaks in the *H NMR spectrum show the typical shifted peaks for the 
europium(III) metal complex. The spectrum is very similar to that of the 
nitrobenzyl benzimidazole europium(III) complex (34a). A similar isomer 
distribution pattern can be seen here with the 4 peaks between 39.75 - 29.48 
ppm for the square antiprism and the peaks for the twisted square antiprism 
between 11.07 - 10.1 ppm in a 2:1 ratio.
The *H NMR spectrum of the lanthanum(III) complex is shown in figure 130. 
The *H NMR spectrum is broad with overlapping CH2 peaks from the DO3A 
ring making complete assignment difficult. The two singlet peaks at 4.79 and 
5.87 ppm can be assigned to the CHa groups on the benzimidazole unit and 
amino benzyl group respectively. The I3C NMR spectrum in figure 131, shows 
the shift in the C peak to 125.0 ppm compared to the lanthanum(III) nitrobenzyl 
benzimidazole DOS A complex (34d) due to the conversion of the nitro group to 
an amine.
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4.5 Synthesis of a chelator bearing an aminobenzyl 
derivative
As an alternative compound to the nitrobenzyl benzimidazole runctionalised 
chelator (7), 4-nitrobenzylbromide was coupled to DOS A (31) to form 1,4,7- 
tris(tert-butoxycarbonylmethyl)-10-(4-nitrobenzyl))-1,4,7,10- 
tetraazacyclododecane (38). This synthetic method is well characterised in the 
literature, Maillet et al have shown that the formation of the nitrobenzyl DO3A 
derivative can be undertaken by the selective reaction of 4-nitrobenzylbromide 
with a ten-fold excess of cyclen in the prescence of sodium hydride, followed by 
treatment with bromoacetate to give the desired product in a yield of 50%. 191 
They also investigated an alterative synthetic route, where the tri-substituted 
cyclen with three ethyl bromoacetate arms was synthesised initially and then 
substituted with 4-nitrobenzylbromide on the remaining secondary amine 
position. They reported a lower overall yield of 37% in comparison to other 
reports which quote yields of greater than 69%. 191 The nitro group can be 
converted to a primary amine to form l,4,7-tris(/er/-butoxycarbonylmethyl)-10- 
(4-aminobenzyl))-l,4,7,10-tetraazacyclododecane (39) using palladium on 
carbon. 94 As (31) had already been prepared in good yields, it was decided to 
couple 4-nitrobenzylbromide to (31), followed by the conversion of the nitro 
group to an amino group (figure 132).
NH N ^(
-o
31 38 39
Figure 132 Reaction scheme for the preparation of (39)
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4.5.1 Synthesis of 1,4,7-tris(tert-butoxycarbonylmethyl)-10-(1- 
(4-aminobenzyl))-1,4,7,10-tetraazacyclododecane (39)
The synthetic procedure used to synthesise (38) was the same as that used to 
synthesise the benzimidazole compound (32). (31) was dissolved in dry 
acetonitrile, with both an eight fold excess of sodium hydrogen carbonate and a 
slight excess of 4-nitrobenzylbromide added. The reaction mixture was heated 
to 70°C and stirred for 24 hours under a nitrogen atmosphere. The compound 
was then purified by flash column chromatography on silica with an increasing 
gradient of methanol in dichloromethane to yield a white solid. In the 'H NMR 
spectrum, the tert-butyl peak was at 1.23 ppm, with a multiplet between 2.0 - 
3.09 ppm with a total integration of 24 protons representing the Cf^ protons. 
The aromatic region shows two coupled doublets at 7.5 and 8.0 ppm with a total 
integration of 4 protons, and a splitting constant of 8.44 Hz. The 13C NMR 
spectrum contains the tert-butyl CHs peak at 27.9 ppm, with six CEb peaks 
ranging from 50.0 - 65.7 ppm. The C(CH3)3 peaks appear at 82.5 and 83.0 
ppm, with the aromatic CH peaks at 123.6 and 131.1 ppm and the aromatic 
carbon peaks at 145.3 and 147.2 ppm. The carbonyl peaks are at 172.6 and 
173.7 ppm.
To reduce the nitro group on compound (38) to give the corresponding amino 
compound (39), the literature procedure using 5% palladium on carbon was 
followed. This resulted in a white solid (39) in 85% yield. Both the 'H NMR 
and 13C NMR spectra showed a shift in the aromatic peaks due to the formation 
of the amino group. The identity of the product was also confirmed by 
electrospray mass spectrometry
4.5.2 Synthesis of lanthanide complexes of 1,4,7- 
tris(carboxymethyl)-10-(4-aminobenzyl))-1,4,7,10- 
tetraazacyclododecane (41 a-c)
The lanthanide complexes of the amino benzyl DO3A chelator (39) were 
prepared after removal of the tert-butyl groups from the acetate arms with acid.
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The reaction scheme detailing the synthesis of the lanthanide complexes (41a-c) 
is shown in figure 133.
C"1 . v"-N-'O -K::JO" N N --O
^TA ,° o EU<CF3!> °^^°
H2N^>7N^Cl>-^- H2N^V, ^  ^ ° / H2N^>^ ^  
' ^ ^^ ^=J /N N. NOH X=/ > ,NC^OC r^-^_^c 5PWQ> —— ^r^/? ^^ 33°^?-o7^ ^o/l )l_yv_v\_^ oo
\ HO OH ^La(CF3SO3)3 
39 40 \, 41b
^ H2N-/>^^ ^ ° 
X=/ V ,N -O
C-M:0
ON N --Q
O^^^O
41C
Figure 133 The synthetic scheme for the synthesis of the lanthanide complexes (41a-c)
Trifluoroacetic acid has previously been used to remove the tert-butyl groups 
from acetate arms. The method attempted with (39) was to suspend the 
compound in a solution of trifluoroacetic acid in dichloromethane and then stir 
for 24 hours at room temperature. After 24 hours, t.l.c. analysis was performed 
but this showed that only starting material (39) was present. Thus the 
deprotection was carried out by stirring in concentrated hydrochloric acid for 3 
hours, which resulted in a yellow solid. The 'H NMR spectrum was very broad, 
however the peaks that represented the tert-butyl groups are no longer present.
The europium(III), gadolinium(III) and lanthanum(III) complexes of the 
aminobenzyl DO3A chelator (51a-c) were prepared in yields of greater than 
75%. Electrospray mass spectrometry was used to identify the molecular ion 
peaks of the lanthanide complexes.
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4.6 Synthetic strategy for the preparation of multi- 
modality imaging agents
The synthetic strategy used in the preparation of a multi-modality agent 
involves coupling an optical dye (rhodamine and BODIPY derivatives) and a 
DO3A chelator. A number of strategies were investigated and the routes are 
depicted in figure 135.
4.6.1 The attempted preparation of lanthanide(lll) complexes of 
1,4,7-tris(carboxymethyl)-10-(4-(5-(4-thioureaphenylene) 
borondipyrromethane) benzyl)-1,4,7,10-tetraazacyclododecane 
(42a-c) (route 1)
The initial strategy investigated for the preparation of a multimodality imaging 
agent involved the reaction between the lanthanide DO3A chelator bearing a 
benzyl amine group (41a-c) with an isothiocyanate functionalised optical dye 
(21) (route 1). Meade and co-workers have reported the conjugation of 
rhodamine B isothiocyanate to a gadolinium(III) DO3A complex bearing a 
benzyl amine group, however no yields were given. 2 The proposed synthetic 
procedure is shown in figure 134.
H7N v. /-A /-O VK
0-..N, N 3 N|";;Ln,J
/-\-''M' NM"V>
o
42a-c
Ln = Eu, Gd, La
Figure 134 Proposed synthetic strategy for the preparation of a dual functional lanthanide agent 
(42a-c)
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The lanthanide complexes (42a-c) were dissolved into water with the addition 
of 1M potassium hydroxide to make a pH 9 solution, followed by the addition 
of (21) in dimethylformamide. The reaction was monitored by t.l.c., but after 
fourteen days, there was no sign of the formation of the desired product. The 
reaction was performed in aqueous conditions, which may have hydrolysed the 
isothiocyanate group and prevented product formation. The reaction was 
repeated with the amino benzyl DOS A chelator (40) in case the presence of the 
lanthanide metal ion was preventing the formation of the product.
4.6.2 The attempted preparation of 1,4,7-tris(carboxymethyl)- 
10-(4-(5-(4-thioureaphenylene) borondipyrromethane) benzyl)- 
1,4,7,10-tetraazacyclododecane (43) (route 2)
The second route investigated (route 2) involved the coupling between the 
BODIPY isothiocyanate (21) and the uncomplexed DO3A derivative bearing an 
aminobenzyl unit (40). The synthetic scheme is shown in figure 136.
H?N
.„ N OH 
HO N N OH
40
Figure 136 The proposed synthetic scheme for the preparation of (43)
The reaction was stirred for 14 days with a mixture dimethylformamide and 
water at pH 9 as solvent. Analysis by t.l.c. showed that no product was formed. 
The BODIPY isothiocyanate analogue (21) has previously been shown to 
couple with alkyl amines such as oligodeoxynucleotides by Boyle and co- 
workers. 173 The attempted coupling reaction of the BODIPY functionalised 
with an isothiocyanate group (21) with a phenylamine did not result in the
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formation of the desired product (22). To investigate whether this was an issue 
with the reaction attempted here, the coupling of phenylisothiocyanate to the 
DOS A benzylamine chelator (40) was investigated (figure 137).
H,N- ...... -NCS
Figure 137 Proposed synthetic scheme for the preparation of (44)
The reaction conditions were varied slightly, with the reaction performed in 
pure dimethylformamide and stirred for 24 hours. An attempt was made to 
isolate the product (44), however, the 'H NMR spectrum showed that no 
product was formed. This suggests that the benzyl amine on both (36) and (40) 
are insufficiently reactive to couple to an isothiocyanate group under these 
conditions.
4.6.3 The attempted preparation of 1,4,7-tris(carboxymethyl)- 
10-(4-(5-(4-thioureaphenyl) borondipyrromethane benzyl)-2- 
methyl benzimidazole)-1,4,7,10-tetraazacyclododecane (47) 
(route 3)
Route 3 involves converting the benzyl amine on (32) and (40) to an 
isothiocyanate group that can then be coupled to a benzyl amine on the 
BODIPY optical dye (20) as shown in the scheme in figure 138. Thiophosgene 
was used to convert the benzyl amine to an isothiocyanate, in a biphasic solution 
of water and a chlorinated solvent.
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H,N
CSCI,
SCN
„ N OH 
HO N N OH
45
0
SCN
CSCI2
Figure 138 Synthetic scheme for the preparation of the isothiocyanate derivatives (45) and (46)
In the first method attempted (40) was dissolved into water, and the pH adjusted 
to pH 9 by the addition of 0.05 M sodium hydrogen carbonate solution. The 
thiophosgene was added as a solution in chloroform and the reaction mixture 
was stirred overnight. After extraction with chloroform, the aqueous solution 
was then collected, and the solvent removed to yield a yellow solid. Infra-red 
analysis did not show the characteristic isothiocyanate stretching frequency at 
around 2000 cm" 1 . The literature was searched for alternative methods. Kline et 
al. investigated the conversion of an aromatic amine on a DOTA derivative to 
the isothiocyanate group, see figure 139. 192 While they still used thiophosgene, 
here a greater excess of the thiophosgene was used in carbon tetrachloride. 
They then reacted this with the selected amine compound in acidic conditions 
and stirred for six hours, isolating the desired product in a reported yield of 
99%.
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CSCI2 / CCI4 
3MHCI
Figure 139 The Kline et al. method for the conversion of an amine to a reactive isothiocyanate group 192
These conditions were repeated with the benzyl amine DO3A chelator (40) and 
the amine benzimidazole DO3A chelator (32). The 'H NMR spectrum showed 
a shift up field in the position of the peaks compared to the amine derivatives. 
High resolution mass spectrometry and infra-red data confirm that the 
isothiocyanate compounds have been formed.
Attempts were then made to couple the reactive isothiocyanate group on the 
benzimidazole DO3A chelator (46) with the amine BODIPY analogue (20) 
(figure 140).
.0
,. N OH 
O N N O
HO OH
46
0
OH
Figure 140 The proposed synthetic scheme for the attempted synthesis of (47)
The reaction was performed in a biphasic solution of water and dichloromethane 
at pH 8. The reaction mixture was monitored by t.l.c. for twenty-one days, with 
no product formed. The literature data does suggest that there are problems
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with the reactivity of aromatic amines, and in many cases the reactions are too 
slow and do not go to completion. 193 m
4.6.4 The preparation of the lanthanum(lll) complexes of DO3A 
chelators bearing a isothiocyanatobenzyl group (route 4)
The literature data suggests that alkyl amines will undergo nucleophilic 
substitution reactions with an isothiocyanate group more readily. 173 To 
investigate the feasibility of this reaction, the coupling of an isothiocyanate 
DO3A chelator to an alkylamine bearing optical dye was attempted initially. 
The isothiocyanate benzimidazole DO3A chelator (46) and the isothiocyanate 
benzyl DO3A chelator (45) were coupled to a benzyl amine, followed by the 
formation of the lanthanum(III) complex. The proposed synthetic schemes for 
the preparation of the lanthanum(III) complexes of (49) and (51) are depicted in 
figures 141-142.
SCN
NH, ^ N OH 
ON NO
HO OH
48
La(CF3S03)3
H H
//
O''"N
49
Figure 141 Proposed synthetic scheme for the preparation of the lanthanum(lll) complex of 
(49)
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SCN
NH,
La(CF3S03)3
Figure 142 Proposed synthetic scheme for the preparation of the lanthanum(III) complex of 
(51)
The reaction to form the isothiocyanate was performed in water at pH 9 and 
stirred for 24 hours. The aqueous layer was washed with dichloromethane to 
remove the starting material. After isolation of a solid, the compound was 
purified using a sephadex LH-20 column (eluted with methanol) to give a white 
solid for both (66) and (68). The 'H NMR spectra were very broad with 
overlapping peaks making assignment difficult. The electrospray mass spectral 
data confirmed the identity of the compounds, while the infra-red spectrum 
showed the loss of the isothiocyanate group and the formation of the thiourea 
moiety.
The lanthanum(III) complexes of (66) and (68) were also prepared, and both 
isolated as white solids, (67) and (69), with the product formation confirmed by 
electrospray mass spectrometry.
4.6.5 Attempted synthesis of a dual modality MRI agent 
bearing a rhodamine derivative
The coupling of the ethylamine rhodamine derivative (16) to the isothiocyanate 
cyclen derivatives was investigated (figure 143-144). Initial attempts involved
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the benzyl cyclen derivative (45) dissolved into water with the pH adjusted to 
pH 8 by the addition of a 1 M sodium hydrogen carbonate solution. Rhodamine 
B base ethylamine (16) dissolved in dichloromethane was added to the reaction 
mixture, which was stirred for 48 hours. Analysis of the isolated compound 
showed that no reaction occurred. The reaction was repeated replacing the 
dichloromethane/water solvent mixture with either dichloromethane or a 
dimethylformamide/water mixture. However, no product was isolated in any of 
these reactions.
N
N OH B2N
HO LN N J OH <M v^ v-<
a o
45
Figure 143 The synthetic scheme for the preparation of an aminobenzyl DO3A compound 
attached to a rhodamine derivative (52)
,^^^-N
^^° 
O ^N' O ^ N } °H
HO^ ^OH °«,N^NIA° 
46 HO-^ 10H
53
Figure 144 The synthetic scheme for the preparation of a benzimidazole DO3A compound 
attached to a rhodamine derivative (53)
As the alkyl amine rhodamine derivative (16) may be forming an unreactive 
salt, it was washed with sodium hydrogen carbonate solution, and then extracted 
into dichloromethane. The solvent was removed, and the solid (16) went from a 
pale pink colour to a pure white solid. This was then directly added to a 
solution of either (45) or (46) in dimethylformamide and the reactions stirred for 
24 hours. The *H NMR spectra of (52) and (53) suggested that the desired 
ligand was formed. T.l.c. was also performed and this showed the formation of 
a new peak that did not correspond to the starting material. However, 
electrospray mass spectral data showed that the compound was not formed as no
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molecular ion peak was formed. Instead, the data suggested that washing (16) 
with base resulted in the formation of a polymeric species incorporating the 
rhodamine compound, which prevented the formation of the multimodality 
imaging agent. This was confirmed by comparing the electrospray mass 
spectrometry data from this reaction with the spectrum obtained for the 
rhodamine derivative (16).
4.6.6 Attempted synthesis of a dual modality MRI agents 
bearing a BODIPY derivative
The reaction to couple the alkyl amine BODIPY analogue (29) to the 
isothiocyanate benzimidazole cyclen derivative (46) was also attempted, with 
the proposed reaction scheme shown in figure 145.
SCN0,
HO
.o
,.. N OH 
ON NO
OH
46
Figure 145 Proposed synthesis to prepare a dual modality MRI agent bearing a BODIPY 
derivative (56)
The alkyl amine bearing BODIPY dye (39) was washed with base (sodium 
hydrogen carbonate solution) and then extracted into dichloromethane. The 
reaction with (46) was carried out in dimethylformamide and the solution was 
stirred at room temperature for 24 hours. The solvent was removed, and the 
resulting solid was washed with diethyl ether to remove excess starting material 
and extracted into water. This gave a red coloured compound that is 
characteristic of the BODIPY dyes. A t.l.c. analysis was performed that showed 
the formation of a new compound that did not correspond to the starting 
material. Electrospray mass spectral data showed that (56) was not formed, and 
only a peak at 993 that may correspond to the formation of a BODIPY polymer.
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4.6.7 Attempted preparation of 1,4,7-tris(carboxymethyl)-10-(4- 
(5-(4-thioureaamidophenyl)borondipyrromethane) 
methylamidobenzyl)-1,4,7,10-tetraazacyclododecane (58) 
(route 5)
The attempted preparation of an alkyl amine bearing a DO3A derivative (58) 
was briefly explored, as this compound could then be directly coupled to the 
BODIPY isothiocyanato compound (21), with the scheme shown in figure 146. 
An alkyl amine group on the DO3A chelator would offer an appropriate 
precursor for coupling to a range of optical dyes. The proposed route involves 
phthaloyl p-alanine chloride being coupled to the aromatic amine on the benzyl 
DO3A (40). The phthaloyl unit can then be removed to leave an alkyl amine 
(58), which can be reacted with the BODIPY isothiocyanato compound (21) to 
give (59).
o
H,N-
OH
H2N'^rN- 
O C
HO
2) NH2 NH2 HO
<H
P
OH
50
Figure 146 Proposed synthetic strategy for the preparation of (59)
There are numerous examples in the literature where phthaloyl |3-alanine
chloride is used as a protecting group for alkyl amines. 195 Gransey et al.
refluxed yV-phtaloylglycine with oxalyl chloride to form the acid chloride that 
can then be added dropwise to the aromatic amine compound in
triethylamine. The reaction mixture was stirred for 3 hours and gave yields of
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ca. 70%. A possible problem with this method is that the acid chloride could 
react with the triethylamine. Yoon et al. performed a similar reaction and used 
magnesium oxide as the base, which is less likely to react with the acid 
chloride. 197
Following the second method, gave a compound in which the phthaloyl group 
could potentially be removed by heating to reflux in hydrazine. 198The resulting 
solid containing this alkyl amine was used crude and coupling to the BODIPY 
isothiocyanate analogue (29) attempted. The product (59) would be a bright red 
colour, and this could be readily identified as a red band when purifying using a 
sephadex column. The coupling reaction was carried out in a biphasic solution 
of water and dichloromethane at pH 8 and stirred for 24 hours under nitrogen at 
room temperature. T.l.c. analysis showed that a number of products were 
formed and isolation of (59), if it is present in the mixture, would be difficult 
due to the similar r.f. values. The transfer of impurities between steps resulted 
may have contributed to a complex mixture of products.
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4.7 Conclusion
The chapter presented a discussion of the preparation of multi-modality imaging 
agents that consist of a DO3A chelator with a benzimidazole or benzyl unit that 
is coupled to an optical dye.
The initial aim was to synthesise a DO3A derivative that can be further 
functionalised to allow for conjugation to an optical dye. From this, a number 
of experiments were carried out to determine the best method to attach an 
optical dye to the lanthanide chelator. The synthesis of a cyclen chelator that 
contains functionality for the coupling of an optical dye was achieved. Tri- 
substituted cyclen (DOSA (31)) was attached to either l-(4-nitrobenzyl)-2- 
chloromethyl benzimidazole (7) or 4-nitrobenzylbromide. The optimum 
conditions for the substitution were determined and applied to the synthesis of 
the nitrobenzyl benzimidazole DO3A chelators (32) and the nitrobenzyl DO3A 
chelator (38). The nitro group was converted to a secondary amine with 
sulfurated sodium borohydride for (32) and palladium on carbon for (38). The 
lanthanide complexes were prepared with the nitrobenzyl benzimidazole DO3A 
ligands (34a-d), the aminobenzyl benzimidazole DO3A ligands (37a-d) and the 
aminobenzyl DO3A ligand (41a-c).
A number of routes were investigated to couple the DO3A chelators to an 
optical dye to form a multimodality imaging agent. The initial strategy involved 
the reaction of an aromatic amine on the DO3A chelator with an isothiocyanate 
group on the optical dye. This was not successful, probably due to the reduced 
reactivity of the aromatic amine preventing product formation. Investigations 
then turned to coupling an alkyl amine on the BODIPY (29) or rhodamine (16) 
derivatives with an isothiocyanate bearing DO3A chelators (45) or (46). 
Initially, to test the reaction, benzyl amine was successfully coupled to (45) and 
(46) and the lanthanum(III) complexes formed. However, when coupling of the 
optical dyes to DO3A was attempted using the same procedures the reactions 
were not successful. To make certain that the optical dyes were fully
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deprotonated they were washed with base, however this appeared to result in 
polymer formation.
The preparation of an alkyl amino functionalised chelator from the benzyl 
amine DO3A chelator (50) was also investigated. The route involved the 
subsitution of phthaloyl p-alanine chloride onto the benzylamine, followed by 
deprotection of the pthaloyl group by hydrazine. Attempts were made to couple 
this compound with the isothiocyanate BODIPY (30) but the desired product 
was not isolated.
Overall, suitable component molecules have been synthesised and appropriate 
reactions to produce multimodality imaging agents have been characterised but 
further work is required to fully exploit this chemistry.
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5. Studies of the physical properties and cellular 
uptake of lanthanide complexes and novel dye 
conjugates
173
5.1 Introduction
Lanthanide complexes of l,4,7-tris(carboxymethyl)-10-(l-(4-nitrobenzyl)-2- 
methyl benzimidazole)-1,4,7,10-tetraazacyclododecane [(34a-c) europium(III), 
terbium(III), and gadolinium(III)], l,4,7-tris(carboxymethyl)-10-(l-(4- 
aminobenzyl)-2-methyl benzimidazole)-1,4,7,10-tetraazacyclododecane [(37a- 
c) europium(III), terbium(III), and gadolinium(III)] and 1,4,7- 
tris(carboxymethyl)-10-(4-aminobenzyl)-1,4,7,10-tetraazacyclododecane [(41b) 
gadolinium(III)] have been prepared (chapter 4). These molecules were 
investigated for their physical properties and interaction with cellular systems, 
alongside the gadolinium(III) complex l,4,7-tris(carboxymethyl)-10-(2-methyl 
benzimidazole)-1,4,7,10-tetraazacyclododecane (60), (supplied by C.Fisher). 
The structures of these molecules are given in figure 147.
- x -v ,r~-~v ' --'i
^Ln'^ W' / ^ >< 
O' N N -
o
37a-c
H,N
41 b
O- N
->-"-
o xo 
60
Figure 147 Structures of the lanthanide(III) complexes (34a-c) and (37a-c), (where 34/37a = 
EuL, 34/37b = TbL, 34/37c = GdL), (41 b) and (60)
Initially, the luminescence properties of the europium(III) and terbium(III) 
complexes of (34a-b) and (37a-b) were investigated with the excitation and 
emission spectra recorded and the number of bound water molecules (q)
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determined from luminescence lifetime measurements. Other physical 
measurements performed include NMR studies of the gadolinium(III) 
complexes that were used to calculate the relaxivity values for (60), (34c), (37c) 
and (41 b). MR imaging studies were carried out on samples consisting of a 
10mm diameter tube (containing water) with a 5mm tube (containing a 
gadolinium(III) complex) placed inside. In vitro MRI imaging studies were 
also carried out to investigate the cellular uptake of these four gadolinium(III) 
complexes. Each contrast agent was incubated with Jurkat cells and cell pellets 
formed for imaging experiments. Cellular uptake properties were also 
investigated for the BODIPY compound bearing a triethylamine moiety (27), 
which was incubated with HT-29 cells and the location tracked using 
fluorescence microscopy. Fluorescence microscopy was undertaken at the 
University of Hull by Huguette Savoie.
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5.2 Photophysical properties
The excitation and emission spectra were recorded for the europium(III) and 
terbium(III) complexes of the nitro and amino benzimidazole DO3A chelators 
(34a-b) and (37a-b). The luminescence lifetimes in water and D2O were 
measured to allow calculation of the q values (number of bound water 
molecules) for each complex. Luminescence lifetimes measurements were 
recorded and analysed at the University of Leicester by Dr Mark Lowe.
5.2.1 Emission spectra of the lanthanide complexes
The emission spectra were recorded for europium(III) and terbium(III) 
complexes of the nitrobenzyl and aminobenzyl benzimidazole DO3A chelators 
(34a-b) and (37a-b). All of the complexes gave characteristic emission spectra, 
indicating incorporation of the lanthanide(III) ion within the metal binding site. 
In the excitation spectra, benzimidazole chromophores generally absorbed at 
around 272 nm, the structural differences within the chelators did not shift the 
excitation wavelength significantly. Solutions of concentration 2.5x10"5 M were 
prepared and the luminescence emission spectra recorded at an excitation 
wavelength of 272 nm. The transitions giving rise to the peaks can be assigned 
on the basis of the lanthanide energy levels, europium(III) has a 5Do excited 
state which results in an emission peak at 17,200 cm" 1 (A.em = 615 nm) on 
returning to the 7Fo ground state. Other emission peaks are present for 
europium(III) at 580, 595, 655 and 700 nm. Terbium(III) has a 5D4 excited state 
which results in an emission peak at 20,500 cm ' (kem = 545 nm) on returning to 
the 7F6 ground state. The emission spectra for the complexes are shown in 
figures 148-151.
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Europium{lll)l,4,7-tris(carboxymethyl)-10-{l-(4-nitrobenzyl)-2- 
methylbenzimidazole)-lA7,10-tetraazacyclododecane
220 320 420 520 620 720 820
Wavelength {nm)
Figure 148 The emission spectrum of the europium(III) complex (34a)
Terbium(lll) l,4,7-tris(carboxymethyl)-10-(l-(4-nitrobenzyl) 
-2-methyl benzimidazole)-l,4,7,10-tetraazacyclododecane
700
600
220 320 420 520 620 
Wavelength (nm}
720 820
Figure 149 The emission spectrum of the terbmm(lil) complex (34b)
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Europium(lll)l,4/7-tris(carboxymethyl)-10-{l-(4-aminobenzyl)-2- 
methyl benzimidazole(-1,4,7, 10-tetraazacyclododecane
70 -I 
60 -
so -
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20 ^ 
10 
0
220 320 420 520 620
Wavelength (nrn)
720 820
Figure 150 The emission spectrum of the europium(III) complex (37a)
Terbium(lll) l,4,7-tris(carboxymethyl)-10-(l-(4-aminobenzyl)-2- 
methyl benzimida2ole)-l,4,7,10-tetraazacydododeeane
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Figure 151 The emission spectrum of the terbium(III) complex (37b)
The spectrum of the europium(III) complex with the nitrobenzyl benzimidazole 
DO3A chelator (34a) has emission peaks at 270, 294, 540, 589, 611 and 801 
nm. The peaks in the spectrum between 540 - 611 nm can be assigned to the 
various levels of emission from the lowest lying triplet (T) level. The peak at 
540 nm represents the 5D0 —»• 7F0 transition, the peak at 589 nm represents the 
5D0 —> 7F t transition and the peak at 611 nm represents the 5D0 -> 7F2 transition. 
The europium(III) aminobenzyl benzimidazole DO3A chelator (37a) shows a
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similar spectrum, with the characteristic peaks at 542 nm (5D0 -> 7F0), 590 nm 
(5D0 -» 7F,) and 617 nm (5D0 -> 7F2).
The terbium(III) complexes have better sensitisation of the lanthanide ion due to 
a more efficient overlap of the excited states of the benzimidazole and the 
terbium(III) ion. For the nitrobenzyl benzimidazole DO3A terbium(III) 
complex (34a), the peak at 488 nm represents the 5D4 —* 7F6 transition, the peak 
at 544 nm represents the 5D4 —> 7F5 transition, the peak at 583 nm represents the 
5D4 —> 7F4 transition and the peak at 616 nm represents the 5D4 —> 7Fs transition. 
The aminobenzyl benzimidazole DO3A terbium(III) complex is also similar to 
the equivalent nitrobenzyl complex, with peaks at 487 nm (5D4 —> 7F6), 543 nm 
(5D4 -* 7F5 ), 585 nm (5D4 -» 7F4) and at 617 nm (5D4 -» 7F3).
5.2.2 Luminescent lifetimes and q values
From the luminescent lifetimes (T) of the complexes, it is possible to calculate 
the number of bound water molecules (q value) by measuring the rate constant 
for depopulation of the excited state in H2O and D2O, provided that a correction 
is made for the effect of unbound (closely diffusing) H2O molecules, and for 
other exchangeable XH oscillators (e.g. amide NH, amine NH). Each amide 
NH oscillator contributes 0.075 ms ' to quenching of the europium(III) 5Do 
excited state but does not contribute to the quenching of the terbium(III) 5D4 
excited state. This allows the q values for europium(III) or terbium(III) 
complexes to be calculated. The decay rates measured in H2O and D2O are used 
to calculate the q value for europium(III) and terbium(III) complexes. The 
fitted decay emission profiles in D2O are shown in figures 152 - 156 for the 
europium(III) and terbium(III) complexes.
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Figure 152 Fitted decay emission spectrum for (34a) in D2O
120000
100000
g- 80000
.f 60000
c
•M
- 40000 
20000
TbNO2 in D2O Xex = 278 nm
4 
time / ms
Figure 153 Fitted decay emission spectrum for (34b) in D20
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Figure 154 Fitted decay emission spectrum for (37a) in D2O at X^ = 318 nm
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Figure 155 Fitted decay emission spectrum for (37a) in D2O at Xex = 395 nm
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Figure 156 Fitted decay emission spectrum for (37b) in D2O
To compare different methods of calculating the q value for the europium(III) 
complexes, both the original Horrock's equation and the modified version were 
used along with Parker's modified equation. 200"202 For the terbium(III) 
complex, Parker's modified equation was used. 73 ' 201 These are shown in table 
11.
For Eu(III):
Horrocks original equation:
Parker's modification: 
Horrocks modification: 1.11[&H20-
- 0.25] 
- 0.31]
For Tb(III):
Parker's modified equation: q = 5[&H2O - ^D2O - 0-06]
Table 11 Equations used to calculate the q value for europium(III) and terbium(III) complexes 
using both the Horrocks and Parker equation
Luminescence lifetime measurements were made for the europium(III) and 
terbium(III) complexes of (34a-b) and (37a-b). The luminescence lifetimes in 
both HiO and D2O, and the calculated q values are given in table 12.
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(34a)(?iex =
395 nm)
(37a)(?iex =
318 nm)
(37a)(A.ex =
395 nm)
(34b) (Xex
= 278 nm)
(37b)(?lex
= 289 nm)
*H20
(rns' 1 )
2.28
2.29
2.27
0.91
1.14
*D20
(ms' 1 )
1.04
1.44
1.39
0.60
1.20
q
(Horrocks
original)
1.30
0.89
0.92
q (Parker
modification)
1.19
0.72
0.76
1.25
-0.6
q (Horrocks
modification)
1.03
0.60
0.63
Table 12 Rate constants (ms ') for depopulation of the excited states in H2O and D20 with q 
values
The rate constants for the europium(III) complexes are in the range 2.27 - 2.29 
ms" 1 . For the europium(III) nitro complex (34a), the q value using the Parker 
modification is 1.19. With the europium(III) amino complex (37a), the q value 
is lower at 0.7-0.8, which both suggest one inner-sphere water molecule is 
bound. The terbium(III) complexes have much lower rate constant of 0.91 - 
1.14 ms" 1 . With the terbium(III) nitro complex (34b), the q value of 1.25 
indicated one inner sphere water was present, however with the terbium(III) 
amino complex (37b) the calculation gave a negative answer suggesting that 
there may be an impurity in this sample. Free terbium(III) ions may be present 
in solution suggesting that the purification of the complex using a sephadex 
column had not successfully removed all the unreacted metal salts.
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5.3 T-, relaxation studies
The gadolinium(III) contrast agents (60), (34c), (37c) and (41b) have been 
investigated for their NMR relaxation properties of water molecules.203 These 
compounds (60), (34c), and (37c) have been shown to incorporate one bound 
water molecule, while the aminobenzyl compound (41b) contains more than 
one bound water molecule (q = 2), and hence an improvement in the relaxation 
properties should be observed.
5.3.1 Longitudinal relaxivity (rt) of 1,4,7-tris(carboxymethyl)- 
10-(2-methylbenzimidazole)-1,4,7,10-tetraazacyclododecane 
(60)
Relaxation measurements was made on the non-functionalised complex (60) at 
three different pH values (6.3, 3.5, and 1.5). At low pH it was expected that the 
Nl-position on the benzimidazole, which was bound to the gadolinium(III) ion, 
will become protonated, and hence no longer be coordinated. This may allow 
access for an additional water molecule (increasing q from 1 to 2) that in turn 
would lead to an improvement in the relaxivity (r/) (figure 157).
R-
H+
O
Figure 157 Possible effect of the protonation on the functionalised gadolinium(III) 
benzimidazole DOS A complex (where R= NO2 and NH2)
To measure the longitudual relaxivity (r,) for a contrast agent interacting with 
water, the relaxation time (7/) needs to be recorded in aqueous solutions at a 
range of concentrations (1 mM, 0.75 mM, 0.5 mM, 0.25 mM and 0.125 mM 
were selected). A graph can be plotted of I/ Tj vs. concentration with the
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gradient equating to the relaxivity rate (r,). The graph for (60) at pH 6.8 is 
shown in figure 158.
1/T1 vs. Concentration, pH 6.8
4.5 -,
4 
3.5 -
3 -
2.5 -
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0
= 3.400x + 0.485
0 0.2 0.4 0.6 0.8 1 
Concentration of Gd(benzimidazole) mM
1.2
Figure 158 Graph to show \IT, vs. Concentration at pH 6.8 for (60)
From this plot, the relaxivity (r/) was found to be 3.4 s^mM"1 at pH 6.8. This 
was repeated at pH 3.5 and 1.5, with the results shown in table 13.
pH
6.8
3.5
1.5
Relaxivity (s^mM"1 )
3.40
2.90
3.33
Table 13 The relaxivity of (60) at different pH values
The relaxivity of (60) at pH 3.5 was found to be 2.90 s^rnM" 1 , while at pH 1.5 it 
was found to be at 3.33 s^mM"1 . These results show that pH does not have an 
effect on the relaxivity. Protonation of the Nl-position does not lead to an 
increase in the relaxivity and so the number of bound water molecules is 
unchanged. Typically, lanthanide complexes can be 9-coordinate, however, it 
may be that in this case, instead of the free coordination site being occupied by
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a water molecule, structural rearrangement occurs to give an 8-coordinate 
complex that still has only one bound water molecule.
5.3.2 Longitudinal relaxivity (rr; of gadolinium(lll) 1,4,7- 
tris(carboxymethyl)-10-(1 -(4-nitrobenzyl)-2-methyl 
benzimidazole)-1,4,7,10-tetraazacyclododecane (34c)
The relaxivity rate was recorded for the gadolinium(III) 
nitrobenzylbenzimidazole DO3A compound (34c). It was recorded at three 
different pH values, 4.6 3.5 and 1.5. The graph is shown for (34c) at pH 4.6 in 
figure 159.
1/T1 vs. Concentration, pH 4.6
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Figure 159 Graph to show 1/T/ vs. concentration at pH 4.6 for (34c)
PH
6.8
3.5
1.5
Relaxivity (s^mM"1)
6.22
5.96
6.22
Table 14 Relaxation rates of (34c) at varying pH
The data shows that the relaxivity is not affected by pH, as was observed for the 
benzimidazole complex (60), once again a decrease in pH which should 
protonate the benzimidazole at the Nl-position did not change the relaxivity 
properties. The relaxivity values observed are greater than those measured for 
the non-functionalised benzimidazole complex (60). A similar relaxivity rate 
might be expected because they both contain one bound water molecule. The
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slight increase in the relaxivity maybe due to the increase in the molecular 
weight of the gadolinium(III) complex (34c) resulting in a decrease in the 
tumbling rate (TR).
5.3.3 Comparison of the longitudinal relaxivity (r-,) for the 
gadolinium(lll) complexes
The relaxivity values were also recorded for the gadolinium(III) complex of 
aminobenzyl benzimidazole DO3A chelator compound (37c), and aminobenzyl 
DO3A chelator (41b) and for comparison, the commercial DTPA contrast agent 
Omniscan, with the results shown in table 15.
Compound
60
34c
37c
41b
Omniscan
Relaxivity (s^rnM'1)
3.40
6.22
4.51
7.86
5.52
Table 15 Relaxivity values of the gadolinium(III) contrast agents
The relaxivity values were found to be 4.5 s^mM" 1 for (37c), 7.86 s^mM" 1 for 
(41b) and 5.52 s^mM" 1 for Omniscan. The relaxivity values for the 
aminobenzyl and nitrobenzyl benzimidazole compounds are comparable to the 
commercially available contrast agent omniscan. The nitrobenzyl 
benzimidazole derivative (34c) has a higher relaxivity than both the 
aminobenzyl benzimidazole compound (37c) and the non-functionalised 
benzimidazole complex (60). The nitro complex (34c) has a higher relaxivity 
than (37c), this is possibly due to the more favourable environment of (34c) for 
water exchange [increase in residency time (im)]. Both (34c) and (37c) have a 
higher relaxivity than (60), perhaps due to a decrease in the tumbling rate (TR) 
that occurs due to the increase in the molecular weight of the gadolinium(III) 
complexes (34c) and (37c). The aminobenzyl DO3A complex (41b), has the 
highest relaxivity out of all the complexes studied in this work, which can be 
attributed to the higher number of bound water molecules (q value) relative to 
the other complexes.
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5.4 Imaging with contrast agents
The TI (spin-lattice relaxation time) and 7^ (spin-spin relaxation time) are 
important properties in creating signal contrast. By controlling the repetition 
time (time between successive 90° pulses) and echo time (time from the 90° 
pulse to the received signal from the sample), can favour whether a Tj or a 7> 
weighted image is produced. To record a I>weighted image, short repetition 
(<750 ms) and echo times (<40 ms) are required. While for 7>weighted 
images, long repetition (>1500 ms) and echo times (>75 ms) are required,
5.4.1 Tube within a tube images
/"/-weighted images were performed with the gadolinium(III) contrast agents 
(60), (34c), (37c) and (41b). The images show a 10 mm NMR tube containing 
water, with a 5 mm NMR tube inside of it containing the contrast agent. The 
image intensity values cannot be compared between experiments as they 
depend on the parameters of the individual measurement. Therefore, the 
variation in image intensity due to the contrast agents (1 mMol) was compared 
to an internal standard (distilled water). The images are shown in figure 160. A 
'region of interest' was selected containing over 1000 voxels in both the inner 
and outer tubes allowing a percentage increase in contrast to be calculated 
relative to the water. The results showing the percentage increase in image 
intensity due to the gadolinium(III) contrast agents are shown in table 16.
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a)
c)
b)
d)
e)
Figure 160 Images showing the contrast enhancement due to the gadolinium(III) contrast 
agents (internal tube) relative to water, a) (60), b) (34c), c) (37c), d) (41 b) and e) Omniscan
Sample
60
34c
37c
41b
Omniscan
% increase in intensity from water
51
124
64
148
71
Table 16 Relative image intensity increase due to the gadolinium(III) contrast agents
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The results show the expected increase in image intensity due to the 
gadolinium(III) contrast agent when compared to water using a 7>weighted 
pulse sequence. This data is consistent with the results for the relaxivity rates 
(r/) reported in section 5.2 showing that the aminobenzyl DO3A complex (41b) 
has the largest relative intensity increase, with the benzimidazole complex (60) 
giving the smallest contrast enhancement.
5.4.2 In vitro MR cellular studies
In vitro MR studies to show whether cellular uptake of the complexes occurred 
were carried out with (60), (34c), (37c) and Omniscan, at a field strength of 11.7 
T. These studies were performed with Jurkat cells and the aim was to 
investigate whether these compounds penetrated into the cells. Figure 161 
contains the images recorded in the MR study using Jurkat cells with both ?/ 
and TV weighted images shown. In this case the medium above the cell pellet 
was used as the internal standard, the cells had been exposed to the contrast 
agents at a high concentration and then this solution was washed away and 
replaced by growth medium.
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Sample
control
60
34c
37c
Omniscan
% difference in intensity from medium
20.4
23.2
4.8
0
28.3
Table 17 Intensity variation in the TV weighted images of cell pellets in medium
The Tj- weighted images showed no difference in intensity when compared to 
the medium. In the 7> weighted images, the cell pellet is generally seen to be 
darker, showing the negative effect on the image intensity that is consistent with 
a T2 contrast agent. The contrast variation in the T2- weighted images was 
found to be larger than in the Tr weighted images. This is consistent with work 
reported by Mishra et al, where they suggest that the 7? effect is due to the 
accumulation of the compound in intracellular vesicles that induces local 
magnetic field inhomogenities due to compartmentalization. 107 However, the 
control also shows a contrast variation in the 7> weighted image, which is 
comparable to the samples containing contrast agents, suggesting that the 
compound is not being taken up into the cells. The aminobenzyl benzimidazole 
DO3A complex (37c) shows little difference in contrast between the cell pellet 
and the medium in both TI and ^-weighted images. It may be the case that the 
contrast agents were taken up into the cells, but by the time the image was 
taken, the complex had diffused or been transported back out of the cells. The 
conditions need to be optimised for all of these experiments. Ideally, to assist 
uptake of the contrast agents by the cells, a further functional group could be 
attached to the molecule that will enhance the cellular uptake pathways and 
result in a greater contrast difference between the medium and the cell pellet.
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5.5 Cellular studies of5-(4- 
triethylammoniummethylamidophenyl) 
borondipyrromethene chloride (27)
A number of groups have reported the preparation of BODIPY analogues as 
probes for optical imaging. Sunahara et ol. have reported the synthesis of a 
library of meso substituted BODIPY derivatives with ON/OFF switching 
capabilities in the presence of changes in solvent polarity that have been 
employed to establish the polarity at the surface of a protein and at the 
membrane in living cells. 168 Hall et al have reported the preparation of 
BODIPY dyes that are based on a tetraarylazadipyrromethene fluorophores that 
employs a receptor-methylene spacer-fluorophore architecture. 204 This 
molecule has also been used as a sensing molecule to detect polarity and pH 
changes. In vivo cellular imaging has been performed to show that the complex 
locates within the cytoplasm.
The BODIPY dye 5-(4-triethylammoniummethylamidophenyl) 
borondipyrromethene chloride (27) has been prepared. The compound has the 
potential to be used as an optical dye in biological imaging experiments, and the 
quaternary amine group, will impart greater aqueous solubility that may 
improve cellular uptake properties and may also influence localisation within 
the cells. The fluorescence emission spectrum was recorded, see figure 162, 
showing the emission peak at 537 nm.
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5-(4-triethylammoniummethylamidophenyl) 
borondipyrromethene chloride (27)
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Figure 162 Emission spectrum of the compound 5-(4-triethylammoniummethylamidophenyl) 
borondipyrromethene chloride (27)
The BODIPY dye (27) was incubated with HT-29 cells for 1 hour, and after 22 
hours of plating, fluorescence microscopy was performed. The images in figure 
163 show the localisation of the BODIPY dye in the cell.
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Figure 163 Fluorescence microscopy of the BODIPY dye into HT-29 cells. The top image is 
of a fluorescence scan detecting the BODIPY dye (green); the bottom image is an overlay of a 
fluorescence image and a phase contrast image to show localisation within the cells
The images show that the BODIPY optical dye is taken up by the cell, while 
there is a faint diffused fluorescence, the localised brighter fluorescence is 
likely to be due to uptake of the dye into lysosomes. To confirm this, co- 
localisation studies can be undertaken with a known dye that locates within the 
lysosomes.
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5.6 Conclusions
This chapter contains a discussion of the physical properties and cellular uptake 
of the lanthanide contrast agents synthesised and the BODIPY dye (27). The 
photophysical properties of the europium(III) and terbium(III) complexes of the 
nitrobenzyl and aminobenzyl benzimidazole ligands (34a-b) and (37a-b) were 
investigated. The benzimidazole component can act as a weak sensitizer for 
lanthanide ion based emission. The luminescence emission spectrum of the 
terbium(III) complex contained more defined peaks, suggesting that the 
benzimidazole ligand provides better sensitisation for this metal ion. The 
complexes were shown to each have one bound inner sphere water molecule.
Relaxivity studies were undertaken on the gadolinium(ni) contrast agents (60), 
(34c), (37c) and (41b). Initially, pH variation effects were investigated using 
compounds (60) and (34c), as it was believed that at low pH, the Nl-position 
would become protonated and dissociate from the gadolinium(III) ion leading 
to an increase in the bound water molecules and therefore an improvement in 
relaxivity properties. However, varying the pH did not change the relaxivity, 
which suggests that the protonation of the Nl-position on the benzimidazole 
leads to a structural rearrangement from a 9 coordinate compound to an 8 
coordinate compound with no net change in the number of inner sphere water 
molecules. The gadolinium(IH) contrast agents (60), (34c), (37c) and 
Omniscan all have one bound water molecule, while (41b) contains two bound 
water molecules and therefore, it was expected that the latter will have the 
greatest relaxivity value. This trend was observed and the results also showed 
that (60) had the lowest relaxivity in comparison to the functionalised 
benzimidazoles (34c) and (37c). This is possibly due to the increase in 
molecular weight and a decrease in the rumbling rate (TR). The aminobenzyl 
benzimidazole complex (37c) had a lower relaxivity than the nitrobenzyl 
benzimidazole complex (34c). An explanation could be that the nitro 
benzimidazole complex (34c) had a more favourable environment for water 
exchange that may effect the residency time (tm).
196
The 7>weighted images of a 5 mm NMR tube containing the gadolinium(III) 
contrast agent located inside a 10 mm NMR tube containing distilled water 
were produced. The image intensity variation of the contrast agent solutions 
was scaled to an internal standard and the increases in intensity were in the 
same order that was observed for the longitudinal relaxation rates. The next 
step was to investigate their cellular uptake properties. This was undertaken by 
incubating the contrast agent with Jurkat cells and forming cell pellets. Tj- 
weighted images showed no difference in contrast between the medium and the 
cell pellet. However, with the T^-weighted images, there was some negative 
contrast differences i.e. darker cell pellet [except for (37c)]. This may suggest 
that the contrast agent is accumulating in the intracellular vesicles. However, 
the control sample of the cell pellet and medium also had a similar intensity 
differences, which may suggest that the agent is not being taken up into the cell 
under these experimental conditions. The aminobenzyl benzimidazole complex 
(37c), had no effect on the image intensity in either the TI or the /^-weighted 
image highlighting that there may have been issues with the contrast agent 
either diffusing or being transported out of the cells prior to collection of the 
images.
Fluorescence microscopy was performed with the BODIPY dye (27) to 
investigate whether it was taken up into HT-29 cells. The images show that the 
dye was taken up into the cells and appeared to localise in the lysosomes.
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6. Conclusion and Further Work
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6.1 Introduction
This thesis reported the research into the synthesis of dual modality imaging 
agents that have the potential to act as both MRI and optical contrast agents, and 
could also target cellular function. The initial aim of this research was to 
synthesise a compound that has the capability to encapsulate a lanthanide metal 
ion and has further functionality for the attachment of an optical dye. The 
physical properties and cellular uptake/ localisation where then investigated for 
the resulting multi-modality imaging agents.
To achieve this, there are three main components that are required, the chelator 
(DO3A), the chromophore/linker (benzimidazole) and the optical dye 
(rhodamine B or BODIPY) (figure 3). Chapter 2 presented the synthesis of the 
chromophore/linker group benzimidazole that contains a reactive alkyl halide 
for coupling to the secondary amine position on the chelator and a nitro group to 
convert to an amine at a later stage for the attachment of an optical dye. 
Chapter 3 discussed the preparation of fluorescent dyes based on rhodamine and 
BODIPY backbones that have isothiocyanate or amine groups for coupling to 
the DO3A chelator derivative. Chapter 4 reported the synthesis of DO3A 
chelators that contain a chromophore/linker group with an appropriate 
functional group for coupling to the optical dye and proposed methodologies for 
the preparation of multimodality agents. Studies of the physical properties and 
cellular uptake of lanthanide complexes and novel dye conjugates were 
investigated and detailed in chapter 5, with the lanthanide complexes of the 
nitrobenzyl and aminobenzyl benzimidazole DO3A chelators (34a-c), and (37a- 
c), benzylamineDO3A chelators (41a-c), Gd(III) benzimidazole DO3A chelator 
(60), and the BODIPY triethylamine compound (27) studied.
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6.2 Concluding remarks on the synthesis of 
benzimidazole derivatives
The synthesis of the chromophore unit was based on the compound 
benzimidazole. The benzimidazole derivative has to contain the functionality 
for attachment to both the cyclen unit DO3A (31) and a fluorescent dye 
(rhodamine B or BODIPY). The initial strategy involved the functionalisation 
of 1,2-phenylenediamine with 4-acetamidobenzaldehyde to form l-(4- 
acetamidomethylene)phenylenediamine (1), with the imine group reduced by 
sodium borohydride to form l-(4-acetamidomethyl)phenylenediamine (2). 
Efforts to form the benzimidazole (3) involved using methyl chloroacetimidate 
hydrochloride with (2), however the desired product was not formed. The use 
of an amide protecting group on the benzimidazole unit was deemed initially to 
be a better approach than the use of a nitro functionality due to the ease of 
conversion to an amine (acid hydrolysis). However, due to the difficulties in 
forming the amide derivative benzimidazole, the route to the nitro containing 
compound was investigated.
The phenylenediamine derivative l-(4-nitrobenzyl)phenylenediamine (5), was 
readily formed by the coupling of 1,2-phenylenediamine and 4-nitrobenzyl 
bromide. Efforts to prepare l-(4-nitrobenzyl)-2-chloromethyl benzimidazole (7) 
using chloroacetic acid resulted in the displacement of the chloro substiutent 
with either hydroxide or ammonia during work up. An alternative method 
involved using glycolic acid to yield l-(4-nitrobenzyl)-2-hydroxymethyl 
benzimidazole (6), followed by the conversion of the hydroxo to the chloro 
substituent, to give the desired molecule, l-(4-nitrobenzyl)-2-chloromethyl 
benzimidazole (7).
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6.3 Concluding remarks on the synthesis of optical dyes
The development of ftmctionalised rhodamine B and BODIPY optical dye 
derivatives is reported in chapter 3 of this thesis. The optical dyes need to 
contain a reactive group that can be coupled to the chromophore/linker 
compound. The initial route for the synthesis of rhodamine derivatives involved 
following the method reported by Nguyen et al. where a piperazine was coupled 
to the rhodamine B base to form a fluorescent rhodamine B piperazine amide 
(12). 155 According to the reported research, this can undergo reactions with acid 
chlorides (chloroacetyl chloride and bomoacetyl chloride) and alkyl halides (3- 
bromopropanol). These reactions were attempted herein, but proved 
unsuccessful.
As an alternative, the rhodamine B derivative with an ethylenediamine moiety 
was also prepared (16). This was synthesised by coupling rhodamine B and 
hydrazine to yield a non-fluorescent rhodamine compound, due to the formation 
of a lactam. Due to the lack of fluorescent properties this derivative is of 
limited use and further compounds must be synthesised to meet the 
requirements of a multi-modality imaging agent. The molecule does however 
have potential as a mercury(II) sensor, as other research groups have reported an 
increase in fluorescence of similar molecules occurring due to lactam cleavage 
upon complexation of mercury(II).
BODIPY analogues that contain an isothiocyanate or an amine function have 
been synthesised. The method involved the condensation reaction between 4- 
acetamidobenzaldehyde and 3-ethyl-2,3-dimethylpyrrole to form the 
dipyrromethane, that can then be converted to the dipyrromethene (2,8-diethyl- 
l,3,7,9-5-(4-acetamidophenyl)dipyrromethene (19) by DDQ oxidation. The 
amide protecting group was then cleaved to give an amine by acid hydrolysis, 
and the dipyrromethene complexed with boron to form 5-(4-aminophenyl) 
borondipyrromethene (20). The amine was converted to an isothiocyanate 
group using of TOP to form (21).
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An alkyl amine bearing BODIPY dye was prepared due to the reduced reactivity 
of the aromatic amine with isothiocyanate groups. The initial method used was 
based on a modified version of the synthesis reported by Biron et al. where a 
molecule with a Boc protected amine and an activated carboxylic acid group 
(23) was coupled to the amino BODIPY (20).m This formed the Boc-protected 
BODIPY, 5-(4-Boc-aminobutylamidophenyl) borondipyrromethene (24). 
Unfortunately, the deprotection step resulted in the decomplexation of the 
boron. This reaction was repeated with 5-(4-aminophenyl) dipyrromethene, 
using the activated carboxylic acid containing compound (23),which resulted in 
the formation of 5-(4-bocaminobutylamidophenyl)-dipyrromethene (24). 
Attempts to deprotect the Boc group, and then complex with boron in one 
continuous process were unsuccessful.
A further method to synthesise alkyl amine containing dye derivatives was then 
investigated. 5-(4-aminophenyl) dipyrromethene was reacted with bromoacetyl 
chloride in the presence of triethylamine. Instead of forming the desired 
compound (28), the triethylamine acted as a nucleophile and formed 5-(4- 
triethylammoniummethylamidophenyl) borondipyrromethene chloride (27). To 
prepare (28), 5-(4-aminophenyl) dipyrromethene was washed with base to 
deprotect the phenyl amine, and then coupled to bromoacetyl chloride to give 
the desired compound, 5-(bromomethylamidophenyl) borondipyrromethene 
(28), which was then treated with ethylenediamine to form 5- 
(ethylenediaminemethylamidophenyl) borondipyrromethene (29)
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6.4 Concluding remarks on the synthesis of macrocyclic 
ligands for lanthanides
The coupling reaction between DO3A (31) and either the benzimidazole (7) or 
4-nitrobenzyl bromide was found to be problematic. After numerous attempts, 
the optimal conditions were found to require an initial wash of (31) with base 
and then the use of an excess of sodium hydrogen carbonate in the presence of 
the desired chromopore/linker unit while heating at reflux for 24 hours.
The nitro group on the chromophore/linker attached to the DO3A chelalor was 
reduced to an amine with either sulfurated sodium borohydride for the 
benzimidazole DO3A chelator, or using a palladium on carbon catalyst in the 
presence of hydrogen for the nitrobenzyl DO3A chelator. The lanthanide 
complexes were formed with the nitrobenzyl and aminobenzyl benzimidazole 
DO3A chelators (34a-d) and (37a-d), and for the aminobenzyl DO3A chelators 
(51a-c).
A number of strategies were investigated in order to couple the optical dye to 
the benzimidazole/benzyl DO3A chelators. This involved the reaction of an 
isothiocyanate function with the phenylamine group on either the DO3A 
chelator or on the optical dye. However, these reactions did not proceed at all 
or were extremely slow and so an alternative approach was required.
An alkyl amine bearing BODIPY dye was prepared due to the reduced reactivity 
of the aromatic amine with isothiocyanate groups. The initial method was 
based on a modified version by Biron et al. where a Boc protecting amine with 
an activated carboxylic acid group (23) was coupled to the amino BODIPY 
(20). 176 This was confirmed, by the formation of (48) and (50), the DO3A 
chelator derivative bearing an isothiocyanate group (46) and (45) was reacted 
with benzylamine. The lanthanum complexes were then formed to demonstrate
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that this was a valid route to produce multi-modality imaging agents 
incorporating lanthanide ions.
Continuing with this approach, an attempt was made to couple the two optical 
dyes with alkyl amine groups, ethylenediamine rhodamine (16) or the BODIPY 
analogue (29), to the isothiocyanate group on the DO3A chelator derivatives. 
Initially, the alkyl amine optical dye was stirred with the DO3A chelator, which 
did not give the desired compound. The alkyl amine optical dye was then 
washed with base before attempting the coupling reaction with the DO3A 
chelator, unfortunately this resulted in the polymerisation of the optical dye 
prior to reaction. This route appears to be the best approach to the production of 
multi-modality contrast agents but requires further optimisation of the 
conditions.
Attempts were made to attach an alkyl amine onto the DO3A chelator derivative 
(50). Phthaloyl p-alanine chloride was reacted with the phenylamine, followed 
by the deprotection of the phthaloyl group using hydrazine. Attempts were 
made to couple this to the isothiocyanate BODIPY (21), but t.l.c. analysis 
showed formation of multiple products. This again appears to be a viable route 
to synthesise multi-modality imaging agents but also requires further 
optimisation of the reaction conditions.
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6.5 Concluding remarks on the studies of the physical 
properties and cellular uptake of lanthanide complexes 
and novel dye conjugates
The emission and the luminescence lifetime spectra were recorded for the 
europium(III) and terbium(III) nitrobenzyl and aminobenzyl benzimidazole 
complexes (34a-b) and (37a-b). The emission spectra showed typical spectra 
for lanthanide complexes, with the terbium(III) complex containing more 
defined peaks, which suggests that the benzimidazole ligand provides better 
sensitisation onto the terbium(III) metal ion. The luminescence lifetime data of 
the complexes allows for determination of the number of inner sphere water 
molecules, which gave values approximating to one bound water for each of the 
complexes.
Relaxivity measurements on the gadolinium(III) contrast agents (60), (34c), 
(37c) and (41b) were made. Variable pH studies were performed on (60) and 
(34c), showing that alterations in pH did not result in changes in relaxivity. 
This was proposed to be due to structural changes on protonation resulting in 
the formation of an 8-coordinate complex from a 9-coordinate complex. The 
gadolinium(III) aminobenzyl contrast agent (41b) contains two bound water 
molecules which, as expected, gave the highest relaxivity value of the 
compounds studied. The relaxivity of (34c) and (37c) was comparable to the 
known contrast agent Omniscan, with the nitrobenzyl benzimidazole complex 
(34c) having a higher relaxivity than the aminobenzyl benzimidazole complex 
(37c). The non-functionalised benzimidazole complex (60) has lower relavitiy 
in comparison to the functionalised benzimidazoles (34c) and (37c).
7>weighted images were produced of a 10 mm NMR tube containing distilled 
water that contained a 5 mm NMR tube containing a solution of gadolinium(III) 
contrast agent. The image intensity of all the contrast agents was shown to be 
much greater than water, with the image intensity difference greatest for the 
aminobenzyl gadolinium(III) complex (41b), and the non-functionalised 
benzimidazole (60) showing the smallest difference. The cellular uptake
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properties of the contrast agents were investigated by incubating the contrast 
agent with Jurkat cells and forming cell pellets. Both the T, and ^-weighted 
images showed little difference in contrast between the medium and the cell 
pellet suggesting that the agent may not be accumulating in the cell.
Fluorescence microscopy was undertaken on the BODIPY dye (27) to 
investigate the optical dyes ability to be taken into HT-29 cells. The quaternary 
triethylamine group allowed for uptake into the cells, as confirmed by the 
optical images with the evidence suggesting that the dye was taken up into the 
lysosomes. Co-localisation studies can now be carried out on this potentially 
useful bio-compatible dye molecule.
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6.6 Further work
The individual components of the multi-modality agent have been prepared 
successfully but problems arose when trying to couple the DO3A chelator 
groups with the optical dye. The main issue is the low reactivity of the aromatic 
amines. The initial point for further work would be to investigate this coupling 
reaction again. The most promising route involved the coupling of an alkyl 
amine containing optical dye to an isothiocyanate DO3A chelator. The reaction 
could be repeated, with the starting material prepared and used straight away 
without a base wash of the alkyl amine optical dye to avoid issues of polymer 
formation.
The other promising route was to form the alkyl amine from the DO3A chelator 
(58). An alternative procedure could involve starting from the tert-butyl 
protected DO3A chelator with a benzyl amine group [(35) or (39)] and coupling 
this to the phthaloyl p-alanine chloride, followed by the deprotection of the 
phthaloyl group by hydrazine. Purification could then carried out using column 
chromatography on silica, followed by the deprotection of the acetate arms, and 
coupling to the optical dye.
Once a multi-modality agent has been prepared, a number of studies can be 
undertaken. The starting point would be an investigation of the cellular uptake 
properties to identify the localisation of the compounds within the cell (via co- 
localisation studies with a known optical dye). From this, the properties can be 
modified to optimise where the compound locates within the cell. An area of 
specific interest is the localisation of the contrast agent into the mitochondria, 
with particular reference to the mitochondria in the heart. Dysfunction in the 
mitochondria in the heart is known to have a key role in apoptosis, which is 
associated with heart disease. Agents such as the polyamines spermine and 
spermidine, are known to target the mitochondria. They could be coupled to the 
DO3A chelator to provide a target specific agent to localise in the mitochondria. 
From this, the next step would be to generate a switchable/responsive probe that
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would be able to identify the events occurring in the cell, and in particular to 
detect the first signs of heart disease.
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7. Experimental
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7. 1 General Procedures
7.1.1 NMR Spectroscopy
*H NMR, 13C NMR, and DEPT experiments were performed using a JEOL 
JNM-LA400 FT NMR spectrometer and a Bruker 500 Biospin NMR 
spectrometer. Chemical shifts for *H and I3C NMR spectra are reported in parts 
per million relative to internal standards arising from the partially deuterated 
solvent. Coupling constants are reported in Hertz (Hz). Spectral splitting 
patterns are designated as follows: s = singlet, d = doublet, t = triplet, q = 
quartet, qu = quintet, m = mulitplet, dd = doublet of doublets and br = broad.
7.1.2 Mass Spectrometry
Electrospray mass spectra were recorded at the University of Hull using a 
Thermo Finnigan LCQ Classic-Electrospray LC-MS. Both low resolution and 
high resolution mass spectra were recorded at the EPSRC National Mass 
Spectrometry Service Centre at the University of Swansea using a Finnigan 
MAT 900 XLT.
7.1.3 X-ray crystallography
Single crystal X-ray diffraction data sets were collected on a Stoe IPDS-II 
imaging plate diffractometer, using a 0.5 mm monochromated X-ray beam of 
wavelength 0.71073 A produced by a molybdenum Ka X-ray generator. 
Crystals were maintained at 150 K during data collection, with the temperature 
controlled using an Oxford Systems Cryostream Cooler. Diffraction data were 
solved using direct methods or Patterson syntheses (ShelXS), and the 
refinement was performed using the full-matrix least squares against F~ 
(ShelXL-97) method. Hydrogen atoms were fixed in idealised positions and 
refined against a riding model, with C-H distances of 0.97 A, N-H distances of 
0.91 A, and U;so 1.2 times Ueq of the carrier atom, except where it is stated that 
the hydrogen atoms had been located on the difference map. Data reduction,
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structure solution and refinement carried out by Dr Steve Archibald, Dr Jon 
Silversides and Ryan Mewis.
7.1.4 Solvents
Solvents were supplied by Fisher Scientific. When necessary, solvents were 
dried according to published procedures, but otherwise were used as received. 
Dichloromethane (DCM), and acetonitrile (CH3CN) were distilled from calcium 
hydride. Methanol (MeOH) was dried by distilling from magnesium 
turnings/iodine. Diethyl ether (Et2O), and tetrahydrofuran (THF) were distilled 
from sodium metal using benzophenone as an indicator.
Deuterated solvents were supplied by Goss Scientific Instruments Ltd.
7.1.5 Chemical Reagents
Reagents were purchased from Sigma Aldrich, Fluka, Lancaster Chemicals, and 
Strem Chemicals. All reagents were used as supplied unless otherwise stated.
7.1.6 Photophysical studies
Photophysical measurements on europium(III) and terbium(III) complexes were 
carried out at the University of Hull using an Agilent 8453E UV-visible 
spectroscopy system, a SLM AB2 Luminescence Spectrometer and an Aminco 
Bowman Series 2 Luminescence Spectrometer SLM (Aminco Spectronic 
Instruments). Samples were prepared as aqueous solutions of concentration 2.5 
x!0'5 M.
Excited-state lifetime measurements were made at the University of Leicester 
by Dr Mark Lowe on a Jobin Yvon Horiba Fluoromax-P spectrometer (using 
DataMax for Windows v2.2). Lifetimes were measured by excitation (395 nm 
direct) of the sample with a short 40 ms pulse of light (500 pulses per point) 
followed by monitoring of the integrated intensity of light (615 nm) emitted
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during a fixed gate time of 0.1 ms, at a delay time later. Delay times were set at 
0.1 ms intervals, covering four or more lifetimes. Excitation and emission slits 
were set to 15 and 5 nm bandpasses, respectively. The obtained decay curves 
were fitted to a simple mono exponential first-order decay curve using 
Microsoft Excel.
7.1.7 7"f measurements
The longitudinal relaxivity of the gadolinium(III) complexes was determined 
from the spin-lattice relaxation time, Tj. The Tj measurements were carried out 
using a Bruker 500 Biospin NMR spectrometer operating at 500 MHz. The 
aqueous solutions of gadolinium(III) complexes were made up using distilled 
water and transferred to 5 mm diameter NMR tubes. The Tj measurements 
were made using the standard inversion-recovery pulse sequence (180°-T-90°) 
with phase-sensitive detection and varying the T values ranging from 50 us to 6 
s for each concentration of the complex. The computer programme Topspin 
was used to plot the time versus the signal intensity to get an exponential plot, 
and the 7/ values were calculated from the plot. A delay of at least 5 71/ was 
maintained between successive pulses to allow for complete return of the spin 
system to equilibrium. The T; values of five different concentrations of the 
complex was measured. A plot of I/ T\ versus the concentration of the complex 
gave a straight line, and the slope was taken as the longitudinal relaxivity (r\). 
Five different concentrations of the complex (1, 0.75, 0.5, 0.25 and 1.25 mM) in 
distilled water were used. The longitudinal relaxivity (r\) at different pH values 
were recorded, by adjusting the pH with 0.1 M hydrochloric acid and varying 
the concentration accordingly.
7.1.8 MRI studies (tube within a tube)
A 1 mM solution of a gadolinium(III) complex was placed into the inner 5 mm 
NMR tube, with distilled water in outer 10 mm tube. MR imaging of the 10 
mm NMR tubes was performed at 500 MHz using TI weighted spin-echo
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sequences at room temperature (~ 21°C). The axial slice of interest was 
positioned through the NMR tube. Experimental parameters for 7/ were: 0.9 x 
0.9 cm2, matrix 256 x 128, slice thickness 1.0 mm, TE 2.0 ms, TR 100.0 ms and 
6 averages.
7.1.9 In vitro MR studies
For MR imaging of cells, exponentially growing Jurkat cells were labelled with 
300 uM of the gadolinium(III) contrast agent in 175 cm2 tissue culture flasks for 
18 h. After repeated washings with Hanks' buffered saline, cells were 
trypsinized, centrifuged and resuspended in 0.5 ml Eppendorf tubes at 1 x 107 
cells in 500 uL of complete DMEM. Cells were allowed to settle before making 
MR measurements. Tubes with medium only, cells without gadolinium(III) 
contrast agent, and cells resuspended in medium containing the extracellular 
contrast agent Omniscan at 300 uM were used as a control sample.
MR imaging of the cell pellets was performed at 500 MHz using 7y and T2 
weighted spin-echo sequences at room temperature (~ 21°C). The axial slice of 
interest was positioned through the cell pellet. Experimental parameters for T\ 
were: 0.9 x 0.9 cm2, matrix 256 x 128, slice thickness 1.0 mm, TE 2.0 ms, TR 
100.0 ms and 6 averages. For T2 were: 1.2 x 0.8 cm2, matrix 256 x 256, slice 
thickness 1.0 mm, TE 90.0 ms, 77? 8000.0 ms and 2 averages.
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7.1.10 Cellular uptake assay
For the cellular uptake assay, a frozen culture of HT-29 cells (Human Caucasian 
colon adenocarcinoma) was obtained from ECACC and sub-cultured in 
McCoy's 5a medium (Sigma M8403) supplemented with 2mM Glutamine 
(invitrogen GIBCO 25030) and 10% heat inactivated Foetal Bovine Serum 
(Biosera S1910). Adherent cells in the growing log phase were detached from 
the flask with 1 ml 0.25% Trypsin-EDTA (Invitrogen GIBCO 25200), counted 
and re-suspended at a concentration of 1 x 106 cells/ml in culture medium 
without serum.
To 800 ul of prepared cells, 200 ul of stock solution (8.9 mg compound 
dissolved into 1 ml DMSO (Sigma D2650 DIMETHYL SULFOXIDE (DMSO) 
HYBRI-MAX) giving a concentration of 1.44 x 10"2M) diluted in culture 
medium without serum was added to give a final concentration of IxlO"4 M. 
The cells were returned to the incubator (5% CO2 and 37 degrees C) for a period 
of 1 hour. After the incubation period, a further 3 ml of culture medium without 
serum was added to the cells to wash away any unbound compound and the 
cells were centrifuged at 550 x g for 10 minutes; the supernatant was decanted 
and the pellet re-suspended into 1 ml of McCoy's medium with serum; the 
suspension was then put into 35 mm, glass bottom culture dishes (Mat Tek 
Corporation P35G-0-10-C) and returned to the incubator overnight to allow the 
cells to attach.
22 hours after plating, the cells were imaged using a Leica DM-IRB inverted 
fluorescence microscope, and an ORCA-ER digital camera (Hamamatsu C4742- 
80) with HC Image imaging software. The excitation light was supplied by a 
xenon arc lamp housed in a monochromator (Optoscan Monochromator, Cairn 
Research). The excitation wavelength was set at 480 nm with the input and exit 
slits set at 15 nm; a FITC filter cube was used (Exciter HQ 480/40 nm, dichroic 
Q 505 Ip, Emitter HQ 535/50, Chroma Corporation C34302) and the images 
collected with a 63x PI Fluotar phase objective (Leica) and an acquisition time 
of 1 sec.
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7.2 Synthetic Procedures 
7.2.1 Chromatography
Column chromatography was performed using either MP silica 32-63, 60 A, or 
Aldrich activated neutral aluminium oxide Brockman type I, standard grade, ca. 
150 mesh.
Reactions were monitored using either Merck silica gel 60F 254 or aluminium 
oxide 60F 254 neutral thin layer chromatography (t.l.c) plates and the mobile 
phase indicated.
7.2.2 Air/Moisture Sensitive Reactions
Air and/or moisture sensitive reactions were carried out using Schlenk 
techniques under a nitrogen or argon atmosphere. Glassware was flame-dried 
when required.
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7.3 Experimental procedures
7.3.1 Synthesis of A/-(4-((2-aminophenylimino)methyl)phenyl) 
acetamide (1)
Method 1 - (Preferred Route)
4-Acetamidobenzaldehyde (1 g, 6.1 mmol) in methanol (200 ml), was added 
dropwise to a methanolic solution (250 ml) of 1,2-phenylenediamine (1.95 g, 
18.3 mmol) over 3 A molecular sieves and the resulting mixture was stirred for 
72 h. The solvent was removed under reduced pressure. The solid was re- 
dissolved into a minimum amount of ethanol, the product was allowed to 
precipitate out and was collected by filtration to give a yellow solid (1.06 g, 
69%). 5H (DMSO): 8 2.09 (s, 3H, CH3), 6.86 (s, 1H, CH), 7.17 (m, 2H, arCH), 
7.58 (m, 2H, arCH), 7.74 (d, 2H, arCH, J = 8.68 Hz), 8.08 (d, 2H, arCH, J = 
8.68 Hz), 10.18 (bs,lH, NCR).
Method 2
4-Acetamidobenzaldehyde (1 g, 6.1 mmol) in methanol (200 ml), was added 
dropwise to a methanolic solution (250 ml) of 1,2-phenylenediamine (1.95 g, 
18.3 mmol) then stirred for 4 h at room temperature and heated at reflux for 20 
min. The solvent was removed under reduced pressure. The solid was re- 
dissolved into a minimum amount of ethanol, a solid was allowed to precipitate 
out was collected by filtration to give a red solid. The desired product was not 
isolated using this synthetic procedure.
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7.3.2 Synthesis of A/-(4-((2-aminophenylamino)methyl)phenyl) 
acetamide (2)
To a stirred solution of Af-(4-((2-aminophenylimino)methyl)phenyl) acetamide 
(7.0 g, 2.8 mmol) in ethanol (200 ml), sodium borohydride (4.69 g, 0.124 mol) 
was added in small portions over 20 min. The reaction mixture was heated at 
reflux for 4 h. The solvent was then removed under reduced pressure to give an 
orange solid, which was dissolved in water and extracted into dichloromethane 
(2 x 100 ml). The combined extracts were dried over magnesium sulphate, and 
the solvent removed under reduced pressure to yield an orange solid, (3.74 g, 
53%). 5H (DMSO): 8 2.09 (s, 3H, CH3), 4.51 (s, 2H, CH2), 7.17 (m, 2H, arCH), 
7.49 (m, IH, arCH), 7.62 (m, IH, arCH), 7.74 (d, 2H, arCH, J = 8.68 Hz), 8.08 
(d, 2H, arCH, J = 8.68 Hz), 10.18 (s, IH, NH).
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7.3.3 Attempted synthesis of 1-(4-acetamidobenzyl)-2- 
chloromethyl benzimidazole (3)
NCOCH3
Method 1
Hydrogen chloride gas was bubbled into a solution of chloroacetonitrile (5 ml, 
0.079 mol) in dry ethanol (3 nil) and dry diethyl ether (10 ml) for 5 mins, and 
the reaction mixture was then stirred for 24 h under nitrogen. 7V-(4-((2- 
aminophenylamino)methyl)phenyl) acetamide (0.5 g, 0.002 mol) was added and 
the resulting mixture was heated at reflux for 24 h. The solvent was then 
removed under reduced pressure to give a red solid. The desired product was not 
isolated using this synthetic procedure.
Method 2
Dry methanol (3.7 ml) and sodium (0.0036 g, 0.16 mmol) were stirred under 
nitrogen for 1 h to form sodium methoxide. Chloroacetonitrile (0.59 ml, 1 
mmol) was then added and the reaction mixture was left to stir overnight. N-(4- 
((2-aminophenylamino)methyl)phenyl) acetamide (0.25 g, 1 mmol) dissolved in 
dry methanol (5 ml) was added to the reaction mixture which was then heated at 
reflux overnight. The solvent was removed under reduced pressure to give a 
yellow solid. The desired product was not isolated using this synthetic 
procedure.
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7.3.4 Synthesis of 1-(4-nitrobenzylidene)benzene-1,2-diamine 
(4)
4-Nitrobenzaldehyde (5 g, 0.023 mol) dissolved in methanol (300 ml) was 
added dropwise over 30 min, to a stirred solution of 1,2-phenylenediamine 
(12.51 g, 0.12 mol) in methanol (400 ml) over 3 A molecular sieves. The 
reaction mixture was then stirred at room temperature for 72 h. The solution 
was filtered, and the solvent removed under reduced pressure to give a red solid, 
which was then re-crystallised from ethanol to yield red crystals, (2.35 g, 71%). 
5H (CDC13): 5 6.81 (m, 2H, CH2), 7.15 (m, 2H, CH2), 8.07 (m, 2H, CH2), 8.32 
(m, 2H, CH2), 8.63 (s, 1H, NCH).
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7.3.5 Synthesis of 1-(4-nitrobenzyl)phenylenediamine (5)
Method 1 - (Preferred Route)
4-Nitrobenzylbromide (5 g, 0.023 mol) dissolved in methanol (300 ml) was 
added dropwise to a stirred solution of 1,2-phenylenediamine (12.51 g, 0.12 
mol) in methanol (400 ml) over 30 min. The reaction was stirred at room 
temperature for 4 h. Evaporation of the solvent under reduced pressure gave a 
red solid, which was dissolved in ethanol (250 ml) with heat, and allowed to 
cool. The orange precipitate was collected by filtration. The product was 
purified by column chromatography using dichloromethane as eluent (r.f. = 
0.37) to yield a red/orange solid, (3.56 g, 60%). 6H (CD2C12): 5 3.34 (s, 2H, 
NH2), 3.91 (s, 1H, NH), 4.38 (s, 2H, CH2), 6.39 (dd, 1H, CH2, J = 7.3 Hz, J = 
1.68 Hz), 6.65 (m, 3H, CH2), 7.49 (dt, 2H, CH2 , J = 8.7 Hz, J = 1.97 Hz), 8.0 
(dt, 2H, CH2, J = 8.7 Hz, J = 1.97 Hz), m/z: 244.1 (100 (M-H)+).
Method 2
Sodium borohydride (1,62 g, 40 mmol) was added in small portions over 20 
mins to a stirred solution of l-(4-nitrophenylmethylene)phenylenediamine (1.09 
g, 4 mmol) in ethanol (200 ml). The reaction mixture was then heated at reflux 
for 4 h. The solvent was removed under reduced pressure to give an orange 
solid, which was dissolved in dichloromethane (2 x 100 ml) and washed with 
water. The organic layer was extracted and dried over magnesium sulphate, and 
the solvent removed under reduced pressure to yield a red/orange solid, (0.52 g, 
48%). SH (CDC13 ): 5 4.46 (s, 2H, CH2), 6.46 (dd, 2H, CH2 , J - 7.3 Hz), 6.71 
(m, 2H, CH2), 7.56 (d, 2H, CH2, J = 8.7 Hz), 8.19 (m, 2H, CH2), 8.69 (s, 1H, 
NH).
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7.3.6 Synthesis of 1-(4-nitrobenzyl)-2-hydroxymethyl 
benzimidazole (6)
l-(4-Nitrobenzyl)phenylenediamine (0.2 g, 2 mmol) and glycolic acid (0.07 g, 
2.9 mmol) were dissolved in 5 N hydrochloric acid (10 ml) and the reaction 
mixture was heated at reflux for 48 h to form a dark brown solution. The 
solution was cooled to 0°C, and then the pH adjusted with 5% sodium 
hydroxide solution resulting in a yellow precipitate. The yellow precipitate was 
collected by filtration, and washed with water (20 ml), followed by diethyl ether 
(2 x 20 ml) to give a light brown solid, (0.23 g, 77%). 8H (CD3OD): 8 4.83 (s, 
2H,CH2), 5.69 (s, 2H, CH2), 7.29 (m, 5H,arCH), 7.60 (d, IH, J = 8.14), 8.1 (dt, 
2H, J - 8.7, J = 1.97). 8C (CD3OD): 8 46.89 (CH2), 56.99 (CH2), 110.05 (CH), 
119.25 (CH), 122.92 (CH), 123.64 (CH), 124.08 (CH), 127.54 (CH), 135.0 (C), 
141.28 (C), 143.23 (C), 147.68 (C), 154.17 (C). m/z: 283.8 (100 (M-H)+).
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7.3.7 Synthesis of 1-(4-nitrobenzyl)-2-chloromethyl 
benzimidazole (7)
Method 1 - (Preferred route)
Thionyl chloride (10 ml) was added to l-(4-nitrobenzyl)-2-hydroxymethyl 
benzimidazole (0.5 g, 1.7 mmol) under nitrogen and stirred for 24 h. The 
thionyl chloride was removed under reduced pressure to leave a brown solid. 
The product was then dissolved into the minimum amount of methanol and 
excess diethyl ether was added to precipitate a cream solid, (0.36 g, 68%). 8n 
(CD3OD): 8 5.74 (s, 2H,CH2), 6.32 (s, 2H, CH2), 7.68(m, 2H, arCH), 7.82(m, 
3H, arCH), 8.01 (d, 1H, J = 8.14), 8.1 (dt, 2H, J = 8.7, J = 1.97). 5C (CD3OD): 8 
32.87 (CH2), 48.93 (CH2), 114.08(CH), 116.28 (CH), 124.76 (CH), 127.81 
(CH), 127.03 (CH), 129.44 (CH), 131.60 (C), 133.19 (C), 142.07 (C), 148.85 
(C), 149.53 (C). m/r. 301.8 (100 (M-H)+).
Method 2
l-(4-Nitrobenzyl)phenylenediamine (0.5 g, 2 mmol) and chloroacetic acid (0.25 
g, 2.9 mmol) were dissolved in 5 N hydrochloric acid (50 ml) and refluxed for 
18 h. The solution was cooled to 0°C, and the pH adjusted with ammonia 
hydroxide solution to cause the formation of a precipitate. The resulting oily 
brown solid was collected by filtration, and dissolved in methanol, the solvent 
was then removed under reduced pressure to give a brown solid. The desired 
product was not isolated using this synthetic procedure.
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Method 3
A mixture of l-(4-nitrobenzyl)phenylenediamine (0.5 g, 2 mmol) and 
chloroacetic acid (0.25 g, 2.9 mmol) were dissolved in 5 N hydrochloric acid 
(50 ml) and heated at reflux for 18 h. The solution was then cooled to 0°C, and 
the pH adjusted with 5 % sodium hydroxide solution to cause the formation of a 
precipitate. The resulting oily brown solid was collected by filtration, and 
dissolved in methanol, with the solvent removed under reduced pressure. The 
product was allowed to air dry forming a brown solid. The desired product was 
not isolated using this synthetic procedure.
Method 4
A solution of 4-nitrobenzylbromide (0.75 g, 3.5 mmol) dissolved in 
dichloromethane (50 ml) was added dropwise over 30 min to a solution of 2- 
chloromethyl benzimidazole (0.5 g, 3 mmol) in dichloromethane (100 ml) with 
a drop of triethylamine. The reaction mixture was left to stir for 24 h at room 
temperature. The solvent was removed under reduced pressure. The desired 
product was not isolated using this synthetic procedure.
Method 5
4-Nitrobenzylbromide (1.29 g, 6 mmol) and 2-chloromethyl benzimidazole (1 g, 
6 mmol) were dissolved in tetrahydrofuran (100 ml) with a drop of 
triethylamine and stirred for 24 h at room temperature. The reaction was then 
heated at reflux for 3 h. The solvent was removed under reduced pressure. An 
attempt to purify by flash chromatography (dichloromethane with an increasing 
gradient of methanol from 0 % to 10 %) did not isolate any of the desired 
product.
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Method 6
4-Nitrobenzylbromide (1.43 g, 6.6 mmol), 2-chloromethyl benzimidazole (1 g, 6 
mmol) and potassium carbonate (0.62 g, 4.5 mmol) were dissolved in 
dimethylformamide (40 ml) and the mixture was brought to reflux for 3 h. 
Dichloromethane (100 ml) was added to the reaction mixture causing the 
formation of a precipitate. This was collected by filtration and the solvent 
removed under reduced pressure. The desired product was not isolated using 
this synthetic procedure.
Method 7
4-Nitrobenzylbromide (1.77 g, 8 mmol), 2-chloromethyl benzimidazole (1 g, 6 
mmol) and sodium hydroxide (0.28 g, 6 mmol) were dissolved in acetonitrile 
(100 ml) and the mixture was heated at reflux for 24 h. The reaction mixture 
was filtered and the solvent removed from the filtrate under reduced pressure to 
produce a brown/orange oil. The oil was dissolved into minimum acetonitrile 
and left to recrystallise at 0°C. The desired product was not isolated using this 
synthetic procedure.
Method 8
Sodium hydride (0.086 g, 3.6 mmol) was added in small portions to a mixture of 
4-nitrobenzylbromide (0.65 g, 3 mmol) and 2-chloromethyl benzimidazole (0.5 
g, 3 mmol) dissolved in dimethylformamide (40 ml) over 30 min. The reaction 
was then stirred at room temperature for 1 week, followed by heating to reflux 
for 3 h. Dichloromethane (100 ml) was added to the reaction mixture causing 
the formation of a precipitate to occur. The solid was removed by filtration and 
then the solvent was removed from the filtrate under reduced pressure. The 
solid was dissolved into dichloromethane (100 ml) and washed with water (100 
ml). The organic layer was extracted and dried over sodium sulphate. This 
solution was then filtered and the solvent removed under vacuum. The desired 
product was not isolated using this synthetic procedure.
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Method 9
4-Nitrobenzylbromide (0.97 g, 4.5 mmol), 2-chloromethyl benzimidazole (0.5 g, 
3 mmol) and potassium carbonate (0.83 g, 6 mmol) were dissolved in acetone 
(100 ml) and the resulting mixture brought to reflux for 24 h. The reaction 
mixture was filtered and the solvent removed from the filtrate under reduced 
pressure. The desired product was not isolated using this synthetic procedure.
Method 10
2-Chloromethyl benzimidazole (1 g, 6 mmol) dissolved in dry tetrahydrofuran 
(50 ml) was stirred at -30°C under nitrogen, followed by the dropwise addition 
of lithium diisopropylamide (0.86 g, 4.8 mmol) over 5 min. The reaction 
mixture was allowed to stir at -30°C for 15 min. After 15 min 4- 
nitrobenzylbromide (1.29 g, 6 mmol) in dry tetrahydrofuran (50 ml) was added. 
The reaction mixture was allowed to warm up to room temperature and then left 
to stir overnight under nitrogen. The solvent was removed under reduced 
pressure but the desired product was not isolated.
Method 11
2-Chloromethyl benzimidazole (1 g, 6 mmol) in tetrahydrofuran (50 ml) was 
stirred at -30°C under nitrogen, followed by the dropwise addition of lithium 
diisopropylamide (0.86 g, 4.8 mmol) over 5 min. The reaction was allowed to 
stir for 2 h. After this period, 4-nitrobenzylbromide (1.29 g, 6 mmol) in 
tetrahydrofuran (50 ml) was added. The reaction mixture was allowed to stir 
overnight under nitrogen. The solvent was removed under reduced pressure but 
the desired product was not isolated.
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7.3.8 Attempted synthesis of 1-(4-nitrobenzyl)-2-iodomethyl 
benzimidazole (8)
,N02
l-(4-Nitrobenzyl)-2-chloromethyl benzimidazole (0.5 g, 1.7 mmol) was added 
to a solution of sodium iodide (0.37 g, 2.5 mmol) in acetone (50 ml) and heated 
at reflux for 6 h. The organic layer was washed with water (50 ml), dried over 
magnesium sulphate, filtered, and then the solvent was removed under reduced 
pressure. The desired product was not isolated using this synthetic procedure.
7.3.9 Synthesis of 1-(4-nitrobenzyl)-2-methylpyridinium 
benzimidazole bromide (9)
9
l-(4_Nitrobenzyl)-2-chloromethyl benzimidazole (0.1 g, 3.3 mmol) in pyridine 
(2.68 ml, 33 mmol) was heated at reflux for 30 min. The solvent was removed 
and the resulting solid was recrystallised from methanol to yield a white solid, 
(0.89 g, 52.4%). 5H (CDC13): 5 6.14 (s, 2H, CH2), 6.97 (s, 2H, CH2), 7.30 (m, 
5H, arCH), 7.65 (d, 1H, arCH, J = 8.14 Hz), 7.93 (m, 4H, arCH), 8.35 (t, 1H, 
arCH, J = 8.7 Hz), 9.67 (d, 2H, arCH, J = 6.6 Hz). 5C (CDC13): 5 46.83 (CH2), 
56.03 (CH2), 110.33 (CH), 120.28 (CH), 124.05 (CH), 124.70 (CH), 127.73 
(CH), 127.93 (CH), 142.06 (C), 143.34 (C), 145.74 (C), 146.12 (C), 146.65 (C). 
m/z: 345.8 (100 (M-H)+).
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7.3.10 Attempted synthesis of 2-chloromethyl benzimidazole 
(10)
Method 1
1,2-Phenylenediamine (2 g, 0.018 mol) and chloroacetic acid (2 g, 0.0029 mol) 
were dissolved in 5 N hydrochloric acid (50 ml) and heated at reflux for 18 h. 
The solution was cooled to 0°C, and the pH adjusted with aqueous ammonia 
solution to cause the formation of a precipitate to occur. The solid was 
collected by filtration, dissolved into methanol and the solvent removed under 
reduced pressure. The product was allowed to air dry to give a brown solid. 
The desired product was not isolated using this synthetic procedure.
Method 2
Hydrogen chloride gas was bubbled into a solution of chloroacetonitrile (0.25 
ml,'4 mmol) in a mixture of dry ethanol (2 ml) and dry diethyl ether (8 ml) for 5 
min, and then the reaction mixture was stirred for 24 h under nitrogen. 1,2- 
Phenylenediamine (0.38 g, 3.5 mmol) dissolved in dry dichloromethane was 
added at 0°C and the mixture was then left to stir for 24 h at room temperature. 
The solvent was then removed under reduced pressure to give a white solid. The 
desired product was not isolated using this synthetic procedure.
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7.3.11 Synthesis of rhodamine B base (11)
,P
Rhodamine B (5 g, 0.001 mol) was partitioned between aqueous 1 M NaOH and 
ethyl acetate. After separation of the organic layer, the aqueous layer was 
extracted with two additional portions of ethyl acetate. The combined organic 
layers were washed with NaOH and then with brine. The resulting organic 
solution was dried over Na2SO4, filtered, and concentrated under reduced 
pressure to yield a bright pink solid, (4.39 g , 93%). 5H (CD3OD): 5 1.19 (t, 
12H, J = 7.16 Hz), 3.56 (q, 8H, J = 7.16 Hz), 6.81 (d, 2H, J = 2.56 Hz), 6.89 (m, 
2H), 7.16 (m, 3H), 7.52 (m, 2H), 7.97 (m, 1H).
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7.3.12 Synthesis of rhodamine B piperazine amide (12)
A 2.0 M solution of trimethyl aluminium in toluene (1.13 ml, 2.26 mmol) was 
added dropwise to a solution of piperazine (0.4 g, 4.5 mmol) in dry 
dichloromethane (35 ml) at room temperature for 1 h. A solution of rhodamine 
B base (0.5 g, 1.13 mmol) in dry dichloromethane (20 ml) was then added 
dropwise. After heating at reflux for 24 h the reaction mixture was then allowed 
to cool to room temperature at which point a 0.1 M aqueous solution of HC1 
was added dropwise until gas evolution ceased. The solution was filtered and 
washed in turn with dichloromethane followed by a 4:1 
dichloromethane/methanol solution. The solvent was removed under reduced 
pressure, and the resulting solid was then partitioned between dilute aqueous 
NaHCOa and ethyl acetate. The aqueous layer was separated and washed with 3 
additional portions of ethyl acetate to remove residual starting material. The 
aqueous layer was saturated with NaCl, acidified with 1 M aqueous HC1 and 
then extracted with multiple portions of 2:1 propan-2-ol/dichloromethane, until 
only a faint colour persisted. The combined organic layers were then dried over 
Na2SO4, filtered, and concentrated under reduced pressure. The resulting purple 
solid was dissolved into a minimum amount of methanol and precipitated out by 
the addition of a large volume of diethyl ether. The product was collected by 
filtration as a dark purple solid, (0.33 g, 57%). 5H (CD3OD): 5 1.32 (t, 12H, 
J=7.12), 3.33 (brs, 4H), 3.69 (m, 12H), 6.97 (d, 2H, J = 2.4 Hz), 7.1 (d, 2H, J = 
2.4 Hz, 9.52 Hz), 7.27 (d, 2H, J = 9.52 Hz), 7.51 (m, 1H), 7.78 (m, 3H). 5C 
(CD3OD): 5 14.93 (CH3), 49.08 (CH2), 51.09 (CH2), 51.3 (CH2), 51.9 (CH2), 
99.46, 116.91, 117.58, 130.97, 133.49, 133.69, 133.96, 135.13, 158.80, 159.32, 
161.34, 171.58 (CO), m/r. 511 (100(M-H)+).
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7.3.13 Attempted synthesis of rhodamine B 4-(2- 
chloroacetyljpiperazine amide (13)
Rhodamine B piperazine amide (0.5 g, 0.9 mmol) was dissolved in 
dichloromethane (2 ml) and cooled to 0°C. Chloroacetyl chloride (0.229 g, 1.96 
mmol) and pyridine (0.186 g, 2.35 mmol) were added in turn, and the reaction 
mixture was allowed to warm to ambient temperature over a period of 4 h. The 
dark red solution was concentrated under reduced pressure and partitioned 
between diethyl ether and aqueous 1 M K^COs, After washing with 3 portions 
of 1:4 isopropanol/dichlromethane, the combined organic layers were separated, 
dried over NaaSO^ filtered, and concentrated. The desired product was not 
isolated using this synthetic procedure.
230
7.3.14 Attempted synthesis of rhodamine B 4-(2- 
bromoacetyl)piperazine amide (14)
Rhodamine B piperazine amide (0.5 g, 0.9 mmol) was dissolved in 
dichloromethane (2 ml) and then cooled to 0°C. Bromoacetyl chloride (0.3 g, 
1.96 mmol) and pyridine (0.186 g, 2.35 mmol) were added and the reaction 
mixture was allowed to warm to ambient temperature over a period of 4 h. The 
dark red solution was concentrated under reduced pressure and partitioned 
between diethyl ether and aqueous 1 M K^CCb. After washing with 3 portions 
of 1:4 isopropanol/dichloromethane, the combined organic layers were 
separated, dried over NaaSO4, filtered, and concentrated. The desired product 
was not isolated using this synthetic procedure.
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7.3.15 Attempted synthesis of rhodamine B 4- 
(propoxy)piperazine amide (15)
NEt2
A mixture of 3-bromopropanol (0.105 ml, 1.22 mmol) and 
diisoethylpropylamine (0.29 ml, 1.7 mol) was added to rhodamine B piperazine 
amide (0.5 g, 0.9 mmol) in dimethylformamide (2 ml) under nitrogen and stirred 
for 24 h. After 24 h, a further portion of 3-bromopropanol (0.105ml, 1.22mmol) 
and diisoethylpropylamine (0.29 ml, 1.7 mol) were added and the solution 
stirred for a further 2 h. The dark red solution was concentrated under reduced 
pressure and partitioned between diethyl ether and aqueous 1 M K^CCh. After 
washing with 3 portions of 1:4 isopropanol/dichlromethane, the combined 
organic layers were separated and dried over NaaSO^ filtered, and concentrated. 
The desired product was not isolated using this synthetic procedure.
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7.3.16 Synthesis of rhodamine B base ethylamine (16)
NEto
Rhodamine B (1 g, 2.09 mmol) was dissolved into hot ethanol (20 ml), followed 
by the addition of ethylene diamine (0.7 ml, 10 mmol). The mixture was heated 
at reflux for 6 h, and then the volume was reduced to 5ml by evaporation under 
reduced pressure, followed by the cooling to below 0°C. This resulted in a 
precipitate that was collected by filteration and recrystallised from minimum 
acetonitrile, to produce an orange/pink solid, (0.41 g, 38%). 5H (CDCls): 8 1.08 
(t, 12H, CH3 , J = 67 Hz), 2.32 (t, 2H, CH2 , J = 6.7 Hz), 3.11 (t, 2H, CH2, J - 
6.7 Hz), 3.34 (m, 4H,CH2), 6.18 (m, 2H, arCH), 6.35 (m, 4H, arCH), 7.09 (m, 
1H, arCH), 7.36 (m, 2H, arCH), 7.83 (m, 1H, arCH). 5C (CDC13): 6 12.67 
(CH3), 40.92 (CH2), 44.01 (CH2), 44.42 (CH2), 97.78 (CH), 105.79 (C), 108.22 
(CH), 122.82 (CH), 123.90 (CH), 128.10 (CH), 128.77 (CH), 131.96 (C), 
132.45 (CH), 148.87 (C), 153.35 (C), 153.55 (C), 168.66 (CO).
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7.3.17 Synthesis of rhodamine B base 
ethylaminethioureamethylbenzyl (18)
Rhodamine B base ethylamine (0.05 g, 0.01 mmol) was dissolved in dry 
dichloromethane (50 ml) followed by the addition of phenylisothiocyanate 
(0.014 ml, 0.01 mmol) under nitrogen. The reaction mixture was stirred under 
nitrogen at room temperature for 48 h while protected from light. The solvent 
was then removed under reduced pressure. The crude product was recrystallised 
from the minimum amount of acetonitrile to yield a light pink solid (0.064 g, 
79%). SH (CDC13): 5 1.08 (m, 12H, CH2), 3.2 (m, 12H, CH2), 6.16 (m, 2H, 
CH), 6.28 (d, 4H, CH, J = 9.72), 6.97 (m, IH, CH), 7.2-7.37 (m, 6H, CH), 7.74 
(m, IH, CH). 6C (CDC13 ): 5, 12.69 (CH3), 39.77 (CH2), 44.53 (CH2), 
48.22(CH2), 97.87, 104.42, 108.43, 122.88, 123.99, 127.61, 127.96, 128.26, 
128.44, 128.70, 130.27, 133.0, 137.41, 149.6, 153.35, 153.95, 170.14 (CO), 
181.60 (C=S). m/z: 635.4 (100 (M-H)+).
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7.3.18 Synthesis of 2,8-diethyM ,3,7,9-tetramethyl-5-(4- 
acetamidophenyl) dipyrromethene (19)
19
l-Acetamidobenzaldehyde (1.32 g, 8.1 mmol) and 2-kryptopyrrole (2 g, 16.2 
mmol) were dissolved in anhydrous dichloromethane under an atmosphere of 
nitrogen. A drop of TFA was added and the mixture was left stirring at RT 
overnight. DDQ (1.83 g, 8.1 mmol) was added and then the reaction mixture 
was allowed to stir for Ih at RT. It was then washed with water and dried over 
Na2SC>4. After filtering and removing the solvent under reduced pressure, the 
crude mixture was purified by column chromatography on silica gel (9:1 
dichlrornethane/methanol, r.f. = 0.25) to give a purple solid, (1.16 g, 37%). §H 
(CDC13): 6 1.04-1.17 (m, 6H), 1.87 (s, 6H), 2.15 (m, 4H), 2.37-2.52 (m, 6H), 
7.0-7.02 (d, 2H, J = 8.16), 7.7-7.78 (b, 2H).
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7.3.19 Synthesis of 5-(4-aminophenyl) borondipyrromethene 
(20)
20
2,8-Diethyl-l,3,7,9-tetramethyl-5-(4-acetamidophenyl) dipyrromethane (0.33 g, 
0.84 mmol) was dissolved in a mixture of methanol (20 ml) and 1 M HC1 (20 
ml), and then heated at reflux for 1 h. The reaction mixture was cooled and 
neutralised with 2 M NaOH. The aqueous solution was extracted with 
dichloromethane, and the combined organic extracts dried over Na2SO4. The 
solvent was removed under reduced pressure. The crude product was dissolved 
in anhydrous dichloromethane (50 ml), containing triethylamine (1 ml), and 
BF3.OEt2 (1 ml) and stirred under nitrogen, at room temperature for 3-4 h while 
protected from light. The reaction mixture was washed with water, brine, and 
dried over Na2SO4. The solvent was removed, and the crude product was 
purified by column chromatography on flash silica (2:1 
dichloromethane:hexane, (r.f. = 0.36)) to give a red solid, (0.12 g, 36%). SH 
(CDC13 ): 8 0.79-0.83 (m, 6H), 0.89-0.91 (m, 6H), 2.22 (m, 4H), 2.4 (s, 6H), 
7.37-7.39 (d, 2H, J = 8.44 Hz), 7.68-7.7 (d, 2H, J = 8.44 Hz), m/z: 395 (100 (M-
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7.3.20 Synthesis of 5-(4-isothiocyanatophenyl) 
borondipyrromethene (21)
NCS
21
5-(4-Aminophenyl) borondipyrromethene (0.229 g, 0.51 mmol) was dissolved 
in dry dichloromethane (50 ml) followed by the addition of 1,1-thiocarbonyldi- 
2(lH)-pyridone (0.24g, 1.0 mmol) while under an atmosphere of nitrogen. The 
reaction mixture was stirred under nitrogen, at room temperature for 4 h while 
protected from light. The solvent was removed under reduced pressure. The 
crude product was purified by column chromatography on silica gel with 
hexane-dichloromethane 1:2 as eluent. (r.f. = 0.65 in hexane-dichloromethane 
1:2). The fractions containing the product were combined and the solvent was 
removed under reduced pressure to yield a red solid, (0.24 g, 75%). SH 
(CDC13): 5 0.89 (m, 6H, CH3), 1.21 (s, 6H, CH3), 2.21 (m, 4H, CH2), 2.44 (s, 
6H, CH3), 7.2 (d, 2H, CH, J = 8.08 Hz), 7.27 (d, 2H, CH, J = 8.08 Hz).
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7.3.21 Attempted synthesis of 5-(4-phenylthiourephenyl) 
borondipyrromethene (22)
5-(4-aminophenyl) borondipyrromethane (0.01 g, 0.025 mmol) was dissolved in 
dry dichloromethane (50 ml) followed by the addition of phenylisothiocyanate 
(0.003 ml, 0.025 mmol) under nitrogen. The reaction mixture was then stirred 
under nitrogen at RT for 7 days while protected from light. The solvent was 
removed under reduced pressure. The desired product was not isolated using 
this synthetic procedure.
7.3.22 Synthesis of Boc-aminobutyric acid (23)
A mixture of 4-aminobutyric acid (2 g, 0.019 mol), Boc-ON (5.25 g, 0.021 mol) 
and triethylamine (4 ml, 0.029 mol) in dioxane (20 ml) was stirred for 4 h at 0 
°C under an atmosphere of nitrogen. The solvent was then removed under 
reduced pressure. The resulting white solid was dissolved in water (50 ml) and 
washed with ethyl acetate (2 x 50 ml). The aqueous layer was separated and the 
solvent was removed under reduced pressure to yield a clear oil, (1.94 g, 49%). 
5H (CD3OD): 6 1.30 (s, 9H, CH3), 1.63 (qu, 2H, CH2, J = 7.0 Hz), 2.16 (t, 2H, 
CH2, J = 7.28 Hz), 2.97 (t, 2H, CH2 , J = 7.0 Hz), m/z: 204 (100(M-H)+).
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7.3.23 Synthesis of 5-(4-Boc-aminobutylamidophenyl) 
borondipyrromethene (24)
o
Triethylamine (0.04 ml, 0.29 mmol) and ethylchloroformate (0.024 ml, 0.24 
mmol) were added to Boc-aminobutyric acid (0.05 g, 0.24 mmol) in dry 
dichloromethane (50 ml) under an atmosphere of nitrogen the resulting mixture 
stirred for 30 min at RT. The solvent was removed under reduced pressure. 
The solid was then re-dissolved into dry dichloromethane (50 ml) followed by 
the addition of 5-(4-aminophenyl) borondipyrromethene (0.032 g, 0.086 mmol). 
The reaction mixture was then stirred under nitrogen for 1 h at 0 °C followed by 
1 h at RT. The solvent was removed under reduced pressure and the residue 
purified by column chromatography (using an increasing gradient of 100% 
dichloromethane to 2% methanol in dichloromethane, r.f. = 0.22 in 2% 
methanol in dichloromethane). The fractions containing the product were 
combined and the solvent was removed under reduced pressure to yield a red 
solid (0.04 g, 85%). 5H (CDC13): 5 0.97 (t, 6H, CH3 , J = 7.72 Hz), 1.2 - 2.0 (br, 
15H, CH3/CH2), 2.3 - 2.5 (m, 6H, CH2), 7.21 (d, 2H, CH, J = 8.16 Hz), 7.78 (d, 
2H, CH2, J = 8.16 Hz), m/z: 581.4 (100(M-H)+).
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7.3.24 Attempted synthesis of 5-(4-aminobutylamidophenyl) 
borondipyrromethene (25)
Method 1
5-(4-Boc-aminobutylamidophenyl) borondipyrromethene (0.04 g, 0.07 mmol) 
was dissolved in a mixture of 4 M hydrochloric acid (0.3 ml) and dioxane (1 ml) 
which was then stirred for 4 h at RT. The solvent was removed under reduced 
pressure. The desired product was not isolated using this synthetic procedure.
Method 2
5-(4-Boc-aminoburylamidophenyl) borondipyrromethene (0.04 g, 0.07 mmol) 
was dissolved in a mixture of trifluoroacetic acid (3 ml) and dichloromethane 
(3 ml) which was then stirred for 20 min at RT. The solvent was removed under 
reduced pressure. The desired product was not isolated using this synthetic 
procedure.
Method 3
5-(4-Boc-aminobutylamidophenyl) dipyrromethene (0.018 g, 0.03 mmol) 
dissolved in trifluoroacetic acid (3 ml) and dichloromethane (3 ml) was stirred 
for 1 h at RT. The solvent was then removed under reduced pressure. The 
resulting purple solid was re-dissolved into ethyl acetate and washed with 
aqueous sodium hydrogen carbonate (2 x 50 ml). The organic layer was 
collected and dried over sodium sulphate, filtered and the solvent removed 
under reduced pressure. The crude product was dissolved in anhydrous 
dichloromethane (50 ml), containing dry triethylamine (0.5 ml), and BF3 .OEt2 
(0.5 ml) and the reaction mixture stirred under nitrogen, at room temperature for 
3-4 h, while protected from light. The reaction mixture was washed with water,
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brine, and dried over Na2SO4 . The solvent was removed under reduced pressure. 
The desired product was not isolated using this synthetic procedure.
7.3.25 Synthesis of 5-(4-Boc-aminobutylamidophenyl) 
dipyrromethene (26)
o
Triethylamine (0.04 ml, 0.29 mmol) and ethylchloroformate (0.024 ml, 0.24 
mmol) were added to a solution of Boc-aminobutyric acid (0.05 g, 0.24 mmol) 
in dry dichloromethane (50 ml) under nitrogen and stirred for 30 min. The 
solvent was removed under reduced pressure. The solid was re-dissolved into 
dry dichloromethane (50 ml) followed by the addition of 5-(4-aminophenyl) 
dipyrromethane (0.028 g, 0.082 mmol) under nitrogen. The reaction misxture 
was then stirred at 0 °C for 1 h followed by RT for 1 h. The solvent was 
removed under reduced pressure and the residue purified by column 
chromatography (increasing gradient of 100 % dichloromethane to 10 % 
methanol in dichloromethane, r.f. = 0.22 in 10 % methanol in dichloromethane) 
to yield a purple solid, (0.018 g, 45%). 5H (CDC13 ): 5 0.84 - 2.44 (br, 37H), 
7.24 (m, 2H, CH), 7.88 (m, 2H, CH).
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7.3.26 Synthesis of 5-(4-triethylammoniummethylamidophenyl) 
borondipyrromethene chloride (27)
5-(4-Boc-aminobutylamidophenyl) borondipyrromethene (0.04 g, 0.1 mmol) 
was dissolved in a mixture of dry dichloromethane (10 ml) and triethylamine 
(0.5 ml). The mixture was then cooled in an ice bath at 0 °C under an 
atmosphere of nitrogen. Bromoacetylchloride (0.013 ml, 0.15) was then added 
and the solution stirred for 24 h while protected from the light. The solvent was 
removed under reduced pressure, and the residue was purified by preparative tic 
using 10% methanol in dichloromethane as the eluent, (r.f. = 0.08 in 10% 
methanol in dichloromethane) to yield a red solid, (0.045 g, 82%). 5H (CDC13): 
5 0.94 (t, 6H, CH3 , J = 7.6), 1.37 (s, 6H, CH3), 1.44 (t, 9H, CH3), 2.26 (q, 4H, 
CH2 , J = 7.28 Hz), 2.50 (s, 6H, CH3), 3.74 (q, 6H, CH2, J = 7.28 Hz), 4.62 (s, 
2H, CH2), 7.21 (d, 2H, CH, J = 8.44 Hz), 7.85 (d, 2H, CH, J = 8.44 Hz). 5C 
(CDC13 ): 5 12.08 (CH3), 12.55 (CH3), 14.69 (CH3 ), 17.13 (CH3), 50.87 (CH2), 
54.68 (CH2), 56.96 (CH2), 120.77 (CH), 128.95 (CH), 130.95 (C), 132.19 (C), 
132.86 (C), 138.08 (C), 138.53 (C), 139.76 (C), 153.78 (C), 161.91 (C=O). m/z: 
538.4 (100 (M-H)+). HRMS: calcd. for C^H^N^E^: 536.3607 found 
536.3600.
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7.3.27 Synthesis of 5-(4-bromomethylamidophenyl) 
borondipyrromethene (28)
F F
5-(4-Boc-aminobutylamidophenyl) borondipyrromethene (0.02 g, 0.05 mmol) 
was dissolved in dichloromethane and washed with sodium hydrogen carbonate 
solution. The organic layer was then separated and dried over sodium sulphate. 
The solvent was removed under reduced pressure. The residue was then re- 
dissolved into dry dichloromethane (25 ml) and the resulting solution cooled in 
an ice bath at 0°C under nitrogen. Bromoacetylchloride (0.002 ml, 0.034) was 
added and the reaction mixture stirred for 4 h protected from the light. The 
solvent was removed under reduced pressure, and the compound purified by 
preparative tic using 100% dichloromethane as eluent (r.f. = 0.44 in 100% 
dichloromethane) to yield a red solid, (0.02 g, 77%). 5H (CDC13): 5 0.98 (t, 6H, 
CH3 , J = 7.6 Hz), 1.32 (s, 6H, CH3), 2.31 (q, 4H, CH2, J = 7.6 Hz), 4.06 (s, 2H, 
CH2), 7.26 (d, 2H, CH, J - 8.4 Hz), 7.71 (d, 2H, CH, J = 8.4 Hz). 8C (CDC13): 5 
11.89 (CH3), 12.50 (CH3), 14.59 (CH3), 17.05 (CH3), 29.43(CH2), 120.03 (CH), 
129.19 (CH), 132.13 (C), 132.87 (C), 137.59 (C), 138.24 (C), 139.31 (C), 
158.87 (C), 163.39 (CO). 5B (CDC13) 5 -0.98. m/z: 514.4 (100 (M-H)+).
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7.3.28 Synthesis of 5-(4-ethylenediaminemethylamidophenyl) 
borndipyrromethene (29)
5-(4-Bromomethylamidophenyl) borondipyrromethene (0.16 g, 0.3 mmol) and 
ethylenediamine (0.41 ml, 4.3 mmol) were dissolved in acetonitrile (50 ml) and 
the reaction mixture was stirred overnight under nitrogen protected from the 
light. The solvent was then removed under reduced pressure, the resulting 
residue was re-dissolved into dichloromethane and it was washed with aqueous 
sodium hydrogen carbonate solution (2 x 100 ml). The organic layer was 
collected, dried over sodium sulphate, filtered and the solvent removed under 
reduced pressure. The compound was then purified by preparative tic using 
100% dichloromethane as the eluent, (r.f. = 0.12 in 100% dichloromethane) to 
yield a red solid, (0.02 g, 13%). 5H (CDC13 ): 5 0.91 (t, 6H, CH3, J = 7.28 Hz), 
1.22 (s, 6H, CH3), 2.21 (s, 2H, CH2) 2.34 (q, 4H, CH2, J = 7.28 Hz), 2.45 (s, 
6H, CH3 ), 2.72 (m, 2H, CH2), 2.83 (m, 2H, CH2), 7.14 (d, 2H, CH, J - 8.4 Hz), 
7.72 (d, 2H, CH, J = 8.4 Hz), m/z: 496.3 (100 (M-H)+).
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7.3.29 Synthesis of di-5-(4-aminophenyl) zincdipyrromethene 
(30)
Zinc acetate (0.13 g, 0.7 mmol) dissolved in dry methanol (10 ml) was added to 
a solution of 5-(4-aminophenyl) borondipyrromethene (0.5 g, 1.4 mmol) in dry 
methanol (40 ml) under nitrogen and the mixture was heated at reflux for 24 h. 
The solvent was removed under reduced pressure, the resulting solid was then 
re-dissolved into dichloromethane (50 ml) and washed with water (2 x 50 ml). 
The organic layer was collected, dried over sodium sulphate, filtered, and the 
solvent removed under reduced pressure to yield a green solid, (0.44 g, 83%). 
6H (CD3OD): 6 0.8 (s, 12H, CH3), 1.25 (s, 12H, CH3), 1.84 (s, 12H, CH3), 2.18 
(s, 8H, CH2), 6.67 (s, 4H, CH), 7.00 (s, 4H, CH). m/z: 756 (100 (M-H)+). 
HRMS: calcd. for C46H56N(,Zn : 756.3852 found 756.3859.
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7.3.30 Synthesis of 1,4,7-tris(te/t-butoxycarbonylmethyl)- 
1,4,7,10-tetraazacyclododecane (31)
o 
rA
NH N'.
O N NO
-O O- 
31
Method 1 - (Preferred route)
A solution of fert-butylbromoacetate (10.01 g, 0.052 mol) in acetonitrile (300 
ml) was added dropwise to a mixture of sodium hydrogen carbonate (4.39 g, 
0.052 mol) and 1,4,7,10-tetraazacyclododecane (3 g, 0.018 mol) in acetonitrile 
(900 ml). The solution was stirred at room temperature for 72 h and the 
undissolved material was then removed by filtration. The solvent was removed 
from the filtrate under reduced pressure and the residue purified by column 
chromatography over silica gel, with gradient elution from pure 
dichloromethane to 2% methanol in dichloromethane (r.f. = 0.63 in 5% MeOH 
in DCM) to yield an off-white solid. The product was then washed with diethyl 
ether, and collected by filtration to yield a white solid, (5.4 g, 60%). 
5H(DMSO): 5 1.42 (s, 9H, CH3), 1.42 (s, 18H, CH3), 2.65 - 2.84 (brs, 16H, 
CH2), 2.98 (brs, 4H, CH2), 3.34 (s, 2H, CH2), 8.75 (s, 1H, NH). 5C (DMSO): 5 
27.8 (CH3), 45.4 (CH2), 48.4 (CH2), 49.6 (CH2), 51.3 (CH2), 52.2 (CH2), 55.9 
(CH2), 80.57 (C(CH3)3), 170.5 (OO). m/z: 514 (100, (M-H)+).
Method 2
A solution of tert-butylbromoacetate (9.99 g, 0.051 mol) in chloroform (300 ml) 
was added dropwise to a mixture of potassium carbonate (7.08 g, 0.051 mol) 
and 1,4,7,10-tetraazacyclododecane (2.94 g, 0.017 mol) in chloroform (900 ml). 
The resulting solution was stirred at room temperature for 72 h and any 
undissolved material was then removed by filtration. The solvent was 
evaporated under reduced pressure and the residue purified by column
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chromatography over silica gel, with gradient elution from pure 
dichloromethane to 5% methanol in dichloromethane (r.f. = 0.625 in 5% MeOH 
in DCM) to yield a white solid, (4.9 g, 56%). 5H(DMSO): 5 1.40 (s, 9H, CH3), 
1.41 (s, 18H, CH3), 2.63 - 2.84 (brs, 16H, CH2), 3.01 (brs, 4H, CH2), 3.33 (s, 
2H, CH2), 8.7 (s, IH, NH). 6C (DMSO): 5 27.1 (CH3), 45.6 (CH2), 48.1 (CH2), 
49.6 (CH2), 51.6 (CH2), 52.2 (CH2), 56.01 (CH2), 80.60 (C(CH3)3), 170.8 
(C=0). m/z: 514 (100, (M-H)+).
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7.3.31 Synthesis of 1,4,7-tris(tert-butoxycarbonylmethyl)-10-(1 
(4-nitrobenzyl)-2-methyl benzimidazole)-1,4,7,10- 
tetraazacyclododecane (32)
Method 1 - (preferred route)
1,4,7-Tris(ter/-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane 
hydrobromide salt (0.5 g, 0.97 mmol) was dissolved in dichloromethane and 
the solution was then washed with saturated sodium hydrogen carbonate 
solution. The organic layer was separated and dried over sodium sulphate, 
filtered and then the solvent removed under reduced pressure. The resulting 
white solid was dissolved in dry acetonitrile followed by the addition of l-(4- 
nitrobenzyl)-2-chloromethyl benzimidazole (0.32 g, 1.1 mmol) and sodium 
hydrogen carbonate (0.8 g, 7.8 mmol). The reaction mixture was then stirred 
under an atmosphere of nitrogen, heated to 60°C and left to react for 24 h. The 
solvent was removed under reduced pressure. The resulting residue was 
dissolved in a minimum volume of dichloromethane and then purified by flash 
chromatography (SiO2, dichloromethane with an increasing gradient of 
methanol from 0% to 2%), (r.f. = 0.56 in 10% MeOH in DCM). The eluted 
fractions containing the product were combined and the solvent was removed 
under reduced pressure to give an off white solid, (0.58 g, 76%). SH (CDC13 ): 5 
1.42 (m, 27H, CH3), 2.2-3.5 (brm, 22H,CH2), 3.94 (brs, 2H,CH2), 5.43 (brs, 2H, 
CH2), 7.09 (dt, 1H, CH, J = 6.96 Hz, J = 1.08 Hz), 7.15 (dt, 1H, CH, J = 6.96 
Hz, J = 1.08 Hz), 7.23 (d, 1H, CH, J = 7.8 Hz), 7.33 (d, 2H, CH, J = 8.8 Hz), 
7.42 (d, 1H, CH, J = 7.8 Hz), 8.01(dt, 2H, CH, J = 8.8 Hz, J = 2.0 Hz). 6C 
(CDC13 ): 5 27.9 (CH3), 46.3 (CH2), 50.75(CH2), 55.52 (CH2), 56.4 (CH2), 
(CH2), 80.57 (C(CH3)3), 81.88 (C(CH3)3), 109.34 (CH), 119.31 (CH), 121.91 v, 
122.73 (CH), 124.04 (CH), 127.40 (CH), 135.53 (C), 142.42 (C), 144.02 (C),
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147.43 (C), 153.82 (C), 172.4 (C=O), 172.7 (C=O). m/z: 780.5 (100 (M-H)+). 
HRMS: calcd. For C4 |H62O8N7 : 780.46564 found 780.4645.
Method 2
1,4,7-Tris(fcr/-butoxycarbonylmethyl)-l ,4,7,10-tetraazacyclododecane 
hydrobromide salt (0.5 g, 0.97 mmol) was dissolved in dry acetonitrile and 
stirred under an atmosphere of nitrogen with l-(4-nitrobenzyl)-2-chloromethyl 
benzimidazole (0.29 g, 0.97 mmol) and potassium hydrogen carbonate (0.29 g, 
2.9 mmol) added as solid. The resulting mixture was heated to 60°C and stirred 
for 96 h. The solvent was then removed under reduced pressure. The residue 
was dissolved in a minimum volume of dichloromethane and then purified by 
flash chromatography (SiO2, dichloromethane with an increasing gradient of 
methanol from 0% to 2%), (r.f. = 0.56 in 10% MeOH in DCM). The fractions 
containing the product were combined and the solvent was removed under 
reduced pressure yielding an off white solid, (0.23 g, 30%). 5H (CDC13): 5 1.42 
(m, 27H, CH3), 2.2-3.5 (brm, 22H, CH2), 3.94 (brs, 2H, CH2), 5.43 (brs, 2H, 
CH2), 7.09 (dt, IH, CH, J = 6.96 Hz, J = 1.08 Hz), 7.15 (dt, IH, CH, J = 6.96 
Hz, J = 1.08 Hz), 7.23 (d, IH, CH, J = 7.88 Hz), 7.33 (d, 2H, CH, J = 8.8 Hz), 
7.42 (d, IH, CH, J = 7.88 Hz), 8.01 (dt, 2H, CH, J = 8.8 Hz, J = 2.0 Hz). 5C 
(CDC13 ): 8 27.9 (CH3), 46.3 (CH2), 50.75(CH2), 55.52 (CH2), 56.4 (CH2), 
(CH2), 80.57 (C(CH3)3 ), 81.88 (C(CH3)3), 109.34 (CH), 119.31 (CH), 121.91 v, 
122.73 (CH), 124.04 (CH), 127.40 (CH), 135.53 (C), 142.42 (C), 144.02 (C), 
147.43 (C), 153.82 (C), 172.4 (C=O), 172.7 (C=O).
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Method 3
1,4,7-Tris(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane, 
hydrobromide salt (0.5 g, 0.97 mmol) was dissolved in dry tetrahydrofuran (50 
ml) and stirred under nitrogen. l-(4-Nitrobenzyl)-2-chloromethyl benzimidazole 
(0.29 g, 0.97 mmol) and a catalytic amount of potassium iodide were added, 
The mixture was then heated to 60°C and stirred for 96 h. The solvent was 
removed under reduced pressure after cooling to RT. The resulting residue was 
dissolved in a minimum volume of dichloromethane and purified by flash 
chromatography (SiO2, dichloromethane with an increasing gradient of 
methanol from 0% to 2%), (r.f. = 0.56 in 10% MeOH in DCM). The fractions 
containing the product were combined and the solvent was evaporated yielding 
an off white solid, (0.76 g, 78%). 8H (CDC13): 6 1.42 (m, 27H, CH3), 2.2-3.5 
(brm, 22H, CH2), 3.94 (brs, 2H, CH2), 5.43 (brs, 2H, CH2), 7.09 (dt, IH, CH, J 
= 6.96 Hz, J - 1.08 Hz), 7.15 (dt, IH, CH, J = 6.96 Hz, J = 1.08 Hz), 7.23 (d, 
IH, CH, J = 7.88 Hz), 7.33 (d, 2H, CH, J = 8.8 Hz), 7.42 (d, IH, CH, J = 7.88 
Hz), 8.01(dt, 2H, CH, J = 8.8 Hz, J = 2.0 Hz).
Method 4
l-(4-Nitrobenzyl)-2-chloromethyl benzimidazole (0.29 g, 0.97 mmol) was 
added to a solution of potassium iodide (0.16 g, 0.97 mmol) in acetone (50 ml) 
and heated at reflux for 6 h. The organic layer was washed with water (50 ml), 
dried over magnesium sulphate, filtered, and the solvent removed from the 
filtrate under reduced pressure. The resulting solid was dissolved in acetonitrile 
and 1,4,7-tris(?err-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane 
hydrobromide salt (0.5 g, 0.97 mmol) was added as solid. The reaction mixture 
was heated at reflux for 24 h. The solvent was then removed under reduced 
pressure. The desired product was not isolated using this synthetic procedure.
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Method 5
Sodium hydride (0.05 g, 1.9 mmol) and l,4,7-tris(tert-butoxycarbonylmethyl)- 
1,4,7,10-tetraazacyclododecane hydrobromide salt (0.5 g, 0.97 mmol) were 
added to dry tetrahydrofuran (100 ml) and the mixture was stirred under 
nitrogen for 1 h. l-(4-Nitrobenzyl)-2-chloromethyl benzimidazole (0.29 g, 0.97 
mmol) dissolved in dry tetrahydrofuran (50 ml) was then added and the mixture 
was heated to 60°C and stirred for 24 h. The solvent was removed under 
reduced pressure. The resulting solid was redissolved into dichloromethane 
(100 ml) and washed with water (100 ml). The organic layer was separated, 
dried over sodium sulphate, filtered and the solvent removed under reduced 
pressure. The desired product was not isolated using this synthetic procedure.
Method 6
A mixture of lithium diisopropylamide (0.123 ml, 0.58 mmol) and 1,4,7- 
tris(ter/-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane hydrobromide 
salt (0.1 g, 0.19 mmol) in dry tetrahydrofuran (100 ml) was stirred under 
nitrogen for 2 h. l-(4-Nitrobenzyl)-2-chloromethyl benzimidazole (0.059 g, 
0.19 mmol) dissolved in dry tetrahydrofuran (50 ml) was then added and the 
mixture was stirred for 24 h. The solvent was removed under reduced pressure. 
The resulting solid was then redissolved into dichloromethane (100 ml) and the 
solution washed with water (100 ml). The organic layer was separated, dried 
over sodium sulphate, filtered and the solvent removed under reduced pressure. 
The desired product was not isolated using this synthetic procedure.
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Method 7
1,4,7-Tris(ter/-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane 
hydrobromide salt (0.5 g, 0.97 mmol) dissolved in dry dimethylformamide and 
stirred under nitrogen. l-(4-nitrobenzyl)-2-chloromethyl benzimidazole (0.29 g, 
0.97 mmol) and potassium hydrogen carbonate (0.52 g, 3.9 mmol) were then 
added as solids. The resulting mixture was heated to 60°C and stirred for 24 h. 
The solvent was then removed under reduced pressure. The desired product 
was not isolated using this synthetic procedure.
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7.3.32 Synthesis of 1,4,7-tris(carboxymethyl)-10-(1-(4- 
nitrobenzyl)-2-methyl benzimidazole)-1,4,7,10- 
tetraazacyclododecane (33)
1,4,7-Tris(fcrt-butoxycarbonylmethyl)-10-(1 -(4-nitrobenzyl)-2-methyl 
benzimidazole)-l,4,7,10-tetraazacyclododecane (0.23 g, 0.29 mmol) was 
dissolved in 37% aqueous HC1 (30 ml) and the solution was stirred at room 
temperature for 3 h. The solvent was then removed under reduced pressure, the 
residue was redissolved into water (5 ml) and filtered through a 0.2 \un syringe 
filter. The solvent was removed under reduced pressure to give a yellow solid, 
(0.18 g, 100%). 6H (D2O): 8 2.94-3.68 (brm, 18H,CH2), 3.99 (s, 2H, CH2), 4.12 
(s, 2H, CH2), 4.54 (s, 2H, CH2), 5.95 (s, 2H, CH2), 7.41 (d, 2H, CH, J = 8.8 Hz), 
7.54-7.70 (m, 3H, CH), 7.79 (d, 1H, CH, J = 8.16 Hz), 8.10 (d, 2H, CH, J = 8.8 
Hz). 5 c (D20): 5 48.3 (CH2), 48.55 (CH2), 48.17 (CH2), 51.16 (CH2), 53.07 
(CH2), 53.67 (CH2), 55.07 (CH2), 113.28 (CH), 115.5 (CH), 124.72 (CH), 
127.77 (CH), 128.02 (CH), 128.29 (CH), 130.18 (C), 132.12 (C), 140.74 (C), 
148.01 (C), 149.23 (C), 169.7 (C=O), 177.63 (C=O). m/z: 612.3 (100(M-H)+). 
HRMS: calcd. For C^HssOgN?: 612.2776 found 612.2774.
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7.3.33 Synthesis of europium(lll) 1,4,7-tris(carboxymethyl)-1 ti­ 
ll-(4-nitrobenzy))-2-methyl benzimidazole)-1,4,7,10- 
tetraazacyclododecane (34a)
1,4,7-Tris(carboxymethyl)-10-( 1 -(4-nitrobenzyl)-2-methyl benzimidazole)- 
1,4,7,10-tetraazacyclododecane (0.19 g, 0.26 mmol) and europium(III) 
trifluoromethanesulfonate (0.2 g, 0.26 mmol) were dissolved in water (10 ml) 
and stirred. A solution of potassium carbonate (0.21 g, 1.53 mmol) in water (10 
ml) was added dropwise. The solution was heated at reflux for 18 h. The 
solvent was then evaporated under reduced pressure. The resulting solid was 
dissolved in a minimum of MeOH and purified using a sephadex column LH-20 
(MeOH as eluent). The fractions containing the product were combined and 
evaporated under reduced pressure to give a yellow solid, (0.16 g, 68%). SH 
(D2O): 5 -18.83, -17.96, -16.78, -16.38, -15.25, -14.56, -12.58, -10.87, -9.97, - 
9.76, -9.46, -8.52, -7.58, -7.46, -7.27, -7.12, -6.86, -5.87, -4.99, -3.44, -2.58, - 
1.56, -0.59, 1.25, 2.38, 2.19, 3.16, 3.19, 3.97, 5.63, 6.13, 6.74, 6.93, 7.31, 7.48, 
7.58, 7.90, 8.18, 8.36, 9.50, 10.01, 10.62, 12.57, 28.82, 29.95, 30.09. m/z: 760.1 
(100 (M-H)+). HUMS: calcd. For C29H35O8N7151 Eu: 760.1740 found 760.1739.
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7.3.34 Synthesis of terbium(lll) 1,4,7-tris(carboxymethyl)-10-(1 
(4-nitrobenzyl)-2-methyl benzimidazole)-! ,4,7,10- 
tetraazacyclododecane (34b)
34b
1,4,7-Tris(carboxymethyl)-10-( 1 -(4-nitrobenzyl)-2-methylbenzimidazole)- 
1,4,7,10-tetraazacyclododecane (0.039 g, 0.064 mmol), and terbium(III) 
trifluoromethanesulfonate (0.039 g, 0.064 mmol) were dissolved in water (10 
ml) and stirred. A solution of potassium carbonate (0.044 g, 0.32 mmol) in 
water (10 ml) was added dropwise. The solution was heated at reflux for 18 h. 
The solvent was then evaporated under reduced pressure. The resulting solid 
was dissolved in a minimum of MeOH and purified using a sephadex column 
LH-20 (MeOH as eluent). The fractions containing the product were combined 
and evaporated under reduced pressure to give a yellow solid, (0.038 g, 79%). 
m/z: 768.2 (100(M-H)+). HRMS: calcd. for C^HssOgNTTb: 768.1795 found 
768.1792.
255
7.3.35 Synthesis of gadolinium(lll) 1,4,7-tris(carboxymethyl)- 
1 0-(1 -(4-nitrobenzyl)-2-methylbenzimidazole)-1 ,4,7,1 0- 
tetraazacyclododecane (34c)
l,4,7-Tris(carboxymethyl)-10-(l-(4-nitrobenzyl)-2-methyl benzimidazole)- 
1,4,7,10-tetraazacyclododecane (0.25 g, 0.35 mmol), and gadolinium(III) 
trichloride (0.1 g, 0.35 mmol) were dissolved water (10 ml) and stirred. 
Potassium carbonate (0.24 g, 1.75 mmol) in water (10 ml) was added dropwise. 
The solution was heated at reflux for 18 h. The solvent was then evaporated 
under reduced pressure. The resulting solid was dissolved in a minimum of 
MeOH and purified using a sephadex column LH-20 (MeOH as eluent). The 
fractions containing the product were combined and evaporated under reduced 
pressure to give a yellow solid, (0.21 g, 71%). m/z: 763.2 (100 (M-H)+). 
HRMS: calcd. for C29H35O8N7 154Gd: 763.1750 found 763.1756.
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7.3.36 Synthesis of lanthanum(lll) 1,4,7-tris(carboxymethyl)-10- 
(1 -(4-nitrobenzyl)-2-methyl benzimidazole)-1,4,7,10- 
tetraazacyclododecane (34d)
1,4,7-Tris(carboxymethyl> 10-( 1 -(4-nitrobenzyl)-2-methyl benzimidazole)- 
1,4,7,10-tetraazacyclododecane (0.2 g, 0.27 mmol), and lanthanum(III) 
trifluoromethanesulfonate (0.2 g, 0.27 mmol) were dissolved in water (10 ml) 
and stirred. A solution of potassium carbonate (0.19 g, 1.35 mmol) in water (10 
ml) was added dropwise. The solution was heated at reflux for 18 h. The 
solvent was then evaporated under reduced pressure. The resulting solid was 
dissolved in a minimum of MeOH and purified using a sephadex column LH-20 
(MeOH as eluent). The fractions containing the product were combined and 
evaporated under reduced pressure to give a yellow solid, (0.18 g, 77%). SH 
(D2O): 8 2.02-3.66 (brm, 22H,CH2), 4.23 (s, 2H,CH2), 5.31 (s, 2H,CH2,), 6.99- 
7.06 (m, 6H, CH,), 7.48 (s, 1H, CH), 7.84 (s, 1H, CH). 5C (D2O): 5 46.51 
(CH2), 48.62 (CH2), 50.51 (CH2), 51.49 (CH2), 53.37 (CH2), 59.98 (CH2), 60.72 
(CH2), 110.7 (CH), 118.79 (CH), 120.67 (CH), 123.99 (CH), 127.35 (CH), 
134.38 (C), 139.48 (C), 142.45 (C), 146.97 (C), 153.84(C), 178.95 (C=O), 
179.30 (CO), m/z: 748.2 (lOO(M-Hf). HRMS: calcd. for C29H35O8N7La: 
748.1605 found 748.1601.
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7.3.37 Synthesis of 1,4,7-tris(te/t-butoxycarbonylmethyl)-10-(1- 
(4-aminobenzyl)-2-methylbenzimidazole)-1,4,7,10- 
tetraazacyclododecane (35)
Method 1 - (preferred route)
Sodium borohydride (0.015 g, 0.19 mmol) and sulphur (0.037 g, 0.38 mmol) 
were suspended in dry tetrahydrofuran (50 ml) and stirred under nitrogen for 1 
hour. 1,4,7-Tris(fer/-butoxycarbonylmethyl)-10-(1 -(4-nitrobenzyl)-2-methyl 
benzimidazole)-l,4,7,10-tetraazacyclododecane (0.15 g, 0.19 mmol) dissolved 
in tetrahydrofuran (20 ml) was added and the reaction mixture was heated at 
reflux overnight under nitrogen. The resulting solution was then cooled and 
washed with 5% sodium hydroxide solution (4 x 50 ml), the organic layer was 
separated, dried over sodium sulphate, filtered and the solvent removed from the 
filtrate under reduced pressure. The solid product was purified by flash 
chromatography on alumina (the eluent was dichloromethane with an increasing 
gradient of methanol from 0 to 5%), (r.f. = 0.28 in 10% MeOH in DCM) to give 
a yellow solid, (0.09 g, 65%). 8H (CDC13): 5 1.42 (m, 27H, CH3), 2.2-3.6 (brm, 
24H,CH2), 5.14 (s, 2H, CH2), 6.52 (d, 2H, CH, J = 8.0 Hz), 6.75 (d, 2H, CH, J = 
8.0 Hz), 7.04 (t, 1H, CH, J = 7.16 Hz), 7.14 (t, 1H, CH, J = 7.16 Hz), 7.25 (d, 
1H, CH, J - 8.1 Hz), 7.37 (d, 1H, CH, J = 8.1 Hz). 6C (CDC13): 5 28.07 (CH3) 
48.3 (CH2), 48.55 (CH2), 48.17 (CH2), 51.16 (CH2), 53.07 (CH2), 53.67 (CH2), 
55.07(CH2), 46.61 (CH2), 51.03 (CH2), 55.55 (CH2), 56.43 (CH2), 81.88 
(C(CH3 )3 ), 82.11 (C(CH3)3), 109.57 (CH), 115.48 (CH), 119.21 (CH), 121.58 
(CH), 122.45 (CH), 124.81 (C), 127.52 (CH), 135.74 (C), 142.29 (C), 14.82 (C), 
153.13(C), 171.13 (CO), 172.77 (CO), m/z: 750.5 (100 (M-H)+). HUMS: 
calcd. for C^HwOeN?: 750.4913 found 750.4913.
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Method 2
1,4,7-Tris(/erMxitoxycarbonylmethyl>10-( 1 -(4-nitrobenzyl)-2-methyl 
benzimidazole)-l,4,7,10-tetraazacyclododecane (0.2 g, 0.2 mmol) was dissolved 
in methanol (50 ml) followed by the addition of palladium on carbon (0.05 g). 
The suspension was stirred for 24 h with hydrogen bubbling into the reaction 
mixture. The reaction mixture was then filtered through hyflo to remove the 
Pd/C and the solvent removed from the filtrate under reduced pressure. The 
desired product was not isolated using this synthetic procedure.
7.3.38 Synthesis of 1,4,7-tris(carboxymethyl)-10-(1-(4- 
aminobenzyl)-2-methyl benzimidazole)-1,4,7,10- 
tetraazacyclododecane (36)
... N OH
HO N N OH 
O 36 O
l,4,7-Tris(fer/-butoxycarbonylmethyl)-10-(l-(4-aminobenzyl)-2-methyl 
benzimidazole)-l,4,7,10-tetraazacyclododecane (0.18 g, 0.24 mmol) was 
dissolved in aqueous 37% HC1 (30 ml) and stirred at RT for 3 h. The solvent 
was removed under reduced pressure, the residue was redissolved into water (5 
ml) and filtered through a 0.2 um syringe filter. The solvent was again removed 
under reduced pressure to give a yellow solid, (0.13 g, 93%). 8H (D2O): 82.91 
(m, 2H, CH2), 3.01 (m, 2H, CH2), 3.23 (m, 2H, CH2), 3.27 (m, 2H, CH2), 3.50 
(m, 2H, CH2), 3.57 (s, 2H, CH2), 3.68 (m, 6H, CH2), 4.03 (s, 2H, CH2), 4.24 (s, 
2H, CH2), 4.56 (s, 2H, CH2), 5.71 (s, 2H, CH2), 7.43 (m, 4H, arCH), 7.61 (m, 
4H, arCH). 5C (CDC13 ): 8 48.38 (CH2), 48.55 (CH2), 49.07 (CH2), 51.17 (CH2), 
53.09 (CH2), 53.42 (CH2), 54.81 (CH2), 113.37 (CH), 115.23 (CH), 124.43 
(CH), 127.72 (CH), 128.04 (CH), 128.16 (CH), 129.09 (CH), 130.01 (C), 
130.52 (C), 134.78 (C), 148.99 (C), 168.58 (C=O). m/z: 582.3 (100 (M-H)+). 
HRMS: calcd. for C43H4oO6N7 : 582.3035 found 582.3030.
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7.3.39 Synthesis of europium(lll) 1,4,7-tris(carboxymethyl)-10- 
(1-(4-aminobenzyl)-2-methylbenzimidazole)-1,4,7,10- 
tetraazacyclododecane (37a)
37a
l,4,7-Tris(carboxymethyl)-10-(l-(4-aminobenzyl)-2-methyl benzimidazole)- 
1,4,7,10-tetraazacyclododecane (0.05 g, 0.089 mmol), and europium(III) 
trifluoromethanesulfonate (0.05 g, 0.089 mmol) were dissolved in water (10 ml) 
and stirred. A solution of potassium carbonate (0.06 g, 0.43 mmol) in water (10 
ml) was added dropwise. The solution was heated at reflux for 18 h. The 
solvent was then evaporated under reduced pressure. The resulting solid was 
dissolved in a minimum of MeOH and purified using a sephadex column LH-20 
(MeOH as eluent). The fractions containing the product were combined and 
evaporated under reduced pressure to give a yellow solid, (0.06 g, 96%). SH 
(D20): 8 -18.66, -17.83, -16.95, -16.54, -14.53, -13.95, -12.45, -11.47, -10.30, - 
9.27, -9.01, -8.17, -7.59, -7.31, -6.97, -6.60, -5.94, -4.59, -3.21, -2.89, -2.07, - 
1.10, -0.71, 1.04, 1.16, 1.45, 1.90, 2.14, 2.47, 2.72, 3.08, 3.26, 3.54, 4.08, 4.78, 
5.09, 5.60, 5.81, 6.34, 6.60, 6.73, 7.27, 7.52, 7.77, 8.18, 8.34, 8.72, 9.53, 10.11, 
10.71, 11.07, 12.96, 29.48, 29.98, 30.55, 30.75. m/z: 730.2 (100(M- 
H)+).HRMS: calcd. For ^EuC^t^OeNy: 730.1998 found 730.1993.
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7.3.40 Synthesis of terbium(IU) 1,4,7-tris(carboxymethyl)-10-(1 
(4-aminobenzyl)-2-methyl benzimidazole)-1,4,7,10- 
tetraazacyclododecane (37b)
O 37b
1,4,7-Tris(carboxymethyl)-10-( 1 -(4-aminobenzyl)-2-methyl benzimidazole)- 
1,4,7,10-tetraazacyclododecane (0.05 g, 0.089 mmol), and terbium(III) 
trifluoromethanesulfonate (0.052 g, 0.089 mmol) was dissolved in water (10 ml) 
and stirred. A solution of potassium carbonate (0.06 g, 0.43 mmol) in water 
(10 ml) was added dropwise. The solution was heated at reflux for 18 h. The 
solvent was then evaporated under reduced pressure. The resulting solid was 
dissolved in a minimum of MeOH and purified using a sephadex column LH-20 
(MeOH as eluent). The fractions containing the product were combined and 
evaporated under reduced pressure to give a yellow solid, (0.039 g, 62%). m/z: 
738.2(100(M-H)+). HRMS: calcd. for TbC29H37O6N7 : 738.2053 found 
738.2053.
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7.3.41 Synthesis of gadolinium(lll) 1,4,7-tris(carboxymethyl)- 
10-(1-(4-aminobenzyl)-2-methyl benzimidazole)-1,4,7,10- 
tetraazacyclododecane (37c)
H,N
l,4,7-Tris(carboxymethyl)-10-(l-(4-aminobenzyl)-2-methyl benzimidazole)- 
1,4,7,10-tetraazacyclododecane (0.05 g, 0.089 mmol), and gadolinium(III) 
trifluoromethanesulfonate (0.039 g, 0.089 mmol) were dissolved in water (10 
ml) and stirred. A solution of potassium carbonate (0.05 g, 0.43 mmol) in water 
(10 ml) was added dropwise. The solution was heated at reflux for 18 h. The 
solvent was then evaporated under reduced pressure. The resulting solid was 
dissolved in a minimum of MeOH and purified using a sephadex column LH-20 
(MeOH as eluent). The fractions containing the product were combined and 
evaporated under reduced pressure to give a yellow solid, (0.05 g, 79%). m/z: 
733.2 (100(M-H)+). HRMS: calcd. for 154GdC29H37O6N7 : 733.2008 found 
733.2012.
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7.3.42 Synthesis of lanthanum(HI) 1,4,7-tris(carboxymethyl)-10 
(1-(4-aminobenzyl)-2-methylbenzimidazole)-1,4,7,10- 
tetraazacyclododecane (37d)
N
C-K-T"O'"N N'^-(
C 37d
1,4,7-Tris(carboxymethyl)-10-( 1 -(4-aminobenzyl)-2-methyl benzimidazole)- 
1,4,7,10-tetraazacyclododecane (0.05 g, 0.089 mmol), and lanthanum(III) 
trifluoromethanesulfonate (0.05 g, 0.089 mmol) were dissolved in water (10 ml) 
and stirred. A solution of potassium carbonate (0.06 g, 0.43 mmol in water (10 
ml) was added dropwise. The solution was heated at reflux for 18 h. The 
solvent was then evaporated under reduced pressure. The resulting solid was 
dissolved in a minimum of MeOH and purified using a sephadex column LH-20 
(MeOH as eluent). The fractions containing the product were combined and 
evaporated under reduced pressure to give a yellow solid, (0.05 g, 81%). SH 
(D2O): 5 2.62 - 2.93 (m, 8H, CH2), 3.39 - 3.69 (br, 4H CH2), 3.83 - 4.36 (m, 
10H, CH2), 4.79 (br, 2H, CH2), 5.87 (s, 2H, CH2), 7.53 - 7.60 (m, 2H, CH), 
7.71 (m, 2H, CH), 7.87 (m, 2H, CH), 8.14 (m, 2H, CH). 6C (D2O): 8 47.84 
(CH2), 50.20 (CH2), 51.93 (CH2), 53.10 (CH2), 54.72 (CH2), 61.59 (CH2), 
112.19 (CH), 119.98 (CH), 112.59 (CH), 125.21 (CH), 129.42 (CH), 134.21 
(C), 135.78 (C), 140.75 (C), 155.11 (C), 180.62 (C=O). m/z: 728.2 (100(M- 
H)+). HUMS: calcd. for LaCw^OeN?: 718.1863 found 728.1859.
263
7.3.43 Synthesis of 1,4,7-tris(fe/t-butoxycarbonylmethyl)-10-(1- 
(4-nitrobenzyl))-1,4,7,10-tetraazacyclododecane (38)
o
1,4,7-Tris(/err-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane 
hydrobromide salt (1 g, 1.9 mmol) was dissolved in dry acetonitrile and the 
solution stirred under nitrogen. 4-Nitrobenzylbromide (0.46 g, 2 mmol) and 
sodium hydrogen carbonate (1.66 g, 15.2 mmol) were added as solid. The 
reaction mixture was heated to 70°C and stirred for 24 h. The solvent was then 
evaporated under reduced pressure. The resulting residue was dissolved in a 
minimum volume of dichloromethane and purified by flash chromatography 
(SiO2, dichloromethane with an increasing gradient of methanol from 0% to 5%, 
product (r.f. = 0.21 in 5% MeOH in DCM). The fractions containing the 
product were combined and the solvent was removed under reduced pressure to 
give an off-white solid, (1.15 g, 87%). 5H (CDC13): 5 1.23 (s, 27H, CH3), 2.0- 
3.09 (br, 24H, CH2), 7.52 (d, 2H, ar CH, J = 8.44 Hz), 7.95 (d, 2H, arCH, J = 
8.44 Hz). 5C (CDC13 ): 8 27.89 (CH3), 50.0 (CH2), 50.56 (CH2), 55.72 (CH2), 
56.06 (CH2), 58.78 (CH2), 65.68 (CH2), 82.49 (C), 83.05 (C), 123.57 (CH), 
131.123, (CH), 145.25 (C), 147.21 (C), 172.58 (CO), 173.65 (CO), m/z: 
650.3 (100 (M-H)+).
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7.3.44 Synthesis of 1,4,7-tris(tert-butoxycarbonylmethyl)-10-(4- 
aminobenzyl)-1,4,7,10-tetraazacyclododecane (39)
H2N
N N
o-
ON
39
Palladium on carbon (0.1 g) was added to a solution of l,4,7-tris(tert- 
butoxymethyl)-10-(l-(4-nitrobenzyl)-1,4,7,10-tetraazacyclododecane (2 g, 3.2 
mmol) in methanol (50 ml) and the reaction mixture was stirred for 18 h with 
hydrogen bubbling through the solution. The reaction mixture was then filtered 
through hyflo and the solvent removed under reduced pressure to leave a white 
solid, (1.61 g, 85%). 8H (CDC13): 8 1.39 (s, 27H, CH3), 1.98 - 3.03 (br, 24H, 
CH2), 6.56 (d, 2H, arCH, J = 8.4 Hz), 7.14 (d, 2H, arCH, J = 8.4 Hz). Sc 
(CDC13 ): 8 28.07, 28.27 (CH3), 50.81 (CH2), 50.3 (CH2), 59.01 (CH2), 82.30 
(CH2), 82.74 (C), 115.17 (CH), 126.91 (C), 131.10 (CH), 146.03 (C), 172.58 
(C=O), 173.52, (CO), m/z: 634.5 (100 (M-H)*).
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7.3.45 Synthesis of 1,4,7-tris(carboxymethyl)-10-(4- 
aminobenzyl)-1,4,7,10-tetraazacyclododecane (40)
Method 1 - (preferred route)
1,4,7-Tris(fcrt-butoxycarbonylmethyl)-10-(4-aminobenzyl)-1,4,7,10- 
tetraazacyclododecane (0.2 g, 0.3 mmol) was dissolved in 37% aqueous HC1 (30 
ml) and the resulting solution stirred at RT for 3 h. The solvent was then 
evaporated under reduced pressure, the remaining residue was redissolved into 
water (5 ml) and this solution was filtered through a 0.2 (im syringe filter. The 
solvent was removed under reduced pressure to leave a yellow solid, (0.15 g, 
quantitative). 5H (D2O): 8 2.03 - 3.59 (br, 24H, CH2), 6.78 (d, 2H, arCH, J = 
7.56 Hz), 7.08 (d, 2H, arCH, J = 7.56 Hz), m/z: 453.1. (100 (M-H)+).
Method 2
1,4,7-Tris(fcr/-butoxycarbonylmethyl)-10-( 1 -(4-aminobenzyl)-1,4,7,10- 
tetraazacyclododecane (0.2 g, 0.3 mmol) was suspended in a mixture of 
trifluoroacetic acid (5 ml) and dichloromethane (5 ml) and the resulting solution 
stirred at RT for 24 h. The solvent was removed under reduced pressure to 
leave a solid. The desired product was not isolated using this synthetic 
procedure.
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7.3.46 Synthesis of europium(MI) 1,4,7-tris(carboxymethyl)-10-( 
4-aminobenzyl)-1,4,7,10-tetraazacyclododecane (41 a)
x"\ ,' i "i -x__-~Q 
O'''V V~-~o
1,4,7-Tris(carboxymethyl)-10-(4-aminobenzyI)-1,4,7,10-tetraazacyclododecane 
(0.18 g, 0.4 mmol), and europium(III) trimethanesulfonate (0.24 g, 0.4 mmol) 
were dissolved in water (10 ml). A solution of potassium carbonate (0.24 g, 2 
mmol) in water (10 ml) was added dropwise. The solution was heated at reflux 
for 18 h. The solvent was then evaporated under reduced pressure. The 
resulting solid was dissolved in a minimum of MeOH and purified using a 
sephadex column LH-20 (MeOH as eluent). The fractions containing the 
product were combined and evaporated under reduced pressure to give a yellow 
solid, (0.19 g, 81%). m/z: 602.0 (100 (M-H)+).
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7.3.47 Synthesis of gadolinium(lll) 1,4,7-tris(carboxymethyl)- 
10-( 4-aminobenzyl)-1,4J,10-tetraazacyclododecane (41 b)
H,N
o" 41 b Nb
1,4,7-Tris(carboxymethyl)-10-( 1 -(4-aminobenzyl)-1,4,7,10- 
tetraazacyclododecane (0.15 g, 0.33 mmol), and gadolinium(III) trichloride (0.2 
g, 0.33 mmol) were dissolved in water (10 ml) and the resulting solution was 
stirred. A solution of potassium carbonate (0.23 g, 1.7 mmol) in water (10 ml) 
was added dropwise. The solution was heated at reflux for 18 h. The solvent 
was then evaporated under reduced pressure. The resulting solid was dissolved 
in a minimum of MeOH and purified using a sephadex column LH-20 (MeOH 
as eluent). The fractions containing the product were combined and evaporated 
under reduced pressure to give a yellow solid, (0.15 g, 76%). m/z: 607.1 (100
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7.3.48 Synthesis of lanthanum(lll) 1,4,7-tris(carboxymethyl)- 
10-( 4-aminobenzyl)-1,4,7,10-tetraazacyclododecane (41 c)
41 c O
1,4,7-Tris(carboxymethyl)-10-(1 -(4-aminobenzyl)-1,4,7,10-tetraazacyclodecane 
(0.12 g, 0.26 mmol), and lanthanum(III) trimethanesulfonate (0.15 g, 0.26 
mmol) were dissolved in water (10 ml) and the resulting solution was stirred. A 
solution of potassium carbonate (0.23 g, 1.7 mmol) in water (10 ml) was added 
dropwise. The solution was heated at reflux for 18 h. The solvent was then 
evaporated under reduced pressure. The resulting solid was dissolved in a 
minimum of MeOH and purified using a sephadex column LH-20 (MeOH as 
eluent). The fractions containing the product were combined and evaporated 
under reduced pressure to give a yellow solid, (0.19 g, 81%). m/z: 588.2 (100
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7.3.49 Attempted synthesis of europium(lll) 1,4,7- 
tris(carboxymethyl)-10-(4-(5-(4-thioureaphenylene) 
borondipyrromethane) benzyl)-1,4,7,10-tetraazacyclododecane 
(42a)
Europium(III) 1,4,7-tris(carboxymethyl)-10-(4-aminobenzyl)-1,4,7,10- 
tetraazacyclododecane (0.07 g, 0.013 mmol) was dissolved in water (1 ml) and 
1 M potassium hydroxide solution was added until the pH reached 9. A solution 
of 5-(4-isothiocyanatophenyl) borondipyrromethene (0.072 g, 0.165 mmol) 
dissolved in dimethylformamide (2 ml) was added dropwise, the flask was 
covered in aluminium foil and the reaction mixture was stirred for 14 days. The 
solvent was then removed under reduced pressure to give a solid. The desired 
product was not isolated using this synthetic procedure.
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7.3.50 Attempted synthesis of gadolinium(lll) 1,4,7- 
tris(carboxymethyl)-10-(4-(5-(4-thioureaphenylene) 
borondipyrromethane)benzyl)-1,4,7,10-tetraazacyclododecane 
(42b)
Gadolinium(III) 1,4,7-tris(carboxymethyl)-10-(4-aminobenzyl)-1,4,7,10- 
tetraazacyclododecane (0.1 g, 0.165 mmol) was dissolved in water (1 ml) and 1 
M potassium hydroxide solution was added until the pH reached 9. A solution 
of 5-(4-isothiocyanatophenyl) borondipyrromethene (0.072 g, 0.165 mmol) 
dissolved in dimethylformamide (2 ml) was added, the flask was covered in 
aluminium foil and the reaction mixture was stirred for 14 days. The solvent 
was then removed under reduced pressure to give a solid. The desired product 
was not isolated using this synthetic procedure.
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7.3.51 Attempted synthesis of lanthanum(lll) 1,4J- 
tris(carboxymethyl)-10-(4-(5-(4-thioureaphenyenel) 
borondipyrromethane)benzyl)-1,4,7,10-tetraazacyclododecane 
(42c)
Lanthanum(III) 1,4,7-tris(carboxymethyl)-10-(4-aminobenzyl)-1,4,7,10- 
tetraazacyclodecane (0.05 g, 0.0085 mmol) was dissolved in water (1 ml) and 1 
M potassium hydroxide solution was added until the pH reached 9. A solution 
of 5-(4-isothiocyanatophenyl) borondipyrromethene (0.072 g, 0.165 mmol) 
dissolved in dimethylformamide (2 ml) was then added, the flask was covered 
in aluminium foil and the reaction mixture was stirred for 14 days. The solvent 
was then removed under reduced pressure to give a solid. The desired product 
was not isolated using this synthetic procedure.
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7.3.52 Attempted synthesis of 1,4,7-tris(carboxymethyl)-10-(4- 
(5-(4-thioureaphenylene) borondipyrromethane) benzyl)- 
1,4,7,10-tetraazacyclododecane (43)
1,4,7-Tris(carboxymethyl)-10-(4-aminobenzyl)-1,4,7,10-tetraazacyclododecane 
(0.01 g, 0.023 mmol) was dissolved into water (1 ml) followed by the addition 
of 1 M potassium hydroxide to adjust the pH to 9. 5-(4-Isothiocyanatophenyl) 
borondipyrromethane (0.01 g, 0.023 mmol) was dissolved in 
dimethylformamide (2 ml) and was added dropwise to the reaction mixture. The 
resulting solution was stirred at RT for 14 days. The solvent was removed 
under reduced pressure to give a solid. The desired product was not isolated 
using this synthetic procedure.
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7.3.53 Attempted synthesis of 1,4,7-tris(carboxymethyl)-10- 
(benzyl-4-(phenylthiourea))-1,4,7,10-tetraazacyclododecane 
(44)
o
A mixture of l,4,7-tris(carboxymethyl)-10-(4-aminobenzylmethyl)-1,4,7,10- 
tetraazacyclododecane (0.01 g, 0.022 mmol) and phenyl isothiocyanate (0.0026 
ml 0.0022 mmol) was dissolved in dimethylformamide (20 ml) and left to stir 
for 24 h. The solvent was then removed under reduced pressure. The desired 
product was not isolated using this synthetic procedure.
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7.3.54 Synthesis of 1,4,7-tris(carboxymethyl)-10-(4- 
isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane (45)
SCN
Method 1 - (preferred route)
1,4,7-Tris(carboxymethyl> 10-( 1 -(4-aminobenzyl)-1,4,7,10- 
tetraazacyclododecane (0.1 g, 0.22 mmol) was dissolved in 3 M aqueous 
hydrochloric acid (3.5 ml) and then a solution of thiophosgene (0.17 ml, 2.2 
mmol) in carbon tetrachloride (0.17 ml) was added dropwise. The biphasic 
reaction mixture was stirred for 24 h. The solvent was then removed under 
reduced pressure, and the residue dried under vacuum to give a yellow solid, 
(0.087g, 80 %). 8H (D2O): 5 2.71 - 4.71 (m, 24H, CH2), 7.2 (s, 2H, CH), 7.4 (s, 
2H, CH). m/z: 494.2 (100 (M-H+). HRMS: calcd. for C22H32O6N5Si 494.2068 
found 494.2068. I.R. (KBr) 2108.8 cm' 1 u (NCS).
Method 2
l,4,7-Tris(carboxymethyl)-10-(l-(4-aminobenzyl)-1,4,7,10- 
tetraazacyclododecane (0.25 g, 0.5 mmol) was dissolved in water (2 ml), and 
the pH adjusted to 9 by the addition of 0.05 M sodium hydrogen carbonate 
solution. A 0.025 M solution of thiophosgene in chloroform (10 ml) was added, 
the flask was then covered in aluminium foil and the reaction stirred for 24 h at 
RT. Water (10 ml) was added and the aqueous layer was separated and washed 
with chloroform (2 x 10 ml). The solvent was then removed under reduced 
pressure. The desired product was not isolated using this synthetic procedure.
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7.3.55 Synthesis of 1,4,7-tris(carboxymethyl)-10-(1-(4- 
isothiocyanatobenzyl)-2-methylbenzimidazole)-1,4,7,10- 
tetraazacyclododecane (46)
1 ,4,7-Tris(carboxymethyl)- \ 0-( I -(4-aminobenzyll)-2-methyl benzimidazole)- 
1,4,7,10-tetraazacyclododecane (0.066 g, 0.11 mmol) was dissolved in 3 M 
hydrochloric acid solution (3.5 ml), followed by the addition of thiophosgene 
(0.087 ml, 2.2 mmol) in carbon tetrachloride (0.013 ml) and the biphasic 
mixture stirred for 24 h. The solvent was removed under reduced pressure, and 
the residue dried under vacuum to give a yellow solid, (0.07, 83 %). SH (D2O): 
5 2.8 (m, 4H, CH2), 3.00 (m, 4H, CH2), 3.1-3.3 (m, 4H, CH2), 3.39-3.91 (m, 8H, 
CH2), 4.07, (m, 2H, CH2), 4.83 (s, 2H, CH2), 5.78 (S, 2H, CH2), 7.2 (s, 4H, 
CH), 7.56 (m, 2H, CH), 7.73 (m, 2H, CH). m/z: 623 (100(M-H)+). I.R. (KBr) 
2106.5cm' 1 u(NCS).
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7.3.56 Attempted synthesis of 1,4,7-tris(carboxymethyl)-10-(4- 
(5-(4-thioureaphenyl) borondipyrromethane benzyl)-2-methyl 
benzimidazole)-1,4,7,10-tetraazacyclododecane (47)
o
HO N N OH
47
1,4,7-Tris(carboxymethyl)-10-((4-isothiocyanatobenzyl)-2-methyl 
benzimidazole)-1,4,7,10-tetraazacyclododecane (0.06 g, 0.094 mmol) was 
dissolved in water (50 ml) and the pH adjusted to 8 by the addition of 1 M 
potassium hydroxide solution. A solution of 5-(4-aminophenyl) 
borondipyrromethene (0.037 g, 0.094 mmol) in dichloromethane (50 ml) was 
added, the reaction was vessel covered in foil and the solution allowed to stir for 
21 days. The desired product was not isolated using this synthetic procedure.
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7.3.57 Synthesis of 1,4,7-tris(carboxymethyl)-10-(1-(4-(N- 
benzyl)thiourea)benzyl-2-methylbenzimidazole)-1,4,7,10- 
tetraazacyclododecane (48)
48
1,4,7-Tris(carboxymethyl)-10-( 1 -(4-isothiocyanatobenzyl)-2- 
methylbenzimidazole)-l,4,7,10-tetraazacyclododecane (0.01 g, 0.017 mmol) 
was dissolved in water (1 ml) and the pH adjusted to 9 by the addition of 1 M 
sodium hydrogen carbonate solution. Benzyl amine (0.001 ml, 0.017 mmol) 
was added and the reaction mixture left to stir for 24 h. The aqueous layer was 
washed with dichloromethane (4 x 20 ml), and the solvent removed under 
reduced pressure. The resulting solid was re-dissolved into water (2 ml) and the 
salts removed using a sephadex LH-20 column with methanol as the eluent. 
The fractions containing the product were combined and the solvent was 
removed under reduced pressure to yield a white solid. SH (D2O): 8 2.2-4.8 (m, 
28H, CH2), 6.85-7.8 (m, 13H, CH). m/z: 769.3 (100 (M+K)+). I.R. (KBr) 
2925.0 cm' 1 u (NCSN), 2962.4 cm' 1 u (NCSN).
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7.3.58 Synthesis of lanthanum(IH) 1,4,7-tris(carboxymethyl)-10 
(1-(4-(N-benzyl)thiourea)benzyl-2-methylbenzimidazole)- 
1,4,7,10-tetraazacyclododecane (49)
49
1,4,7-tris(carboxymethyl)-10-(1 -(4-(N-benzyl)thiourea)benzyl~2- 
methylbenzimidazole)-1,4,7,10-tetraazacyclododecane (0.009 g, 0.01 mmol), 
and lanthanum(III) trifluoromethanesulfonate (0.0017 g, 0.001 mmol) were 
dissolved in a solution of water (10ml) and the resulting mixture was stirred at 
RT. A solution of potassium carbonate (0.0007 g, 0.005 mmol) in water (5 ml) 
was added dropwise. The solution was then heated at reflux for 18 h. The 
solvent was evaporated under reduced pressure and the product was purified 
using a sephadex LH-20 column (MeOH as eluent). The fractions containing 
the product were combined and the solvent was evaporated under reduced 
pressure to give a yellow solid. 5H (D2O): 5 2.12 - 4.7 (m, 28H, CH2), 6.8 - 
7.51 (m, 13H, CH). m/z: 769.3 (100 (M+K)+).
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7.3.59 Synthesis of 1,4,7-tris(carboxymethyl)-10-(4- 
benzylthiourea)benzyl-1,4,7,10-tetraazacyclododecane (50)
l,4,7-Tris(carboxymethyl)-10-(4-isothiocyanateobenzyl)-l,4,7,10- 
tetraazacyclodecane (0.03 g, 0.06 mmol) was dissolved in water (1 ml) and the 
pH was adjusted to 9 by the addition of 1 M potassium hydroxide solution. 
Benzyl amine (0.0066 ml 0.006 mmol) was added and the resulting solution was 
left to stir for 24 h. The aqueous layer was washed with dichloromethane (4 x 
20 ml), separated and the solvent was removed under reduced pressure. The 
resulting solid was re-dissolved in water (2 ml) and the salts removed using a 
sephadex LH-20 column using methanol as eluent. The collected fractions were 
combined and the solvent was removed under reduced pressure to give a white 
solid. 5H (D2O): 5 2.25 - 3.5 (m, 24H, CH2), 6.9 - 7.51 (m, 11H, arCH). m/z: 
568 (100 (M-H)+). I.R. (KBr) 2924.0 cm' 1 u (NCSC), 2961.9 cm'1 u (NCSN).
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7.3.60 Synthesis of lanthanum(lll) 1,4,7-tris(carboxymethyl)-10- 
(4-benzylthiourea)benzyl-1,4,7,10-tetraazacyclododecane (51)
1,4,7-tris(carboxymethyl)-10-(4-benzylthiourea)benzyl-1,4,7,10- 
tetraazacyclododecane (0.036 g, 0.06 mmol), and lanthanum(III) 
trifluoromethanesulfonate (0.035 g, 0.06 mmol) were dissolved in water (10 ml) 
and the recation mixture was stirred at RT. Potassium carbonate (0.041 g, 0.3 
mmol) in water (5 ml) was added dropwise. The solution was then heated at 
reflux for 18 h. The solvent was evaporated under reduced pressure and the 
residue was purified using a sephadex LH-20 column (MeOH as eluent). The 
fractions containing the product were combined and the solvent was evaporated 
under reduced pressure to leave a white solid. 5n (D2O): 5 2.2 - 3.6 (m, 24H, 
CH2), 6.8-7.46 (m, 11H, arCH). m/z: 704(100(M-H)+).
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7.3.61 Attempted synthesis of 1,4,7-tris(carboxymethyl)-10-( 4- 
(rhodamine B ethylamine) thiourea)benzyl-1,4,7,10- 
tetraazacyclododecane (52)
Method 1
Rhodamine B ethylamine (0.019 g, 0.036 mmol) was dissolved in 
dichloromethane and the solution was washed with an aqueous sodium 
hydrogen carbonate solution. The organic layer was then separated, dried over 
sodium sulphate and the solvent was removed under reduced pressure. 1,4,7- 
Tris(carboxymethyl)-10-(4-isothiocyanatobenzyl)-1,4,7,10- 
tetraazacyclododecane (0.015 g, 0.033 mmol) was added as a solution in 
dimethylformamide (20 ml), the flask was covered in foil and the reaction 
mixture left to stir for 24 h. The solvent was then removed under reduced 
pressure. The pink solid was re-dissolved into water (20 ml) and the aqueous 
solution washed with diethyl ether (2 x 20 ml). The aqueous layer was 
separated and the solvent removed under reduced pressure to give a purple 
solid. The desired product was not isolated using this synthetic procedure.
Method 2
1,4,7-Tris(carboxymethyl)-10-(4-isothiocyanatobenzyl)-1,4,7,10- 
tetraazacyclododecane (0.06 g, 0.13 mmol) was dissolved in water (5 ml) and 
the pH adjusted to 8 by the addition of 1 M sodium hydrogen carbonate 
solution. A solution of rhodamine B ethylamine (0.069 g, 0.13 mmol) dissolved 
in dichloromethane (5 ml) was added, the flask was covered in foil and the 
reaction mixture left to stir for 48 h. The aqueous layer was washed with 
dichloromethane (4 x 20 ml), separated and then the solvent was removed under 
reduced pressure. The desired product was not isolated using this synthetic 
procedure.
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Method 3
1,4,7-Tris(carboxymethyl)-10-(4-isothiocyanatobenzyl)-1,4,7,10- 
tetraazacyclododecane (0.05 g, 0.1 mmol) and rhodamine B ethylamine (0.069 
g, 0.13 mmol) were dissolved in dichloromethane (10 ml), the flask was covered 
in aluminium foil and the reaction mixture left to stir for 72 h. The solvent was 
then removed under reduced pressure. The desired product was not isolated 
using this synthetic procedure.
Method 4
1,4,7-Tris(carboxymethyl)-10-(4-isothiocyanatobenzylmethyl)-1,4,7,10- 
tetraazacyclododecane (0.08 g, 0.2 mmol) was dissolved in water (5 ml) and 
the pH was adjusted to 8 by the addition of 1 M sodium hydrogen carbonate 
solution, followed by the addition of a solution of rhodamine B base ethylamine 
(0.092 g, 0.2 mmol) in dimethylformamide (5 ml). The flask was covered in 
aluminium foil and the reaction mixture was left to stir for 48 h. The solvent 
was removed under reduced pressure. The desired product was not isolated 
using this synthetic procedure.
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7.3.62 Attempted synthesis of 1,4,7-tris(carboxymethyl)-10-(1 
(4-( rhodamine B base ethylamine thiourea)benzyl)-2-methyl 
benzimidazole)-1,4,7,10-tetraazacyclodecane (53)
Et,N'
o
NEt2
Method 1
Rhodamine B base ethylamine (0.016 g, 0.03 mmol) was dissolved in 
dichloromethane and the resulting solution was washed with aqueous sodium 
hydrogen carbonate solution. The organic layer was then separated, dried over 
sodium sulphate and the solvent removed under reduced pressure. 1,4,7- 
Tris(carboxymethyl)-10-( 1 -(4-isothiocyanatobenzyl)-2-methylbenzimidazoIe)- 
1,4,7,10-tetraazacyclododecane (0.017 g, 0.023 mmol) was added as a solution 
in dimethylformamide (20 ml), the flask was covered in foil and the reaction 
mixture left to stir for 24 h at RT. The solvent was then removed under reduced 
pressure. The pink solid was re-dissolved into water (20 ml) and washed with 
diethyl ether (2 x 20 ml). The aqueous layer was separated and the solvent 
removed under reduced pressure to give a purple solid. The desired product 
was not isolated using this synthetic procedure.
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Method 2
1,4,7-Tris(carboxymethyl)-10-( 1 -(4-isothiocyanatobenzyl)-2- 
methylbenzimidazole)-l,4,7,10-tetraazacyclododecane (0.066 g, 0.11 mmol) 
was dissolved in water (5 ml) and the pH adjusted to 8 by the addition of 1 M 
sodium hydrogen carbonate solution. Rhodamine B base ethylamine (0.059 g, 
0.11 mmol) dissolved in dichloromethane (5 ml) was added, the reaction flask 
was covered in foil and the mixture left to stir for 48 h. The aqueous layer was 
washed with dichloromethane (4 x 20 ml), and the solvent removed under 
reduced pressure. The desired product was not isolated using this synthetic 
procedure.
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7.3.63 Synthesis of 1,4,7-tris(carboxymethyl)-10-( 4-(5-(4- 
thioureaethylamidephenyl) borondipyrromethene benzyl)-2- 
methyl benzimidazole)-1,4,7,10-tetraazacyclododecane (56)
o
5-(4-Ethylenediaminemethylamidophenyl)borondipyrromethene (0.02 g, 0.04 
mmol) was dissolved in dichloromethane and the solution was washed with an 
aqueous sodium hydrogen carbonate solution. The organic layer was then dried 
over sodium sulphate and the solvent was removed under reduced pressure. 
l,4,7-Tris(carboxymethyl)-10-(l~(4-isothiocyanatobenzyl)-2-methyl 
benzimidazole)-1,4,7,10-tetraazacyclododecane (0.02 g, 0.037 mmol) dissolved 
in dimethylformamide (20 ml) was added dropwise and the solution was then 
left to stir for 24 h at RT protected from the light. The solvent was removed 
under reduced pressure. The resulting red solid was re-dissolved into water (20 
ml) and washed with diethyl ether (4 x 50 ml). The aqueous layer was 
separated and the solvent removed under reduced pressure to give a red solid. 
The desired product was not isolated using this synthetic procedure.
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7.3.64 Synthesis of 1,4,7-tris(carboxymethyl)-10- 
(aminomethylamidobenzyl)-l, 4,7,10-tetraazacyclododecane 
(58)
HN——(' V——\ __ 
H,N'
58 NOH
jV-Pthaloylglycine (0.025 g, 0.12 mmol) was dissolved in thionyl chloride (10 
ml) and the mixture heated at reflux for 3 h. The solvent was removed under 
reduced pressure and the solid used without further purification. 1,4,7- 
Tris(carboxymethyl)-10-( 4-aminobenzyl)-1,4,7,10-tetraazacyclododecane (0.05 
g, 0.1 mmol) and magnesium oxide (0.007 g, 0.016 mmol) were dissolved in 
water (10 ml) and left to stir at room temperature for 4 h. The reaction mixture 
was allowed to cool to 0°C followed by the addition of phthaloyl p-alanine 
chloride, prepared in the first step. The reaction micxture was stirred for 30 min 
at RT and then stirred for a further 4 h at 50°C. The solvent was removed under 
reduced pressure, the residue was re-dissolved into water (50 ml) and washed 
with dichloromethane (2 x 50 ml). The aqueous layer was separated and the 
solvent removed under reduced pressure to yield a yellow solid. The solid was 
dissolved into a mixture of hydrazine hydrate (5 ml) and ethanol (20 ml). This 
mixture was heated at reflux for 4 h and was then cooled to 0°C. The precipitate 
that appeared upon cooling was removed by filtration. The solvent was then 
removed from the filtrate under reduced pressure to yield a crude product. The 
solid was used crude for the next step.
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7.3.65 Attempted synthesis of 1,4,7-tris(carboxymethyl)-10-(4- 
(5-(4-thioureaamidophenyl)borondipyrromethane) 
methylamidobenzyl)-1,4,7,10-tetraazacyclododecane (59)
59 HO OH
1,4,7-tris(carboxymethyl)-10-(aminomethylamidobenzyl)-1,4,7,10- 
tetraazacyclododecane (0.05 g, 0.098 mmol) was dissolved in water (10 ml) 
followed by the addition of 1 M aqueous sodium hydrogen carbonate solution to 
adjust the pH of the solution to 8. 5-(4-Isothiocyanatophenyl) 
borondipyrromethene (0.04 g, 0.098 mmol) dissolved in dichloromethane (10 
ml) was added and the resulting reaction mixture left to stir for 24 h at RT under 
an atmosphere of nitrogen. The solvent was then removed under reduced 
pressure. The desired product was not isolated using this synthetic procedure.
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8. Appendix
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8.1 Crystallographic data for 1-(4- 
nitrobenzyl)phenylenediamine (5)
Crystals were grown by slow evaporation of a dichloromethane solution over a 
period of two weeks. Colourless blocks were separated from the solvent and a 
suitable crystal was selected and mounted on a glass fibre using 
perfluoropolyether oil.
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Identification code 
Empirical formula 
Formula weight 
Temperature 
Wavelength 
Crystal system 
Space group 
Unit cell dimensions
Volume 
Z
Density (calculated)
Absorption coefficient
F(OOO)
Crystal size
Theta range for data collection
Index ranges
Reflections collected
Independent reflections
Completeness to theta = 34.75°
Refinement method
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2sigma(I)]
R indices (all data)
Extinction coefficient
Largest diff. peak and hole
sja88_06
C13H13N3O2
243.26
150(2)K
0.71073 A
monoclinic
P21/c
a =10.503(2) A a=90°.
b = 6.7427(9) A (5= 94.032(15)°
c= 16.452(3) A y=90°.
1162.3(4) A3
4
1.390Mg/m3
0.097 mm-'
512
0.50 x 0.46 x 0.44 mm3
2.48 to 34.75°.
-16<=h<=16, -10<=k<=8, -26<=1<=26
19826
4980 [R(mt) = 0.0533]
99.1 %
Full-matrix least-squares on F2
4980/0/176
1.028
Rl = 0.0593, wR2 = 0.1582
Rl = 0.1089, wR2 = 0.1941
0.065(8)
0.385 and -0.342 e.A'3
Table 18 Crystal data and structure refinement for l-(4-nitrobenzyl)phenylenediamine (7)
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G(1)-C(6)
C(1)-N(1)
C(1)-C(2)
C(2)-C(3)
C(2)-N(2)
C(3)-C(4)
C(3)-H(3)
C(4)-C(5)
C(4)-H(4)
C(5)-C(6)
C(5)-H(5)
C(6)-H(6)
C(7)-N(1)
C(7)-C(8)
C(7)-H(7A)
C(7)-H(7B)
C(8)-C(9)
C(8)-C(13)
C(9)-C(10)
C(9)-H(9)
C(10)-C(11)
C(10)-H(10)
C(11)-C(12)
C(11)-N(3)
C(12)-C(13)
C(12)-H(12)
C(13)-H(13)
N(1)-H(14)
N(2)-H(16)
N(2)-H(15)
N(3)-0(2)
N(3)-0(l)
1.391(2)
1.3961(18)
1.412(2)
1.394(2)
1.3998(19)
1.394(2)
0.9500
1.378(2)
0.9500
1.395(2)
0.9500
0.9500
1.4570(19)
1.5085(19)
0.9900
0.9900
1.391(2)
1.3984(19)
1.387(2)
0.9500
1.3858(19)
0.9500
1.381(2)
1.4678(18)
1.384(2)
0.9500
0.9500
0.92(2)
0.91(2)
0.91(2)
1.2242(18)
1.2268(17)
Table 19 Bond lengths [A] for (5)
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C(6)-C(1)-N(1)
C(6)-C(1)-C(2)
N(1)-C(1)-C(2)
C(3)-C(2)-N(2)
C(3)-C(2)-C(1)
N(2)-C(2)-C(1)
C(4)-C(3)-C(2)
C(4)-C(3)-H(3)
C(2)-C(3)-H(3)
C(5)-C(4)-C(3)
C(5)-C(4)-H(4)
C(3)-C(4)-H(4)
C(4)-C(5)-C(6)
C(4)-C(5)-H(5)
C(6)-C(5)-H(5)
C(1)-C(6)-C(5)
C(1)-C(6)-H(6)
C(5)-C(6)-H(6)
N(1)-C(7)-C(8)
N(1)-C(7)-H(7A)
C(8)-C(7)-H(7A)
N(1)-C(7)-H(7B)
C(8)-C(7)-H(7B)
H(7A)-C(7)-H(7B)
C(9)-C(8)-C(13)
C(9)-C(8)-C(7)
C(13)-C(8)-C(7)
122.91(13)
119.50(13)
117.54(12)
121.72(13)
118.86(13)
119.32(12)
121.04(14)
119.5
119.5
119.88(13)
120.1
120.1
120.00(14)
120.0
120.0
120.71(14)
119.6
119.6
108.98(12)
109.9
109.9
109.9
109.9
108.3
119.59(13)
120.70(12)
119.69(13)
C(10)-C(9)-C(8)
C(10)-C(9)-H(9)
C(8)-C(9)-H(9)
C(11)-C(10)-C(9)
C(11)-C(10)-H(10)
C(9)-C(10)-H(10)
C(12)-C(11)-C(10)
C(12)-C(11)-N(3)
C(10)-C(11)-N(3)
C(11)-C(12)-C(13)
C(11)-C(12)-H(12)
C(13)-C(12)-H(12)
C(12)-C(13)-C(8)
C(12)-C(13)-H(13)
C(8)-C(13)-H(13)
C(1)-N(1)-C(7)
C(1)-N(1)-H(14)
C(7)-N(1)-H(14)
C(2)-N(2)-H(16)
C(2)-N(2)-H(15)
H(16)-N(2)-H(15)
0(2)-N(3)-0(1)
0(2)-N(3)-C(11)
0(1)-N(3)-C(11)
120.62(13)
119.7
119.7
118.10(13)
120.9
120.9
122.91(13)
118.51(12)
118.58(13)
118.17(12)
120.9
120.9
120.60(13)
119.7
119.7
119.22(11)
112.9(11)
113.9(12)
111.6(14)
115.6(13)
110.2(18)
123.16(13)
118.63(12)
118.22(13)
Symmetry transformations used to generate equivalent atoms:
Table 20 Bond angles [°] for (5)
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8.2 Crystallographic data for 1-(4-nitrobenzylmethyl)-2- 
chloromethyl benzimidazolium chloride (7).HCI
Crystals were grown by slow evaporation of a dichloromethane solution over a 
period of two weeks. Colourless blocks were separated from the solvent and a 
suitable crystal was selected and mounted on a glass fibre using 
perfluoropolyether oil.
CI2
CM
01
02
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Identification code 
Empirical formula 
Formula weight 
Temperature 
Wavelength 
Crystal system 
Space group 
Unit cell dimensions
Volume
Z
Density (calculated)
Absorption coefficient
F(OOO)
Crystal size
Theta range for data collection
Index ranges
Reflections collected
Independent reflections
Completeness to theta = 34.85°
Absorption correction
Refinement method
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2sigma(I)J
R indices (all data)
Largest diff. peak and hole
sjalO_07
C15H13C12N3O2
338.18
150(2)K
0.71073 A
Monoclinic
P21/n
a = 5.4863(4) A <x= 90°.
b = 13.4457(15) A P= 92.358(6)°
c = 20.1533(16) A y=90°.
1485.4(2) A3
4
1.508Mg/m3
0.447 mm- 1
692
0.51 x 0.33 x 0.05 mm3
2.53 to 34.85°.
-8<=h<=8, -21 <=k<=21, -31 <=1<=32
39664
6409 [R(int) = 0.1507]
99.1 %
None
Full-matrix least-squares on F2
6409/1 /202
0.823
Rl =0.0769, wR2 = 0.1788
Rl =0.1077, wR2 = 0.1944
0.657 and -0.690 e.A'3
Table 21 Crystal data and structure refinement for (7).HC1
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C(1)-N(2)
C(1)-N(1)
C(1)-C(15)
C(2)-N(2)
C(2)-C(7)
C(2)-C(3)
C(3)-N(1)
C(3)-C(4)
C(4)-C(5)
C(5)-C(6)
C(6)-C(7)
C(8)-N(1)
C(8)-C(9)
C(9)-C(14)
C(9)-C(10)
C(10)-C(11)
C(11)-C(12)
C(12)-C(13)
C(12)-N(3)
C(13)-C(14)
C(15)-C1(1)
N(3)-0(l)
N(3)-0(2)
N(2)-C(1)-N(1)
N(2)-C(1)-C(15)
N(1)-C(1)-C(15)
N(2)-C(2)-C(7)
1.328(4)
1.345(3)
1.481(4)
1.384(3)
1.389(4)
1.397(3)
1.390(3)
1.397(3)
1.369(4)
1.409(4)
1.378(4)
1.466(3)
1.512(4)
1.388(3)
1.391(4)
1.386(4)
1.373(4)
1.376(4)
1.474(4)
1.384(4)
1.801(3)
1.217(4)
1.230(4)
109.8(2)
123.3(3)
126.8(3)
130.9(2)
N(2)-C(2)-C(3)
C(7)-C(2)-C(3)
N(1)-C(3)-C(2)
N(1)-C(3)-C(4)
C(2)-C(3)-C(4)
C(5)-C(4)-C(3)
C(4)-C(5)-C(6)
C(7)-C(6)-C(5)
C(6)-C(7)-C(2)
N(1)-C(8)-C(9)
C(14)-C(9)-C(10)
C(14)-C(9)-C(8)
C(10)-C(9)-C(8)
C(11)-C(10>C(9)
C(12)-C(11)-C(10)
C(11)-C(12)-C(13)
C(11)-C(12)-N(3)
C(13)-C(12)-N(3)
C(12)-C(13)-C(14)
C(13)-C(14)-C(9)
C(1)-C(15)-C1(1)
C(1)-N(1)-C(3)
C(1)-N(1)-C(8)
C(3)-N(1)-C(8)
C(1)-N(2)-C(2)
0(1)-N(3)-0(2)
0(1)-N(3)-C(12)
0(2)-N(3)-C(12)
106.8(2)
122.3(2)
106.3(2)
132.6(2)
121.1(2)
116.7(2)
121.9(3)
121.8(3)
116.1(3)
111.5(2)
119.1(2)
120.3(2)
120.5(2)
120.6(2)
118.5(3)
122.5(2)
118.7(2)
118.8(2)
118.4(2)
120.8(2)
110.15(18)
108.3(2)
125.5(2)
125.8(2)
108.8(2)
124.2(3)
118.5(3)
117.3(3)
Table 22 Bond lengths [A] and angles [°] for (7).HC1
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8.3 Crysta/ographic data for 1-(4-nitrobenzylmethyl)-2- 
methylpyridine benzimidazole (9)
Crystals were grown by slow evaporation of a dichloromethane solution over a 
period of two weeks. Colourless blocks were separated from the solvent and a 
suitable crystal was selected and mounted on a glass fibre using 
perfluoropolyether oil.
CI1
OC6
297
Identification code 
Empirical formula 
Formula weight 
Temperature 
Wavelength 
Crystal system 
Space group 
Unit cell dimensions
Volume
Z
Density (calculated)
Absorption coefficient
F(OOO)
Crystal size
Theta range for data collection
Index ranges
Reflections collected
Independent reflections
Completeness to theta = 34.87°
Absorption correction
Refinement method
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2sigma(I)]
R indices (all data)
Extinction coefficient
Largest diff. peak and hole
sja21_07
C20H17C1N4O3
396.83
150(2)K
0.71073 A
Monoclinic
P21/c
a =15,97(3) A a=90°.
b= 11.877(12) A p= 104.00(11)°
c= 10.922(16) A j=90°.
2010(5) A3
4
1.311Mg/m3
0.218mm- 1
824
0.4x0.1 x 0.06 mm3
3.10 to 34.87°.
-25<=h<=25, -19<=k<=18, -17<=1<= 15
67963
8682[R(int) = 0.4112]
99.3 %
None
Full-matrix least-squares on F2
8682 / 0/263
0.691
Rl = 0.075 l,wR2 = 0.1668
Rl =0.3175, wR2 = 0.2275
0.0030(12)
0.727 and -0.348 e.A-3
Table 23 Crystal data and structure refinement for (9)
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C(1)-N(2)
C(1)-N(1)
C(1)-C(15)
C(2)-N(2)
C(2)-C(3)
C(2)-C(7)
C(3)-C(4)
C(3)-N(1)
C(4)-C(5)
C(4)-H(4)
C(5)-C(6)
C(5)-H(5)
C(6)-C(7)
C(6)-H(6)
C(7)-H(7)
C(8)-N(1)
C(8)-C(9)
C(8)-H(8A)
C(8)-H(8B)
C(9)-C(10)
C(9)-C(14)
C(10)-C(11)
C(10)-H(10)
C(11)-C(12)
C(11)-H(11)
C(12)-C(13)
1.306(4)
1.366(5)
1.486(5)
1.388(5)
1.391(6)
1.407(5)
1.377(6)
1.388(5)
1.393(6)
0.9300
1.384(7)
0.9300
1.368(6)
0.9300
0.9300
1.447(5)
1.523(6)
0.9700
0.9700
1.361(7)
1.367(7)
1.391(7)
0.9300
1.275(9)
0.9300
1.334(9)
C(12)-N(3)
C(13)-C(14)
C(13)-H(13)
C(14)-H(14)
C(15)-N(4)
C(15)-H(15A)
C(15)-H(15B)
C(16)-N(4)
C(16)-C(17)
C(16)-H(16)
C(17)-C(18)
C(17)-H(17)
C(18)-C(19)
C(18)-H(18)
C(19)-C(20)
C(19)-H(19)
C(20)-N(4)
C(20)-H(20)
N(3)-0(l)
N(3)-0(2)
0(3)-0(4)
0(4)-0(3)
1.547(8)
1.460(8)
0.9300
0.9300
1.472(6)
0.9700
0.9700
1.339(5)
1.362(6)
0.9300
1.375(6)
0.9300
1.377(5)
0.9300
1.353(6)
0.9300
1.338(5)
0.9300
1.123(9)
1.267(9)
1.438(9)
1.438(9)
Table 24 Bond lengths [A] for (9)
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N(2)-C(1)-N(1) 114.1(3)
N(2)-C(1)-C(15) 125.4(4)
N(1)-C(1)-C(15) 120.4(3)
N(2)-C(2)-C(3) 110.4(3)
N(2)-C(2)-C(7) 130.9(4)
C(3)-C(2)-C(7) 118.7(4)
C(4)-C(3)-N(1) 130.9(4)
C(4)-C(3)-C(2) 123.7(4)
N(1)-C(3)-C(2) 105.3(3)
C(3)-C(4)-C(5) 116.4(4)
C(3)-C(4)-H(4) 121.8
C(5)-C(4)-H(4) 121.8
C(6)-C(5)-C(4) 120.8(4)
C(6)-C(5)-H(5) 119.6
C(4)-C(5)-H(5) 119.6
C(7)-C(6)-C(5) 122.6(4)
C(7)-C(6)-H(6) 118.7
C(5)-C(6)-H(6) 118.7
C(6)-C(7)-C(2) 117.8(4)
C(6)-C(7)-H(7) 121.1
C(2)-C(7)-H(7) 121.1
N(1)-C(8)-C(9) 114.0(4)
N(1)-C(8)-H(8A) 108.8
C(9)-C(8)-H(8A) 108.8
N(1)-C(8)-H(8B) 108.8
C(9)-C(8)-H(8B) 108.8
H(8A)-C(8)-H(8B) 107.6
C(10)-C(9)-C(14) 118.4(5)
C(10)-C(9)-C(8) 123.3(4)
C(14)-C(9)-C(8) 118.3(5)
C(9)-C(10)-C(11) 122.1(6)
C(9)-C(10)-H(10) 119.0
C(11)-C(10)-H(10) 119.0
C(12)-C(11)-C(10) 118.3(7)
C(12)-C(11)-H(11) 120.8
C(10)-C(11)-H(11) 120.8
C(11)-C(12)-C(13) 125.5(6) 
Figure 164 Bond angles [°] for (9)
C(12)-C(13)-C(14) 116.9(5)
C(12)-C(13)-H(13) 121.5
C(14)-C(13)-H(13) 121.5
C(9)-C(14)-C(13) 118.6(6)
C(9)-C(14)-H(14) 120.7
C(13)-C(14)-H(14) 120.7
N(4)-C(15)-C(1) 111.5(3)
N(4)-C(15)-H(15A) 109.3
C(1)-C(15)-H(15A) 109.3
N(4)-C(15)-H(15B) 109.3
C(1)-C(15)-H(15B) 109.3 
H(15A)-C(15)-H(15B) 108.0
N(4)-C(16)-C(17) 120.0(4)
N(4)-C(16)-H(16) 120.0
C(17)-C(16)-H(16) 120.0
C(16)-C(17)-C(18) 119.2(4)
C(16)-C(17)-H(17) 120.4
C(18)-C(17)-H(17) 120.4
C(17)-C(18)-C(19) 119.7(4)
C(17)-C(18)-H(18) 120.1
C(19)-C(18)-H(18) 120.1
C(20)-C(19)-C(18) 119.2(4)
C(20)-C(19)-H(19) 120.4
C(18)-C(19)-H(19) 120.4
N(4)-C(20)-C(19) 120.4(4)
N(4)-C(20)-H(20) 119.8
C(19)-C(20)-H(20) 119.8
C(1)-N(1)-C(3) 105.8(3)
C(1)-N(1)-C(8) 128.0(3)
C(3)-N(1)-C(8) 125.3(4)
C(1)-N(2)-C(2) 104.4(3)
C(20)-N(4)-C(16) 121.5(4)
C(20)-N(4)-C(15) 119.1(3)
C(16)-N(4)-C(15) 119.4(3)
0(1)-N(3)-O(2) 127.2(7)
O(1)-N(3)-C(12) 119.0(9)
O(2)-N(3)-C(12) 113.8(7)
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8.4 Crystallographic data for 1,4,7-tris(tert- 
butoxycarbonylmethyl)-10-(1-(4-nitrobenzyl)-2-methyl 
benzimidazole)-1,4,7,10-tetraazacyclododecane (32)
Crystals were grown by slow evaporation of a dichloromethane solution over a 
period of two weeks. Colourless blocks were separated from the solvent and a 
suitable crystal was selected and mounted on a glass fibre using 
perfluoropolyether oil.
O9
C24
301
Identification code 
Empirical formula 
Formula weight 
Temperature 
Wavelength 
Crystal system 
Space group 
Unit cell dimensions
Volume
Z
Density (calculated)
Absorption coefficient
F(OOO)
Crystal size
Theta range for data collection
Index ranges
Reflections collected
Independent reflections
Completeness to theta = 34.96°
Absorption correction
Refinement method
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2sigma(I)]
R indices (all data)
Extinction coefficient
Largest diff. peak and hole
sja06_07
C41H61BrN7NaO9
898.87
150(2) K.
0.71073 A
Monoclinic
P21/n
a =18.5814(15) A cc=90°.
b = 12.8752(8) A 3= 96.745(7)°
c= 19.524(2) A y=90°.
4638.6(7) A3
4
1.287Mg/m3
0.953 mm- 1
1896
0.4 x 0.4 x 0.3 mm3
2.63 to 34.96°.
-29<=h<=29, -20<=k<=20, -30<=1<=31
143731
19992 [R(int) = 0.1222]
98.1 %
None
Full-matrix least-squares on F2
19992 / 0/533
0.876
Rl = 0.1059, wR2 = 0.2775
Rl = 0.1938, wR2 = 0.3208
0.134(5)
3.583 and-0.790 e.A'3
Table 25 Crystal data and structure refinement for (32)
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C(1)-N(I)
C(1)-C(2)
C(2)-N(2)
C(3)-N(2)
C(3)-C(4)
C(4)-N(3)
C(5)-N(3)
C(5)-C(6)
C(6)-N(4)
C(7)-N(4)
C(7)-C(8)
C(8)-N(1)
C(9)-N(1)
C(9)-C(10)
C(10)-0(2)
C(10)-0(l)
C(11)-C(12)
C(H)-0(1)
C(11)-C(14)
C(11)-C(13)
C(15)-N(2)
C(15)-C(16)
C(16)-0(4)
C(16)-0(3)
C(16)-Na(l)
C(17)-C(19)
C(17)-0(3)
C(17)-C(18)
C(17)-C(20)
C(21)-N(3)
C(21)-C(22)
C(22)-0(6)
C(22)-0(5)
C(23)-0(5)
1.470(6)
1.510(6)
1.473(5)
1.472(6)
1.508(7)
1.472(6)
1.468(6)
1.515(6)
1.486(6)
1.489(6)
1.505(7)
1.453(6)
1.462(6)
1.510(7)
1.200(6)
1.335(6)
1.460(10)
1.474(6)
1.490(8)
1.494(9)
1.427(5)
1.522(7)
1.204(5)
1.328(5)
3.022(5)
1.498(9)
1.505(7)
1.509(9)
1.526(7)
1.441(5)
1.525(6)
1.218(5)
1.314(5)
1.475(5)
C(23)-C(24)
C(23)-C(25)
C(23)-C(26)
C(27)-N(4)
C(27)-C(28)
C(28)-N(6)
C(28)-N(5)
C(29)-C(30)
C(29)-N(5)
C(29)-C(34)
C(30)-C(31)
C(31)-C(32)
C(32)-C(33)
C(33)-C(34)
C(34)-N(6)
C(35)-N(5)
C(35)-C(36)
C(36)-C(41)
C(36)-C(37)
C(37)-C(38)
C(38)-C(39)
C(39)-C(40)
C(39)-N(7)
C(40)-C(41)
N(l)-Na(l)
N(2)-Na(l)
N(3)-Na(l)
N(4)-Na(l)
N(6)-Na(l)
N(7)-0(8)
N(7)-0(7)
O(2)-Na(l)
0(4)-Na(l)
O(6)-Na(l)
1.476(6)
1.518(7)
1.532(7)
1 .446(6)
1.499(6)
1.312(5)
1.372(6)
1.388(7)
1.399(6)
1.405(6)
1.386(7)
1.401(7)
1.358(7)
1.385(6)
1.402(6)
1.454(5)
1.500(6)
1.357(7)
1.397(7)
1.361(7)
1.363(8)
1.359(9)
1.460(7)
1.405(8)
2.632(4)
2.649(4)
2.596(4)
2.487(4)
2.498(4)
1.223(8)
1.252(7)
2.594(4)
2.451(4)
2.681(3)
Table 26 Bond lengths [A] for (32)
303
N(1)-C(1)-C(2) 112.4(4)
N(2)-C(2)-C(1) 113.1(4)
N(2)-C(3)-C(4) 112.8(4)
N(3)-C(4)-C(3) 114.3(4)
N(3)-C(5)-C(6) 113.6(4)
N(4)-C(6)-C(5) 113.9(4)
N(4)-C(7)-C(8) 111.4(4)
N(1)-C(8)-C(7) 114.5(4)
N(1)-C(9)-C(10) 111.5(4)
O(2)-C(10)-O(1) 124.7(5)
0(2)-C(10)-C(9) 126.1(5)
O(1)-C(10)-C(9) 109.1(4)
C(12)-C(11)-O(1) 103.5(5)
C(12)-C(11)-C(14) 114.2(6)
O(1)-C(11)-C(14) 109.8(4)
C(12)-C(11)-C(13) 107.7(5)
O(1)-C(11)-C(13) 109.9(5)
C(14)-C(11)-C(13) 111.4(5)
N(2)-C(15)-C(16) 111.7(3)
O(4)-C(16)-O(3) 125.2(4)
O(4)-C(16)-C(15) 123.1(4)
O(3)-C(16)-C(15) 111.7(4)
O(4)-C(16)-Na(l) 51.0(2)
O(3)-C(16)-Na(l) 141.6(3)
C(15)-C(16)-Na(l) 84.4(2)
C(19)-C(17)-O(3) 107.7(5)
C(19)-C(17)-C(18) 113.3(5)
O(3)-C(17)-C(18) 111.0(4)
C(19)-C(17)-C(20) 112.7(6)
O(3)-C(17)-C(20) 102.1(4)
C(18)-C(17)-C(20) 109.4(6)
N(3)-C(21)-C(22) 109.1(4)
O(6)-C(22)-O(5) 125.3(4)
O(6)-C(22)-C(21) 122.5(4)
0(5)-C(22)-C(21) 112.2(4)
O(5)-C(23)-C(24) 103.8(4)
O(5)-C(23)-C(25) 110.4(4)
C(24)-C(23)-C(25) 110.7(4)
O(5)-C(23)-C(26) 108.1(4)
C(24)-C(23)-C(26) 111.0(4)
C(25)-C(23)-C(26) 112.5(4)
N(4)-C(27)-C(28) 110.6(4)
N(6)-C(28)-N(5) 113.9(4)
N(6)-C(28)-C(27) 122.9(4)
N(5)-C(28)-C(27) 123.2(4)
C(30)-C(29)-N(5) 132.5(4)
C(30)-C(29)-C(34) 122.4(4)
N(5)-C(29)-C(34) 105.1(4)
C(31)-C(30)-C(29) 116.3(5)
C(30)-C(31)-C(32) 121.2(5)
C(33)-C(32)-C(31) 121.9(4)
C(32)-C(33)-C(34) 118.4(5)
C(33)-C(34)-N(6) 130.2(4)
C(33)-C(34)-C(29) 119.8(4)
N(6)-C(34)-C(29) 110.0(4)
N(5)-C(35)-C(36) 114.9(4)
C(41)-C(36)-C(37) 119.1(4)
C(41)-C(36)-C(35) 120.3(5)
C(37)-C(36)-C(35) 120.5(4)
C(38)-C(37)-C(36) 121.2(5)
C(37)-C(38)-C(39) 118.8(6)
C(40)-C(39)-C(38) 121.8(5)
C(40)-C(39)-N(7) 118.7(6)
C(38)-C(39)-N(7) 119.5(6)
C(39)-C(40)-C(41) 119.1(5)
C(36)-C(41)-C(40) 119.9(5)
C(8)-N(1)-C(9) 111.7(3)
C(8)-N(1)-C(1) 111.6(4)
C(9)-N(1)-C(1) 110.3(4)
C(8)-N(l)-Na(l) 106.5(3)
C(9)-N(l)-Na(l) 105.7(3)
C(l)-N(l)-Na(l) 110.8(2)
C(15)-N(2)-C(3) 113.0(3)
C(15)-N(2)-C(2) 112.4(4)
C(3)-N(2)-C(2) 109.5(4)
C(15)-N(2)-Na(l) 101.5(3)
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C(3)-N(2)-Na(l)
C(2)-N(2)-Na(l)
C(21)-N(3)-C(5)
C(21)-N(3)-C(4)
C(5)-N(3)-C(4)
C(21)-N(3)-Na(l)
C(5)-N(3)-Na(l)
C(4)-N(3)-Na(l)
C(27)-N(4)-C(6)
C(27)-N(4)-C(7)
C(6)-N(4)-C(7)
C(27)-N(4)-Na(l)
C(6)-N(4)-Na(l)
C(7)-N(4)-Na(l)
C(28)-N(5)-C(29)
C(28)-N(5)-C(35)
C(29)-N(5)-C(35)
C(28)-N(6)-C(34)
C(28)-N(6)-Na(l)
C(34)-N(6)-Na(l)
0(8)-N(7)-0(7)
O(8)-N(7)-C(39)
O(7)-N(7)-C(39)
C(10)-O(1)-C(11)
C(10)-O(2)-Na(l)
C(16)-O(3)-C(17)
C(16)-O(4)-Na(l)
C(22)-O(5)-C(23)
C(22)-O(6)-Na(l)
O(4)-Na(l)-N(4)
0(4)-Na(l)-N(6)
N(4)-Na(l)-N(6)
O(4)-Na(l)-O(2)
110.4(3)
109.7(3)
112.5(4)
109.6(3)
110.8(4)
105.1(3)
106.7(2)
111.9(3)
112.4(4)
109.8(3)
110.3(4)
104.7(3)
107.5(2)
112.0(3)
106.3(3)
127.7(4)
126.1(4)
104.7(4)
109.8(3)
144.8(3)
123.9(5)
118.5(6)
117.5(6)
122.9(4)
110.1(3)
120.1(4)
106.5(3)
123.3(4)
112.1(3)
152.64(13)
127.29(14)
68.41(13)
75.01(12)
N(4)-Na(l)-O(2)
N(6)-Na(l)-0(2)
O(4)-Na(l)-N(3)
N(4)-Na(l)-N(3)
N(6)-Na(l)-N(3)
O(2)-Na(l)-N(3)
O(4)-Na(l)-N(l)
N(4)-Na(l)-N(l)
N(6)-Na(l)-N(l)
O(2)-Na(l)-N(l)
N(3)-Na(l)-N(l)
0(4)-Na(l)-N(2)
N(4)-Na(l)-N(2)
N(6)-Na(l)-N(2)
O(2)-Na(l)-N(2)
N(3)-Na(l)-N(2)
N(l)-Na(l)-N(2)
O(4)-Na(l)-O(6)
N(4)-Na(l)-O(6)
N(6)-Na(l)-O(6)
0(2)-Na(l)-O(6)
N(3)-Na(l)-0(6)
N(l)-Na(l)-O(6)
N(2)-Na(l)-O(6)
O(4)-Na(l)-C(16)
N(4)-Na(l)-C(16)
N(6)-Na(l)-C(16)
O(2)-Na(l)-C(16)
N(3)-Na(l)-C(16)
N(l)-Na(l)-C(16)
N(2)-Na(l)-C(16)
O(6)-Na(l)-C(16)
87.35(13)
81.13(13)
123.40(12)
73.13(12)
90.55(14)
160.46(14)
82.51(12)
70.93(13)
127.02(13)
64.38(12)
108.58(13)
64.50(12)
109.66(14)
158.37(14)
120.50(13)
68.86(12)
68.60(11)
80.06(11)
126.96(12)
80.95(11)
130.31(13)
64.74(11)
151.99(13)
84.09(11)
22.46(11)
158.93(15)
132.53(14)
97.46(13)
101.15(13)
92.61(13)
50.45(12)
63.95(11)
Symmetry transformations used to generate equivalent atoms:
Figure 165 Bond angles [°] for (32)
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5.5 Physical data for europium(lll) 1,4,7- 
tris(carboxymethyl)-10-(1-(4-nitrobenzyl)-2~methyl 
benzimidazole)-1,4,7,10-tetraazacyclododecane (34a)
EuNO2 in D2O Xex = 395 nm
80000
. *
70000 \
*
£- 60000
w \r; soooo^^ « ."±
c 40000 
o>
I 30000
»
20000
•
10000
2 
time / ms
Figure 166 Fitted decay emission graph for (34a) in D2O
50000 EuN02 inH20>.ex =
45000
40000
35000 \ 
§ 30000 \ 
£ 25000 \W) *
I 20000c
15000 * 
10000 
5000
*-..
0 ———————————±—*————^
2 
time / ms
Figure 167 Fitted decay emission graph for (34a) in H20
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8.6 Physical data for terbium(lll) 1,4,7-tris(carboxymethyl)- 
10-(1-(4-nitrobenzyl)-2-methyl benzimidazole)-1,4,7,10- 
tetraazacyclododecane (34b)
120000 TbNO2 in D2O Xex = 278 nm
100000 
~ 80000
60000
c 
^ 
- 40000
20000
4 
time / ms
Figure 168 Fitted emission decay graph for (34b) in D2O
90000 1 TbN02 in H 20 Xex =
80000 i
I ^
70000 -j \
\ ~ 60000 i \
- 50000
^^ *J *
'" 40000 
£
£ 30000
i •
20000 -i
*
10000 -!
0
4 
time / ms
Figure 169 Fitted emission decay graph for (34b) in H2O
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8.7 Physical data for europium(lll) 1,4J- 
tris(carboxymethyl)-10-(1-(4-aminobenzyl)-2-methyl 
benzimidazole)-1,4,7,10-tetraazacyclododecane (37a)
90000 EuNH2 inD2OXex =
80000
70000 f
\
~ 60000 \
- 50000
~ \
c 40000
£
- 30000 
20000
•
10000
0 
0 1 2
time / ms
Figure 170 Fitted decay emission graph for (37a) in D^O at Xex = 318 nm
100000 EuNH2 inD2OXex =
90000 \
80000 
70000 
§ 60000 *
£ 50000w •
I 40000_c •
30000
20000
*•
10000 *••..
* »
0 ———————————————————— 
0 1 2
time / ms
Figure 171 Fitted decay emission decay for (37a) in D2O at Xex = 395 nm
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80000
70000
60000
¥ 50000 
w,
£ 40000 </>
| I 30000 
20000 
10000 
0
EuNH2 in H 2O Xex = 318 nm
2 
time / ms
Figure 172 Fitted decay emission decay for (37a) in H20 at Xex = 318 nm
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8.8 Physical data for terbium(lll) 1,4,7-tris(carboxymethyl)- 
10-(1-(4-aminobenzyl)-2~methyl benzimidazole)-1,4, 7, 1 0- 
tetraazacyclododecane (37b)
250000
TbNH2 in D 2O Xex = 289 nm
200000 \
j \ 
150000
^
I w
I 100000
50000
0123
time / ms
Figure 173 Fitted decay emission decay for (37b) in D:O
250000 TbNH2 inH2CUex =
200000
150000
M
I 100000c
50000
0 -
0123
time / ms
Figure 174 Fitted decay emission decay for (37b) in H:O
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8.9 Physical data for gadolinium(IH) 1,4,7- 
tris(carboxymethyl)-10-(2-methyl benzimidazole)~1,4,7,10- 
tetraazacyclododecane (60)
Concentration 
(mM)
0.125
0.25
0.5
0.75
1.0
7>(s)
1.15
0.75
0.45
0.33
0.26
I/TV1)
0.87
_ 1.34
2.24
3.00
3.89
Table 27 Relaxivity data at pH 6.8 for (60)
1/T1 vs. Concentration, pH 3.5
3.5
3
2.5
y = 2.903x + 0.315
0.5 
0
0.2 0-4 0.6 0.8 
Concentration of Gd(benzimidazole) mM
Figure 175 Graph to show \IT, vs. concentration at pH 3.5 for (60)
Concentration (mM)
0.11
0.225
0.45
0.675
0.9
TIM
1.47
1.02
0.60
0.51
0.32
1/T/r.'1 )
0.68
0.98
1.68
1.96
3.12
Table 28 Relaxivity data at pH 3.5 for (60)
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1/T1 vs. Concentration, pH 1.5
3.5 n
3 - 
2.5 -
r-i 2 - 
Vt
£ 1.5 
" 1
0.5 ^
0
= 3.326x + 0.280
0 0.2 0.4 0.6 0.8 
Concentration of Gd(benzimidazole) mM
Figure 176 Graph to show IIT, vs. concentration at pH 1.5 for (60)
Concentration (mM)
0.11
0.225
0.45
0.675
0.9
TIM
1.5
1.04
0.60
0.44
0.30
l/J/h 1 )
0.67
0.96
1.67
2.26
3.32
Table 29 Relaxivity data at pH 1.5 for (60)
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8.10 Physical data for gadolinium(lll) 1,4,7- 
tris(carboxymethyl)-10~(1-(4-nitroobenzyl)~2-methyl 
benzimidazole)-1,4,7,10-tetraazacyclododecane (34c)
Concentration (mM)
0.125
0.25
0.5
0.75
1.0
TIM
1.08
0.64
0.34
0.23
0.15
1/7V>
0.93
1.56
2.94
4.32
6.50
Table 30 Relaxivity data at pH 4.6 for (34c)
1/T1 vs. Concentration, pH 3.5
0 0.2 0.4 0.6
Concentration of Gd(benzimidazole) mM
Figure 177 Graph to show I IT, vs. concentration at pH 3.5 for (34c)
0.8
Concentration (mM)
0.12
0.22
0.47
0.71
0.94
TIM
0.93
0.60
0.31 _^
0.22
0.17
1/TV>
1.07
1.68
3.25
4.50
5.96
Table 31 Relaxivity data at pH 3.5 for (34c)
313
1/T1 vs. Concentration, pH 1.5
7 -, 
6
5
2 H
1
0
y = 6.220x + 0.252
0 0.2 0.4 0.6 0.8 
Concentration of Gd(benzimidazole) mM
Figure 178 Graph to show IIT, vs. concentration at pH 1.5 for (34c)
Concentration (mM)
0.11
0.23
0.46
0.69
0.90
TIM
0.93
0.63
0.33
0.22
0.17
l/Tni1 )
1.07
1.59
3.02
4.64
5.85
Table 32 Relaxivity data at pH 1.5 for (34c)
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8.11 Physical data for gadolinium(lll) 1,4,7- 
tris(carboxymethyl)-10-(1-(4-aminobenzyl)-2-methyl 
benzimidazole)-1,4,7,10-tetraazacyclododecane (37c)
1/T1 vs. Concentration
6
5
4
3
1
0
= 4.517x + 0.337
0.2 0.4 0.6 0.8 1 
Concentration of Gd(benzimidazole) mM
1.2
Figure 179 Graph to show IIT, vs. concentration for (37c)
Concentration (mM)
0.125
0.25
0.50
0.75
1.0
TKS)
1.04
0.68
0.40
0.27
0.20
1/W)
0.96
1.46
2.52
3.70
4.91
Table 33 Relaxivity data for (37c)
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8.12 Physical data for gadolinium(lll) 1,4,7- 
tris(carboxymethyl)-10-(4-aminobenzyl)- 1,4,7,10- 
tetraazacyclododecane (41 c)
1/Tlvs. Concentration
9 
8 
7 
6
5 - 
4 - 
3 - 
2 - 
1 - 
0
y = 7.861x + 0.146
0 0.2 0.4 0.6 0.8 1 
Concentration of Gd(benzyl) mM
1.2
Figure 180 Graph to show \IT, vs. concentration for (37c)
Concentration (mM)
0.125
0.25
0.50
0.75
1.0
Tj(s)
0.89
0.48
0.26
0.16
0.13
1/7WS
1.14
2.08
3.92
6.41
7.81
Table 34 Relaxivity data for (37c)
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8.13 Physical data for Omniscan
1/T1 vs. Concentration
7
6
5
4
3
2
1
0
y=5.523x + 0.604
0.2 0.4 0.6 0.8
Concentration of Gd(benzimidazole) mM
1.2
Figure 181 Graph to show l/T, vs. concentration for Omniscan
Concentration (mM)
0.125
0.25
0.50
0.75
1.0
TIM
0.74
0.48
0.32
0.21
0.16
l/T, (i\
1.35
2.09
3.12
4.73
6.23
Table 35 Relaxivity data for Omniscan
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